Compstatin analogs and their medical uses

Abstract

Compstatin analogs are described that have improved binding and complement inhibitory activity compared to the 13-amino acid compstatin peptide (ICWQDWGHHRCT(cyclic C2-C12)), particularly compstatin analogs that have additional useful physicochemical properties. The analogs have a thioether bond, rather than a disulfide bond, between the side chains of the residues corresponding to cysteine ​​2 and cysteine ​​12 of compstatin, which may increase stability. The analogs may also have an isoleucine residue instead of the wild-type valine residue at position 3, which provides compstatin peptides with improved binding and complement inhibitory activity and also allows for the introduction of other modifications, such as modifications that may increase solubility, such as the introduction of a charged or polar amino acid at position 9 and / or the introduction of N- and / or C-terminal sequences.

Description

Technical Field

[0001] The present invention relates to inhibiting the activation of the complement cascade in the body, and more particularly to compstatin analogs that can bind to C3 protein and inhibit complement activation. The present invention also relates to the medical use of compstatin analogs, particularly for the treatment of conditions characterized by the undesired activation of the complement cascade, such as autoimmune and inflammatory diseases.

Background Art

[0002] The human complement system is a powerful player in the defense against pathogenic organisms and the mediation of immune responses. Complement can be activated via three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. The major activation event shared by all three pathways is the proteolytic cleavage of the central complement protein C3 by a C3 convertase into its activation products C3a and C3b. The generation of these fragments leads to the opsonization of pathogenic cells by C3b and iC3b (the process of making pathogenic cells susceptible to phagocytosis or clearance) and the activation of immune cells through interaction with complement receptors (Markiewski & Lambris, 2007, Am. J. Pathol., 171:715 - 727). Also, the deposition of C3b on target cells induces the formation of new convertase complexes, thereby initiating an autoamplification loop. An ensemble of plasma and cell surface - bound proteins carefully regulates complement activation so as to prevent host cells from self - attack by the complement cascade. However, excessive activation or inappropriate regulation of complement can lead to several pathological conditions ranging from autoimmune diseases to inflammatory diseases (Holers, 2003, Clin. Immunol., 107:140 - 51; Markiewski & Lambris, 2007, supra; Ricklin & Lambris, 2007, Nat. Biotechnol., 25:1265 - 75; Sahu et al., 2000, J. Immunol., 165:2491 - 9). Therefore, the development of therapeutic complement inhibitors is highly desirable. In this context, C3 and C3b have emerged as promising targets. This is because their central role in the cascade enables the simultaneous inhibition of complement initiation, amplification, and downstream activation (Ricklin & Lambris, 2007, supra).

[0003] Compstatin was first identified as a 27 - amino acid peptide and was the first non - host - derived complement inhibitor. It has been shown to be able to block all three activation pathways (Sahu et al., 1996, J. Immunol., 157:884 - 91; U.S. Patent No. 6,319,897). It has been shown that compstatin can be truncated to a 13 - amino acid peptide without loss of activity. However, attempts to further cleave the peptide resulted in loss of activity. The sequence of the 13 - amino acid truncated (or "core") compstatin peptide is Ile 1 -Cys 2 -Val 3 -Val 4 -Gln 5 -Asp 6 -Trp 7 -Gly 8 -His 9 -His 10 -Arg 11 -Cys 12 -Thr 13 -NH2, and Cys 2 and Cys 12 are disulfides that are linked. This cyclic tridecapeptide inhibits the activation of the downstream complement cascade by binding to C3 (and fragments of C3), preventing the cleavage of native C3 by C3 convertase. Its inhibitory efficacy has been confirmed by a series of studies using experimental models that demonstrate its potential as a therapeutic agent (Fiane et al, 1999a, Xenotransplantation, 6:52 - 65; Fiane et al, 1999b, Transplant Proc., 31:934 - 935; Nilsson et al., 1998, Blood, 92:1661 - 1667; Ricklin & Lambris, 2008, Adv. Exp. Med.. Biol., 632:273 - 292; Schmidt et al., 2003, J. Biomed. Mater. Res., A66:491 - 499; Soulika et al., 2000, Clin. Immunol., 96:212 - 221).

[0004] Progressive optimization of the 13-amino acid compstatin peptide led to analogs with improved biological activity (Ricklin & Lambris, 2008, supra; WO 2004 / 026328; WO 2007 / 062249, WO 2013 / 036778, WO 2014 / 100407). Earlier structure-activity studies identified the periodicity of the compstatin peptide and the presence of both β-turns and hydrophobic clusters as important features of the molecule (Morikis et al., 1998, Protein Sci., 7:619-627; WO 99 / 13899; Morikis et al., 2002, J. Biol. Chem., 277:14942-14953; Ricklin & Lambris, 2008, supra). Hydrophobic residues at positions 4 and 7 were found to be particularly important, and their modification with non-natural amino acids produced analogs with 264-fold improved activity relative to the original compstatin peptide (Katragadda et al., 2006, J. Med. Chem., 49:4616-4622; WO 2007 / 062249). Further attempts to optimize compstatin for the treatment of eye disorders are described in WO 2007 / 044668. Previous optimization steps have been based on combinatorial screening studies, solution structures, and computational models (Chiu et al., 2008, Chem. Biol. Drug Des., 72:249-256; Mulakala et al., 2007, Bioorg. Med. Chem., 15:1638-1644; Ricklin & Lambris, 2008, supra). Publications of the co-crystal structure of compstatin complexed with complement fragment C3c (Janssen et al., 2007, J. Biol. Chem., 282:29241-29247; WO 2008 / 153963 pamphlet) have provided a basis for initiating rational optimization. The crystal structure revealed a shallow binding site at the interface of macroglobulin (MG) domains 4 and 5 of C3c. It was also shown that 9 out of 13 amino acids are directly involved in binding by either hydrogen bonding or hydrophobic interactions. Compared to the structure of the compstatin peptide in solution (Morikis et al., 1998, supra), the bound form of compstatin underwent a conformational change in which the location of the β-turn shifted from residues 5-8 to residues 8-11 (Janssen et al., 2007, supra; WO 2008 / 153963 pamphlet).

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Patent Document 5

Non-Patent Documents

[0006] [Non-Patent Document 1] Markiewski&Lambris, 2007, Am. J. Pathol., 171:715-727 [Non-Patent Document 2] Holers, 2003, Clin. Immunol., 107:140-51 [Non-Patent Document 3] Ricklin&Lambris, 2007, Nat. Biotechnol., 25:1265-75 [Non-Patent Document 4] Sahu et al., 2000, J. Immunol., 165:2491-9 [Non-Patent Document 5] Sahu et al., 1996, J. Immunol., 157:884-91 [Non-Patent Document 6] Fiane et al, 1999a, Xenotransplantation, 6:52-65 [Non-Patent Document 7] Fiane et al, 1999b, Transplant Proc., 31:934-935 [Non-Patent Document 8] Nilsson et al., 1998, Blood, 92:1661-1667 [Non-Patent Document 9] Ricklin&Lambris, 2008, Adv. Exp. Med.. Biol., 632:273-292 [Non-Patent Document 10] Schmidt et al., 2003, J. Biomed. Mater. Res., A66:491-499 [Non-Patent Document 11] Soulika et al., 2000, Clin. Immunol., 96:212-221 [Summary of the Invention] [Problems to be Solved by the Invention]

[0007] In view of the therapeutic potential in AMD, C3G, PNH and other diseases, it remains an issue in the art to further optimize the compstatin analogs, for example, to achieve even greater activity and / or to modulate pharmacokinetic properties such as an increase in in vivo half-life and / or physicochemical properties such as an increase in solubility or stability.

Means for Solving the Problems

[0008] Generally, the present invention is based on research to develop a new family of compstatin analogs having improved binding and complement inhibitory activity compared to the 13-amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)). Optionally, these compstatin analogs additionally have useful physicochemical properties such as increased solubility and pharmacokinetic properties. In particular, the inventors have found that introducing an isoleucine residue at position 3 in place of the wild-type valine residue results in a compstatin peptide with improved binding and complement inhibitory activity. The inventors have further discovered that the introduction of isoleucine at position 3 enables the introduction of other modifications, such as modifications that can increase solubility, such as the introduction of glutamic acid at position 6, amino acids with specific charges or polarities at position 9 and / or the introduction of N- and / or C-terminal sequences. Examples of such additional modifications include substitution of Ile at position 1 with Tyr, Phe or Sar; substitution of Val at position 4 with Trp, a Trp analog (described herein); substitution of Asp at position 6 with Glu; substitution of His at position 9 with Ala, Glu, Asp, Lys, Ser or Arg; substitution of Arg at position 11 with Ser; substitution of Thr at position 13 with Ser, Glu, Sar or Ile. Preferred compstatin peptides containing one or more of these modifications have, for example, improved solubility compared to the 13-amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)). Further examples of these compstatin peptides combine the modification at position 9 with an extension to the N-terminus and / or C-terminus of the peptide. Additionally, the addition of acylation has a beneficial effect on pharmacokinetics.

[0009] Furthermore, in the compounds of the present invention, the residues corresponding to cysteine 2 and cysteine 12 of compstatin have side chains linked via thioether bonds instead of the disulfide bonds found in compstatin. Among the advantages, it is considered that the side chains can achieve an improvement in stability (e.g., physical stability or chemical stability) compared to equivalent molecules containing disulfide bonds at the corresponding positions.

[0010] Therefore, the present invention provides a compstatin analog represented by the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula I) wherein, Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, F, V, Y, 1-Me-Trp, D-Trp, N-Me-Trp, 1-For-Trp, 1-Nal, 2-Nal, 5-Me-Trp, Bpa or 2-Igl; X6 is E, K or D; X8 is G or Sar; X9 is H, A, E, D, K, R or S; X11 is R, S or K; X13 is T, S, E, F, H, K, Sar, G, I, D, N-Me-Ile or N-Me-Thr; X2 and X12 are residues whose side chains are linked by thioether bonds; Y2 is NH2, OH or a lipophilic group Φ; R1 is absent, or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent, or is A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D-form; or is a sequence of 1 to 8 amino acid residues selected from Peg3, Peg4 or 8-aminooctanoyl or derivatives thereof; The invention provides a compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof, optionally having a lipophilic group Φ covalently attached to the side chain of one or more amino acid residues.

[0011] In some embodiments, X11 is R or S.

[0012] In some embodiments, when the lipophilic group Φ is linked to the side chain of an amino acid residue, the residue is a residue at position X1, X11 or X13 or a residue within R1 or R2. The residue can be a lysine residue. For example, the residue can be a lysine residue at position X11 or X13 or a lysine residue within R1 or R2.

[0013] In some embodiments, Y1 is hydrogen or acetyl.

[0014] In some embodiments, Y2 is NH2 or OH.

[0015] In some embodiments, the compstatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0016] In some embodiments, the compstatin analog does not contain a lipophilic group Φ.

[0017] The present invention relates to a compstatin analog represented by the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula II) wherein, Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp; X6 is E or D; X8 is G or Sar; X9 is A, E, D, K or S; X11 is R, S or K; X13 is T, S, E, I, Sar, K, G or N-Me-Ile; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2, OH or the lipophilic group Φ; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; The Compstatin analogs further provide, optionally, Compstatin analogs or pharmaceutically acceptable salts and / or solvates thereof having a lipophilic group Φ covalently attached to the side chain of one or more amino acids.

[0018] In some embodiments, X11 is R or S.

[0019] In some embodiments, when the lipophilic group Φ is linked to the side chain of an amino acid residue, the residue is a residue at position X1, X11 or X13 or a residue within R1 or R2. The residue can be a lysine residue. For example, the residue can be a lysine residue at position X13 or a lysine residue within R1 or R2.

[0020] In some embodiments, Y1 is hydrogen or acetyl.

[0021] In some embodiments, Y2 is NH2 or OH.

[0022] In some embodiments, the compstatin analog comprises at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0023] In some embodiments of this formula, the compstatin analog does not contain a lipophilic group Φ.

[0024] The present invention relates to a formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-X11-X12-X13-R2-Y2 (Formula III) A compstatin analog represented by the formula, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X11 is R, S or K; X13 is T, I, S, E, K or Sar; X2 and X12 are residues, the side chains of which are residues linked by a thioether bond; Y2 is NH2, OH or a lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or the corresponding D-form; or is a sequence of 1 to 8 amino acid residues selected from Peg3, or Peg4, or 8-aminooctanoyl or a derivative thereof; The complementastatin analog optionally further provides a complementastatin analog or a pharmaceutically acceptable salt and / or solvate thereof having a lipophilic group Φ covalently attached to the side chain of one or more amino acids.

[0025] In some embodiments, X11 is R or S.

[0026] In some embodiments, when the lipophilic group Φ is linked to the side chain of an amino acid residue, the residue is a residue at position X1, X11 or X13 or a residue within R1 or R2. The residue can be a lysine residue. For example, the residue can be a lysine residue at position X11 or X13 or a lysine residue within R1 or R2.

[0027] In some embodiments, Y1 is hydrogen or acetyl.

[0028] In some embodiments, Y2 is NH2 or OH.

[0029] In some embodiments, the complementastatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0030] In some embodiments of this formula, the complementastatin analog does not contain a lipophilic group Φ.

[0031] The complementastatin analog or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula IV) and can be represented by, wherein, Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X13 is T, S, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2, OH or a lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; The Compstatin analog optionally has a lipophilic group Φ covalently attached to the side chain of one or more amino acids.

[0032] In some embodiments, when the lipophilic group Φ is linked to the side chain of an amino acid residue, the residue is a residue at position X1, X11 or X13 or a residue within R1 or R2. The residue can be a lysine residue. For example, the residue can be a lysine residue at position X13 or a lysine residue within R1 or R2.

[0033] In some embodiments, Y1 is hydrogen or acetyl.

[0034] In some embodiments, Y2 is NH2 or OH.

[0035] In some embodiments, the complestatin analog comprises at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0036] In some embodiments of this formula, the complestatin analog does not comprise a lipophilic group Φ.

[0037] In some embodiments of the previous formula, X6 is D.

[0038] In one aspect, a complestatin analog having no lipophilic group Φ or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula V) wherein: Y1 is hydrogen or acetyl; X1 is Y or F; X4 is W, Y, 1-Me-Trp; X6 is E or D; X9 is A, E or K; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2 or OH; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives.

[0039] A compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-[1-Me-Trp]-Q-X6-W-G-E-H-R-X12-X13-R2-Y2 (Formula VI) wherein Y1 is hydrogen or acetyl; X1 is Y or F; X6 is E or D; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2 or OH; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or the corresponding D-form thereof or Peg3, Peg4 or 8-aminooctanoyl or a derivative thereof; and R2 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or the corresponding D-form thereof; or Peg3, or Peg4, or 8-aminooctanoyl or a derivative thereof.

[0040] In the above formula, X6 can be D. Alternatively, X6 can be E.

[0041] In some embodiments, the compstatin analog has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula VII) wherein Y1 is hydrogen, acetyl or the lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, 1-Me-Trp, 1-Nal or 2-Nal; X6 is E, K or D; X8 is G or Sar; X9 is H, A, E, D, K, R or S; X11 is R, S, K or K * ; X13 is T, S, E, Sar or N-Me-Ile; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2 or OH; R1 and R2 can be as defined in any of the previous formulas or as defined elsewhere in this specification. In some embodiments, R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, K, K * , S, Y or their corresponding D forms; and / or R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, K, K * , P, S, Peg3, γGlu, 8-aminooctanoyl or their corresponding D forms; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its side chain.

[0042] It may be desirable for the compstatin analog to contain at least one lipophilic group Φ, for example exactly one lipophilic group Φ. Alternatively, the compstatin analog may not contain a lipophilic group Φ.

[0043] In an alternative embodiment, a compstatin analog containing a lipophilic group Φ or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula VIII) wherein, Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp; X6 is E or D; X8 is G or Sar; X9 is A, E, D, K or S; X11 is R, S or K * ; X13 is T, S, E, I, Sar, K, G or N-Me-Ile; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2, OH or the lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or their corresponding D forms; R2 is absent or a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain; The compstatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0044] In some embodiments, Y2 is NH2 or OH.

[0045] The compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-X11-X12-X13-R2-Y2 (Formula IX) and can be represented by, where Y1 is hydrogen, acetyl or the lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X11 is R, S or K * ; X13 is T, I, S, E, K or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2, OH or the lipophilic group Φ; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or their corresponding D-forms; R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its side chain; The compstatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0046] In some embodiments, Y2 is NH2 or OH.

[0047] The compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula X) and can be represented by, wherein Y1 is hydrogen, acetyl or the lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X13 is T, S, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2, OH or a lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or its corresponding D form; R2 is absent or a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D form; or Peg3, or Peg4, or 8-aminooctanoyl or a derivative thereof; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its amino acid side chain; The Compstatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0048] In some embodiments, Y2 is NH2 or OH.

[0049] In any of the preceding formulas, X6 can be D. Alternatively, X6 can be E.

[0050] In any of the preceding formulas, X1 can be Y. Alternatively, X1 can be F.

[0051] In any of the preceding formulas, X13 can be Sar. Alternatively, X13 can be T.

[0052] Additionally or alternatively, any of the preceding formulas may include one of the following combinations of residues: X4 is 1-Me-Trp, and X9 is E. X1 is F, X4 is 1-Me-Trp, and X9 is E. X4 is 1-Me-Trp, X9 is E, and X13 is Sar. X4 is 1-Me-Trp, X9 is E, and X13 is T. X4 is 1-Me-Trp, X6 is D, X9 is E, and X13 is Sar. X4 is 1-Me-Trp, X6 is E, X9 is E, and X13 is Sar. X4 is 1-Me-Trp, X6 is D, X9 is E, and X13 is T. X4 is 1-Me-Trp, X6 is E, X9 is E, and X13 is T.

[0053] The Compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof has the formula: Y1-R1-X1-X2-I-[1-Me-Trp]-Q-X6-W-X8-E-H-R-X12-X13-R2-Y2 (Formula XI) and may be represented by the formula, wherein Y1 is hydrogen or acetyl; X1 is Y or F; X6 is E or D; X8 is G or Sar; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH2 or OH; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or their corresponding D-forms; R2 is absent or is A, E, G, L, K, K* , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or a sequence of 1 to 8 amino acid residues selected from Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain; The compstatin analog contains at least one lipophilic group Φ, for example exactly one lipophilic group Φ.

[0054] In some embodiments of Formula XI, X8 is G. In other embodiments, X8 is G or Sar, for example Sar.

[0055] In the compounds of the present invention, the side chains of the residues at positions X2 and X12 are linked by a thioether bond, that is, a thioether bridge is formed. The thioether bridge is considered to provide advantages regarding stability compared to the same molecule having a disulfide bond between the residues at the corresponding positions. Typically, the biological activity (e.g., the efficacy of complement inhibition) is substantially maintained or even increased compared to such molecules.

[0056] In any of the previous formulas, the side chains of the residues at positions X2 and X12 can form a cystathionine (Ctt) bridge, such as a gamma cystathionine bridge (Ctt1) or a delta cystathionine bridge (Ctt2). Cystathionine bridges, especially delta cystathionine bridges, can be particularly advantageous regarding stability and activity (e.g., the efficacy of complement inhibition) compared to the disulfide bond between the residues at the corresponding positions.

[0057] The cystathionine bridge can be shown by representing the residues involved as homocysteine (hC) residues and alanine (A) residues (indicated as "(1)", which means a covalent bond between the side chains). Thus, the residues at X2 and X12 can be hC(1) and A(1) in either order.

[0058] When X2 is hC(1) and X12 is A(1), cystathionine is gamma cystathionine crosslink (Ctt1).

[0059] When X2 is A(1) and X12 is hC(1), cystathionine is delta cystathionine crosslink (Ctt2).

[0060] Alternatively, the side chains of the residues at positions X2 and X12 can form a lanthionine crosslink. The lanthionine crosslink can be indicated by showing the residues involved as cysteine (C) residues and alanine (A) residues (denoted as "(1)" which means a covalent bond between the side chains). Thus, the residues at X2 and X12 can be C(1) and A(1) in either order.

[0061] In some embodiments, the 13-mer peptide portion (X1 - X13) of the compstatin analog is as follows: [Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; [Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-T; [Sar]-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-T; [Sar]-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; [Sar]-X2-IWQDWGEHR-X12-T; F-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]; F-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-T; F-X2-I[1-Me-Trp]QDWGEHK-X12-[Sar]; F-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; F-X2-I[1-Me-Trp]QDWGEHR-X12-E; F-X2-I[1-Me-Trp]QDWGEHR-X12-S; F-X2-I[1-Me-Trp]QDWGEHR-X12-T; F-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; F-X2-I[1-Nal]QDWGEHR-X12-T; F-X2-I[2-Nal]QDWGEHR-X12-T; F-X2-IWQDWGEHR-X12-[Sar]; F-X2-IWQDWGEHR-X12-T; I-X2-I[1-Me-Trp]QDW[Sar]AHR-X12-[N-Me-Ile]; I-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; I-X2-I[1-Me-Trp]QDWGEHR-X12-T; I-X2-I[2-Nal]QDWGEHR-X12-[Sar]; I-X2-IWQDWGAHR-X12-E; I-X2-IWQDWGAHR-X12-T; I-X2-IWQDWGAHS-X12-T; I-X2-IWQDWGDHR-X12-T; I-X2-IWQDWGEHR-X12-[Sar]; I-X2-IWQDWGEHR-X12-E; I-X2-IWQDWGEHR-X12-S; I-X2-IWQDWGEHR-X12-T; I-X2-IWQDWGEHS-X12-T; I-X2-IWQDWGKHR-X12-T; I-X2-IWQDWGRHR-X12-T; I-X2-IWQDWGSHR-X12-T; I-X2-IWQEWGEHR-X12-T; I-X2-IWQKWGAHR-X12-T; I-X2-IWQKWGEHR-X12-T; Y-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; Y-X2-I[1-Me-Trp]QDWGEHR-X12-T; Y-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; Y-X2-I[2-Nal]QDWGEHR-X12-T; Y-X2-IWQDWGEHR-X12-T; Y-X2-I[1-Me-Trp]QDWGEH[K * -X12-[Sar]; and Y-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-[Sar] having a sequence selected from wherein X2 and X12 are residues whose side chains are linked by a thioether bond; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its side chain.

[0062] In some embodiments, the 13-mer peptide portion (X1-X13) of the compstatin analog is as follows: [Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; [Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)T; [Sar]hC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)T; [Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; [Sar]hC(1)IWQDWGEHRA(1)T; FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]; FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)T; FhC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]; FhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; FhC(1)I[1-Me-Trp]QDWGEHRA(1)E; FhC(1)I[1-Me-Trp]QDWGEHRA(1)S; FhC(1)I[1-Me-Trp]QDWGEHRA(1)T; FhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; FhC(1)I[1-Nal]QDWGEHRA(1)T; FhC(1)I[2-Nal]QDWGEHRA(1)T; FhC(1)IWQDWGEHRA(1)[Sar]; FhC(1)IWQDWGEHRA(1)T; IhC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]; IhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; IhC(1)I[1-Me-Trp]QDWGEHRA(1)T; IhC(1)I[2-Nal]QDWGEHRA(1)[Sar]; IhC(1)IWQDWGAHRA(1)E; IhC(1)IWQDWGAHRA(1)T; IhC(1)IWQDWGAHSA(1)T; IhC(1)IWQDWGDHRA(1)T; IhC(1)IWQDWGEHRA(1)[Sar]; IhC(1)IWQDWGEHRA(1)E; IhC(1)IWQDWGEHRA(1)S; IhC(1)IWQDWGEHRA(1)T; IhC(1)IWQDWGEHSA(1)T; IhC(1)IWQDWGKHRA(1)T; IhC(1)IWQDWGRHRA(1)T; IhC(1)IWQDWGSHRA(1)T; IhC(1)IWQEWGEHRA(1)T; IhC(1)IWQKWGAHRA(1)T; IhC(1)IWQKWGEHRA(1)T; YhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; YhC(1)I[1-Me-Trp]QDWGEHRA(1)T; YhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; YhC(1)I[2-Nal]QDWGEHRA(1)T; YhC(1)IWQDWGEHRA(1)T; YhC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]; and YhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar] having a sequence selected from wherein the side chains of the residues designated hC(1) and A(1) form a cystathionine bridge; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its side chain.

[0063] In some embodiments, the 13-mer peptide portion (X1-X13) of the compstatin analog is as follows: [Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]; [Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)T; [Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)T; [Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]; [Sar]A(1)IWQDWGEHRhC(1)T; FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]; FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)T; FA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]; FA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]; FA(1)I[1-Me-Trp]QDWGEHRhC(1)E; FA(1)I[1-Me-Trp]QDWGEHRhC(1)S; FA(1)I[1-Me-Trp]QDWGEHRhC(1)T; FA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]; FA(1)I[1-Nal]QDWGEHRhC(1)T; FA(1)I[2-Nal]QDWGEHRhC(1)T; FA(1)IWQDWGEHRhC(1)[Sar]; FA(1)IWQDWGEHRhC(1)T; IA(1)I[1-Me-Trp]QDW[Sar]AHRhC(1)[N-Me-Ile]; IA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]; IA(1)I[1-Me-Trp]QDWGEHRhC(1)T; IA(1)I[2-Nal]QDWGEHRhC(1)[Sar]; IA(1)IWQDWGAHRhC(1)E; IA(1)IWQDWGAHRhC(1)T; IA(1)IWQDWGAHShC(1)T; IA(1)IWQDWGDHRhC(1)T; IA(1)IWQDWGEHRhC(1)[Sar]; IA(1)IWQDWGEHRhC(1)E; IA(1)IWQDWGEHRhC(1)S; IA(1)IWQDWGEHRhC(1)T; IA(1)IWQDWGEHShC(1)T; IA(1)IWQDWGKHRhC(1)T; IA(1)IWQDWGRHRhC(1)T; IA(1)IWQDWGSHRhC(1)T; IA(1)IWQEWGEHRhC(1)T; IA(1)IWQKWGAHRhC(1)T; IA(1)IWQKWGEHRhC(1)T; YA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]; YA(1)I[1-Me-Trp]QDWGEHRhC(1)T; YA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]; YA(1)I[2-Nal]QDWGEHRhC(1)T; YA(1)IWQDWGEHRhC(1)T; YA(1)I[1-Me-Trp]QDWGEH[K * hC(1)[Sar]; and YA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar] having a sequence selected from wherein the side chains of the residues designated A(1) and hC(1) form a cystathionine bridge; * indicates that the amino acid residue has a lipophilic group Φ covalently attached to its side chain.

[0064] In some embodiments, the 13-mer peptide portion (X1-X13) of the compstatin analog is as follows: [Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; [Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)T; [Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)T; [Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; [Sar]C(1)IWQDWGEHRA(1)T; FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]; FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)T; FC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]; FC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; FC(1)I[1-Me-Trp]QDWGEHRA(1)E; FC(1)I[1-Me-Trp]QDWGEHRA(1)S; FC(1)I[1-Me-Trp]QDWGEHRA(1)T; FC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; FC(1)I[1-Nal]QDWGEHRA(1)T; FC(1)I[2-Nal]QDWGEHRA(1)T; FC(1)IWQDWGEHRA(1)[Sar]; FC(1)IWQDWGEHRA(1)T; IC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]; IC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; IC(1)I[1-Me-Trp]QDWGEHRA(1)T; IC(1)I[2-Nal]QDWGEHRA(1)[Sar]; IC(1)IWQDWGAHRA(1)E; IC(1)IWQDWGAHRA(1)T; IC(1)IWQDWGAHSA(1)T; IC(1)IWQDWGDHRA(1)T; IC(1)IWQDWGEHRA(1)[Sar]; IC(1)IWQDWGEHRA(1)E; IC(1)IWQDWGEHRA(1)S; IC(1)IWQDWGEHRA(1)T; IC(1)IWQDWGEHSA(1)T; IC(1)IWQDWGKHRA(1)T; IC(1)IWQDWGRHRA(1)T; IC(1)IWQDWGSHRA(1)T; IC(1)IWQEWGEHRA(1)T; IC(1)IWQKWGAHRA(1)T; IC(1)IWQKWGEHRA(1)T; YC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]; YC(1)I[1-Me-Trp]QDWGEHRA(1)T; YC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]; YC(1)I[2-Nal]QDWGEHRA(1)T; YC(1)IWQDWGEHRA(1)T; YC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]; and YC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar] having a sequence selected from wherein the side chains of the residues designated C(1) and A(1) form a lactionic bridge, * indicating that the amino acid residue has a lipophilic group Φ covalently attached to its side chain.

[0065] In some embodiments, R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, R, V or Sar or its corresponding D-form, and / or R2 can be a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, R, V or Sar or its corresponding D-form. In some embodiments, Q can also be an option for R1.

[0066] For example, R1 is selected from ESSA, AKGE, ASSE, ASES, GSAE, ESSE, ESGA, SEG, GES, ESS, EGSA, ESE, EGE, ESA, SAE, SGA, YLEA, GSA, KEK, EKG, ES, AS, SE, SA or E, and / or R2 is selected from GAES, EYGS, EGYA, EAGS, EAKS, EKSA, EGGS, EGGA, ESSG, ESAG, GEES, AEES, ESEG, AEGS, ESGS, SEGA, SEG, ESG, EAG, GAE, EGEA, EGE, EA, E, GE, EG, EKE or EKP.

[0067] In an alternative embodiment, R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or the corresponding D-form thereof; or a sequence of 1 to 6 amino acid residues selected from Peg3, Peg4 or 8-aminooctanoyl or a derivative thereof.

[0068] In some embodiments, R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V or Sar or the corresponding D-form thereof.

[0069] For example, R1 may be absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, K, S and Y or the corresponding D-form thereof.

[0070] The lipophilic group Φ may be covalently attached (which may be referred to as K * ) to the side chain of one or more residues within Y1, particularly the side chain of a lysine residue. The residue having Φ may desirably be at the N-terminus of Y1.

[0071] Examples of sequences for the group R1 include: {d}Y, EGSE, AGSE, SASE, EYSE, GSE, ASE, ESSA, KGSA, AKGE, ASGE, ASSE, ASES, GSAE, ESSE, ESGA, SEG, GES, ESS, EGSA, ESE, EGE, ESA, SAE, SGA, YLEA, GSA, KEK, EKG, ES, RS, SR, AE, TE, KE, GE, FE, YE, AS, SE, RS, SR, SA, GE, S, Y and E.

[0072] In some embodiments, R1 is 2 amino acid residues in length, such as AE, TE, KE, GE, FE, YE, AS, SE, SA or GE; preferably AE, TE, KE, GE, FE, YE, SE or GE.

[0073] In some embodiments, R1 is 1 amino acid in length, e.g., E.

[0074] As described above, the lipophilic group Φ is covalently attached to the side chain of one or more residues within Y1, particularly, for example, the side chain of a lysine residue (K * which may be referred to as) to give the sequence K * which may confer GSA.

[0075] R2 may be absent, or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, Peg4 or 8-aminooctanoyl or a derivative thereof.

[0076] For example, R2 may be absent, or is selected from A, E, G, K, S, γGlu, Peg3 or 8-aminooctanoyl, or is a sequence of 1 to 8 amino acid residues selected from A, E, G, K and S.

[0077] When K is present within R2, it may be desirable for K to be present at the C-terminus of R2.

[0078] The lipophilic group Φ may be covalently attached to the side chain of one or more residues within Y2, particularly the side chain of a lysine residue. The residue having Φ may desirably be at the C-terminus of R2.

[0079] Examples of sequences for the radical R2 include the following: EGASGSG, EGAGSG, EGASAG, EGAGAG, EGESGSG, EGEGSG, EGESAG, EGEGAG, EK[γGlu]AK, EGEGG, EGAGG, EGESS, GAESK, EGAK, EGEK, EGG, EGK, EGKK, EGS, EK, EGA, EGAK, EK[γGlu], EK[γGlu]-K, EGE-[Peg3, EGE[Peg3]-K, EGE[Peg3][Peg3], EGE[Peg3][Peg3]-K, EGE[Peg3][Peg3][Peg3], EAE[Peg3][Peg3], EAE[Peg3][Peg3]-K, GESESE, GAESES, EGESES, EGESESK, EGE[Peg3]-ES, EGE[Peg3]-ESK, GESESE, EGE-[8-aminooctanoyl], EGE-[8-aminooctanoyl]-K, EGE-[8-aminooctanoyl]-EK, EGEGGG, EGEGGGK, EK[γGlu]GGG, EK[γGlu]GGGK, EGE-[8-aminooctanoyl]-E, GAES, EYGS, EGYA, EAGS, EAKS, EKSA, ESGA, EGG, EGGA, ESSG, ESAG, GEES, AEES, ESEG, AEGS, ESGS, SEGA, SEG, EGK, ESG, EAG, GAE, EGEA, EGE, EA, E, S, GE, GEK, EG, EA, EKE and EKP.

[0080] Examples of the sequence for the radical R2 include: EGASGSG, EGAGSG, EGASAG, EGAGAG, EGESGSG, EGEGSG, EGESAG, EGEGAG, EK[γGlu]AK, EK[γGlu]A, EGEGG, EGAGG, EGESS, GAESK, EGAK, EGEK, EGG, EGK, EGKK, EGS, EK, EGA, EGAK, EK[γGlu], EK[γGlu]-K, EGE[Peg3], EGE[Peg3]-K, EGE[Peg3][Peg3], EGE[Peg3][Peg3]-K, EGE[Peg3][Peg3][Peg3], EGE[Peg3][Peg3][Peg3]-K, EAE[Peg3][Peg3], EAE[Peg3][Peg3]-K, GESESE, GAESES, EGESES, EGESESK, EGE[Peg3]-ES, EGE[Peg3]-ESK, GESESE, EGE-[8-aminooctanoyl], EGE-[8-aminooctanoyl]-K, EGE-[8-aminooctanoyl]-EK, EGEGGG, EGEGGGK, EK[γGlu]GGG, EK[γGlu]GGGK, EGE-[8-aminooctanoyl]-E, E[Peg3][Peg3], E[Peg3][Peg3]-K, EA[Peg3][Peg3], EA[Peg3][Peg3]-K, GAES, EYGS, EGYA, EAGS, EAKS, EKSA, ESGA, EGGS, EGGA, ESSG, ESAG, GEES, AEES, ESEG, AEGS, ESGS, SEGA, SEG, EGK, ESG, EAG, GAE, EGEA, EGE, EA, E, S, GE, GEK, EG, EA, EKE and EKP.

[0081] As described above, the lipophilic group Φ is covalently bonded to the side chain of one or more residues within R2, particularly, for example, the side chain of a lysine residue, to form the sequence EK[γGlu]AK * , EGKK * , EK[γGlu]K * , EGE[Peg3]-K * , EGESESK * , EGE[Peg3]-ESK * , EGE-[8-aminooctanoyl]-K * , EGE-[8-aminooctanoyl]-EK* , EGEGGGK * , EK[γGlu]GGGK * , EGE[Peg3][Peg3]-K * , EAE[Peg3][Peg3]-K * , GAESK * , EGAK * , EGEK * , EGK * EGE[Peg3]-ESK * , GESESEK * , GEK * or EK * can be provided.

[0082] As described above, the lipophilic group Φ is covalently bonded to the side chain of one or more residues in R2, especially, for example, the side chain of a lysine residue, to form the sequence EK[γGlu]AK * , EGKK * , EK[γGlu]K * , EGE[Peg3]-K * , EGESESK * , EGE[Peg3]-ESK * , EGE-[8-aminooctanoyl]-K * , EGE-[8-aminooctanoyl]-EK * , EGEGGGK * , EK[γGlu]GGGK * , EGE[Peg3][Peg3]-K * , EAE[Peg3][Peg3]-K * , EGE[Peg3][Peg3][Peg3]-K * , E[Peg3][Peg3]-K * , EA[Peg3][Peg3]-K * , GAESK * , EGAK * , EGEK * , EGK * EGE[Peg3]-ESK * , GESESEK * , GEK * or EK * can be provided.

[0083] When R1 or R2 is one amino acid in length, it can be a D-amino acid, such as {d}Y.

[0084] R1 and R2 can independently be present or absent. R2 may desirably be present. Without wishing to be bound by any particular theory, the presence of R1 and / or R2 is thought to be able to improve the stability of the compound.

[0085] Preferred classes of the compstatin analogs and the exemplified compounds are further considered below.

[0086] In a further aspect, the present invention provides a composition comprising a compstatin analog of the present invention or a pharmaceutically acceptable salt or solvate thereof in a mixture with a carrier. In some examples, the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

[0087] In a further aspect, the present invention provides a pharmaceutical composition comprising a compstatin analog of the present invention or a pharmaceutically acceptable salt or solvate thereof in a mixture with a pharmaceutically acceptable carrier, excipient or vehicle.

[0088] In a further aspect, the present invention provides a compstatin analog of the present invention for use in therapy.

[0089] In a further aspect, the present invention provides a compstatin analog of the present invention for use in a method of inhibiting complement activation. As an example, inhibition of complement activation comprises one or more biological activities selected from (1) binding to C3 protein, (2) binding to C3b protein, and / or (3) inhibition of cleavage of native C3 by C3 convertase. Examples of diseases or conditions that can be treated with the compstatin analogs of the present invention are considered below.

[0090] In a further aspect, the present invention provides a compstatin analog of the present invention for use in a method of inhibiting complement activation that occurs during cell transplantation or organ transplantation.

[0091] In a further aspect, the present invention provides a method of inhibiting complement activation for treating a subject in need thereof, the method comprising administering to the subject a compstatin analog of the present invention, thereby inhibiting complement activation in the subject. Examples of diseases or conditions that can be treated with the compstatin analogs of the present invention are discussed below.

[0092] In a further aspect, the present invention provides an ex vivo method of inhibiting complement activation in an extracorporeal shunt of a physiological fluid, the method comprising contacting the physiological fluid with a compstatin of the present invention, thereby inhibiting complement activation.

[0093] In a further aspect, the present invention provides the use of a compstatin analog of the present invention in the preparation of a medicament for inhibiting complement activation. Examples of diseases or conditions that can be treated with the compstatin analogs of the present invention are discussed below.

[0094] Here, embodiments of the present invention will be described by way of example and not limitation. The present invention provides, for example, the following items. (Item 1) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula I) A compstatin analog represented by the formula, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, F, V, Y, 1-Me-Trp, D-Trp, N-Me-Trp, 1-For-Trp, 1-Nal, 2-Nal, 5-Me-Trp, Bpa or 2-Igl; X6 is E, K or D; X8 is G or Sar; X9 is H, A, E, D, K, R or S; X11 is R, S or K; X13 is T, S, E, F, H, K, Sar, G, I, D, N-Me-Ile or N-Me-Thr; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent, or an array of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D form; or Peg3, Peg4 or 8-aminooctanoyl or a derivative thereof; and R2 is absent, or an array of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D form; or Peg3, Peg4 or 8-aminooctanoyl or a derivative thereof; The compstatin analog is optionally a compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof having a lipophilic group Φ covalently bonded to the side chain of one or more amino acid residues. (Item 2) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula II) A compstatin analog represented by the formula, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp; X6 is E or D; X8 is G or Sar; X9 is A, E, D, K or S; X11 is R, S or K; X13 is T, S, E, I, Sar, K, G or N-Me-Ile; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; The said Compstatin analog is optionally a Compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof having a lipophilic group Φ covalently attached to the side chain of one or more amino acids. (Item 3) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-X11-X12-X13-R2-Y2 (Formula III) A Compstatin analog represented by the formula, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X11 is R, S or K; X13 is T, I, S, E, K or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D-form; or a sequence of 1 to 8 amino acid residues selected from Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; The compstatin analog is optionally a compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof having a lipophilic group Φ covalently attached to the side chain of one or more amino acids. (Item 4) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula IV) A compstatin analog represented by the formula, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X13 is T, S, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or is selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D-form or a sequence of 1 to 6 amino acid residues selected from Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D-form; or a sequence of 1 to 8 amino acid residues selected from Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; The compstatin analog is optionally a compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof having a lipophilic group Φ covalently attached to the side chain of one or more amino acids. (Item 5) A compstatin analog according to any one of Items 1 to 4, comprising at least one lipophilic group Φ. (Item 6) A compstatin analog according to Item 5, wherein Y1 or Y2 is a lipophilic group Φ. (Item 7) The compstatin analog according to item 5 or 6, comprising a lipophilic group Φ linked to the side chain of an amino acid residue at position X1, X11 or X13 or an amino acid residue within R1 or R2. (Item 8) The compstatin analog according to item 7, wherein the amino acid residue is a lysine residue. (Item 9) The compstatin analog according to any one of items 1 to 4, which does not contain the lipophilic group Φ. (Item 10) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula V) represented by, wherein Y1 is hydrogen or acetyl; X1 is Y or F; X4 is W, Y, 1-Me-Trp; X6 is E or D; X9 is A, E or K; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 or OH; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives, the compstatin analog according to item 1 or a pharmaceutically acceptable salt and / or solvate thereof. (Item 11) Formula: Y1-R1-X1-X2-I-[1-Me-Trp]-Q-X6-W-G-E-H-R-X12-X13-R2-Y2 (Formula VI) represented by, wherein Y1 is hydrogen or acetyl; X1 is Y or F; X6 is E or D; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 or OH; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms or Peg3, Peg4 or 8-aminooctanoyl or its derivatives; and R2 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives, the Compstatin analog according to item 10 or a pharmaceutically acceptable salt and / or solvate thereof. (Item 12) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-X8-X9-H-X11-X12-X13-R2-Y2 (Formula VIII) represented by, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 2-Nal, 1-Nal or 1-Me-Trp; X6 is E or D; X8 is G or Sar; X9 is A, E, D, K or S; X11 is R, S or K * ; X13 is T, S, E, I, Sar, K, G or N-Me-Ile; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or is a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or their corresponding D-forms; R2 is absent or is a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain; the Compstatin analog contains at least one lipophilic group Φ, the Compstatin analog according to item 1 or a pharmaceutically acceptable salt and / or solvate thereof. (Item 13) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-X11-X12-X13-R2-Y2 (Formula IX) represented by, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, Y, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X11 is R, S or K * ; X13 is T, I, S, E, K or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or its corresponding D form; and R2 is absent or a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or its corresponding D form; or Peg3, or Peg4, or 8-aminooctanoyl or a derivative thereof; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain; The compstatin analog is the compstatin analog according to item 11 or a pharmaceutically acceptable salt and / or solvate thereof that contains at least one lipophilic group Φ. (Item 14) Formula: Y1-R1-X1-X2-I-X4-Q-X6-W-G-X9-H-R-X12-X13-R2-Y2 (Formula X) represented by, wherein Y1 is hydrogen, acetyl or a lipophilic group Φ; X1 is I, Y, F or Sar; X4 is W, V, 1-Nal, 2-Nal or 1-Me-Trp; X6 is E or D; X9 is A, E, D, K or S; X13 is T, S, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 , OH or a lipophilic group Φ; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or its corresponding D form; R2 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or a sequence of 1 to 8 amino acid residues selected from Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its amino acid side chain; The complestatin analog as described in item 12 or 13 or its pharmaceutically acceptable salt and / or solvate, which contains at least one lipophilic group Φ, for example, exactly one lipophilic group Φ. (Item 15) Formula: Y1-R1-X1-X2-I-[1-Me-Trp]-Q-X6-W-X8-E-H-R-X12-X13-R2-Y2 (Formula XI) represented by, wherein Y1 is hydrogen or acetyl; X1 is Y or F; X6 is E or D; X8 is G or Sar; X13 is T, E or Sar; X2 and X12 are residues whose side chains are linked by a thioether bond; Y2 is NH 2 or OH; R1 is absent or a sequence of 1 to 6 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V or Sar or their corresponding D-forms; R2 is absent or a sequence of 1 to 8 amino acid residues selected from A, E, G, L, K, K * , F, P, S, T, W, Y, R, V, Sar, εLys, γGlu, βAsp or βAla or their corresponding D-forms; or Peg3, or Peg4, or 8-aminooctanoyl or its derivatives; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain; The complestatin analog as described in item 1 or its pharmaceutically acceptable salt and / or solvate, which contains at least one lipophilic group Φ, for example, exactly one lipophilic group Φ. (Item 16) The 13-mer peptide portion (X1~X13) of the complestatin analog is [Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; [Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-T; [Sar]-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-T; [Sar]-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; [Sar]-X2-IWQDWGEHR-X12-T; F-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]; F-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-T; F-X2-I[1-Me-Trp]QDWGEHK-X12-[Sar]; F-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; F-X2-I[1-Me-Trp]QDWGEHR-X12-E; F-X2-I[1-Me-Trp]QDWGEHR-X12-S; F-X2-I[1-Me-Trp]QDWGEHR-X12-T; F-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; F-X2-I[1-Nal]QDWGEHR-X12-T; F-X2-I[2-Nal]QDWGEHR-X12-T; F-X2-IWQDWGEHR-X12-[Sar]; F-X2-IWQDWGEHR-X12-T; I-X2-I[1-Me-Trp]QDW[Sar]AHR-X12-[N-Me-Ile]; I-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; I-X2-I[1-Me-Trp]QDWGEHR-X12-T; I-X2-I[2-Nal]QDWGEHR-X12-[Sar]; I-X2-IWQDWGAHR-X12-E; I-X2-IWQDWGAHR-X12-T; I-X2-IWQDWGAHS-X12-T; I-X2-IWQDWGDHR-X12-T; I-X2-IWQDWGEHR-X12-[Sar]; I-X2-IWQDWGEHR-X12-E; I-X2-IWQDWGEHR-X12-S; I-X2-IWQDWGEHR-X12-T; I-X2-IWQDWGEHS-X12-T; I-X2-IWQDWGKHR-X12-T; I-X2-IWQDWGRHR-X12-T; I-X2-IWQDWGSHR-X12-T; I-X2-IWQEWGEHR-X12-T; I-X2-IWQKWGAHR-X12-T; I-X2-IWQKWGEHR-X12-T; Y-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]; Y-X2-I[1-Me-Trp]QDWGEHR-X12-T; Y-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]; Y-X2-I[2-Nal]QDWGEHR-X12-T; Y-X2-IWQDWGEHR-X12-T; Y-X2-I[1-Me-Trp]QDWGEH[K * -X12-[Sar]; and Y-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-[Sar] having a sequence selected from wherein X2 and X12 are residues whose side chains are linked by a thioether bond; * a Compstatin analog according to any one of items 1 to 15, indicating that the amino acid residue has a lipophilic group Φ covalently attached to its side chain. (Item 17) A Compstatin analog according to any one of items 1 to 16, wherein the side chains of the residues at positions X2 and X12 form a cystathionine (Ctt) bridge or a lanthionine bridge. (Item 18) R1 has a sequence selected from {d}Y, EGSE, AGSE, SASE, EYSE, GSE, ASE, ESSA, KGSA, AKGE, ASGE, ASSE, ASES, GSAE, ESSE, ESGA, SEG, GES, ESS, EGSA, ESE, EGE, ESA, SAE, SGA, YLEA, GSA, KEK, EKG, ES, AE, TE, KE, GE, FE, YE, AS, SE, RS, SR, SA, GE, Y, S and E, a Compstatin analog according to any one of items 1 to 17. (Item 19) A Compstatin analog according to item 18, comprising a lipophilic group Φ covalently attached to the amino acid side chain of R1. (Item 20) R1 has the sequence K * GSA, a Compstatin analog according to item 19. (Item 21) R2 is selected from EGASGSG, EGAGSG, EGASAG, EGAGAG, EGESGSG, EGEGSG, EGESAG, EGEGAG, EK[γGlu]AK, EK[γGlu]A, EGEGG, EGAGG, EGESS, GAESK, EGAK, EGEK, EGG, EGK, EGKK, EGS, EK, EGA, EGAK, EK[γGlu], EK[γGlu]-K, EGE[Peg3], EGE[Peg3]-K, EGE[Peg3][Peg3], EGE[Peg3][Peg3]-K, EGE[Peg3][Peg3][Peg3], EGE[Peg3][Peg3][Peg3]-K, EAE[Peg3][Peg3], EAE[Peg3][Peg3]-K, GESESE, GAESES, EGESES, EGESESK, EGE[Peg3]-ES, EGE[Peg3]-ESK, GESESE, EGE-[8-aminooctanoyl], EGE-[8-aminooctanoyl]-K, EGE-[8-aminooctanoyl]-EK, EGEGGG, EGEGGGK, EK[γGlu]GGG, EK[γGlu]GGGK, EGE-[8-aminooctanoyl]-E, E[Peg3][Peg3], E[Peg3][Peg3]-K, EA[Pe g3][Peg3], EA[Peg3][Peg3]-K, GAES, EYGS, EGYA, EAGS, EAKS, EKSA, ESGA, EGGS, EGG, ESSG, ESAG, GEES, AEES, ESEG, AEGS, ESGS, SEGA, SEG, EGK, ESG, EAG, GAE, EGEA, EGE, EA, E, S, GE, GEK, EG, EA, EKE or EKP, and is a Compstatin analog according to any one of items 1 to 20. (Item 22) The Compstatin analog according to item 21, comprising a lipophilic group Φ covalently attached to the amino acid side chain of R2. (Item 23) R2 is the sequence EK[γGlu]AK * , EGKK * , EK[γGlu]K * , EGE[Peg3]-K * , EGESESK * , EGE[Peg3]-ESK * , EGE-[8-aminooctanoyl]-K * , EGE-[8-aminooctanoyl]-EK * , EGEGGGK * , EK[γGlu]GGGK * , EGE[Peg3][Peg3]-K * , EGE[Peg3][Peg3][Peg3]-K * , EAE[Peg3][Peg3]-K * , E[Peg3][Peg3]-K * , EA[Peg3][Peg3]-K * , GAESK * , EGAK * , EGEK * , EGK * EGE[Peg3]-ESK * , GESESEK * , GEK * or EK * The complestatin analog according to item 22, having (Item 24) IhC(1)IWQDWGAHRA(1)T IhC(1)IWQDWGEHRA(1)T ESSAIhC(1)IWQDWGEHRA(1)T IhC(1)I[1MeTrp]QDWGEHRA(1)T IhC(1)IWQDWGKHRA(1)T IhC(1)IWQDWGSHRA(1)T IhC(1)IWQKWGEHRA(1)T IhC(1)IWQKWGAHRA(1)TGAES YhC(1)IWQDWGEHRA(1)T ESSAYhC(1)IWQDWGEHRA(1)T [Sar]hC(1)IWQDWGEHRA(1)T IhC(1)IWQDWGAHRA(1)E IhC(1)IWQDWGEHRA(1)[Sar] ESSAIhC(1)IWQDWGEHRA(1)TGAES IhC(1)IWQDWGEHRA(1)TGAES IhC(1)IWQEWGEHRA(1)T IhC(1)IWQDWGDHRA(1)T IhC(1)IWQDWGRHRA(1)T IhC(1)IWQDWGAHSA(1)T IhC(1)IWQDWGEHSA(1)T IhC(1)IWQDWGEHRA(1)S IhC(1)IWQDWGEHRA(1)E FhC(1)IWQDWGEHRA(1)T IhC(1)IWQDWGEHRA(1)TEGE IhC(1)IWQDWGEHRA(1)TEA IhC(1)IWQDWGEHRA(1)TE IhC(1)IWQDWGEHRA(1)EGE EGSAIhC(1)IWQDWGEHRA(1)[Sar]E EGSAIhC(1)IWQDWGEHRA(1)T EGEIhC(1)IWQDWGEHRA(1)T ESEIhC(1)IWQDWGEHRA(1)T SEIhC(1)IWQDWGEHRA(1)TEA E IhC(1)IWQDWGEHRA(1)TE E IhC(1)IWQDWGEHRA(1)TEGE EGEIhC(1)IWQDWGEHRA(1)EGE ESEIhC(1)IWQDWGEHRA(1)EGE KEKIhC(1)IWQDWGEHRA(1)TEKE EKGIhC(1)IWQDWGEHRA(1)TEKP IhC(1)IWQDWGEHRA(1)TEGK GSAIhC(1)IWQDWGEHRA(1)[Sar]E SAIhC(1)IWQDWGEHRA(1)[Sar]E SAIhC(1)IWQDWGEHRA(1)TEG FhC(1)IWQDWGEHRA(1)TGAE EGSAIhC(1)IWQDWGEHRA(1)[Sar]EGE EGSAFhC(1)IWQDWGEHRA(1)[Sar]E ESSAIhC(1)IWQDWGAHRA(1)T IhC(1)IWQDWGAHRA(1)TGAES {d}YIhC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)-[N-Me-Ile] EGSAIhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIhC(1)I[2-Nal]QDWGEHRA(1)[Sar]E IhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES IhC(1)I[2-Nal]QDWGEHRA(1)TGAES EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIhC(1)IWQDWGEHRA(1)TE EGSAFhC(1)I[1-Nal]QDWGEHRA(1)TE EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFhC(1)I[2-Nal]QDWGEHRA(1)TE FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES FhC(1)I[1-Nal]QDWGEHRA(1)TGAES FhC(1)I[2-Nal]QDWGEHRA(1)TGAES YhC(1)I[2-Nal]QDWGEHRA(1)TGAES YhC(1)IWQDWGEHRA(1)TGAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YhC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS YhC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA EGSAYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES {d}YFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA SEFhC(1)I[1-Me-Trp]QDWGEHRa(1)[Sar]E SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)SEA EFhC(1)I[1-Me-Trp]QDWGEHRA(1)ES SEFhC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA GEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA GE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA SE[Sar]hC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA SE[Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA {d}Y[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA Comprising an array selected from, the side chains of the residues designated as hC(1) and A(1) form cystathionine bridges, the compstatin analog according to item 1. (Item 25) IA(1)IWQDWGAHRhC(1)T IA(1)IWQDWGEHRhC(1)T ESSAIA(1)IWQDWGEHRhC(1)T IA(1)I[1MeTrp]QDWGEHRhC(1)T IA(1)IWQDWGKHRhC(1)T IA(1)IWQDWGSHRhC(1)T IA(1)IWQKWGEHRhC(1)T IA(1)IWQKWGAHRhC(1)TGAES YA(1)IWQDWGEHRhC(1)T ESSAYA(1)IWQDWGEHRhC(1)T [Sar]A(1)IWQDWGEHRhC(1)T IA(1)IWQDWGAHRhC(1)E IA(1)IWQDWGEHRhC(1)[Sar] ESSAIA(1)IWQDWGEHRhC(1)TGAES IA(1)IWQDWGEHRhC(1)TGAES IA(1)IWQEWGEHRhC(1)T IA(1)IWQDWGDHRhC(1)T IA(1)IWQDWGRHRhC(1)T IA(1)IWQDWGAHShC(1)T IA(1)IWQDWGEHShC(1)T IA(1)IWQDWGEHRhC(1)S IA(1)IWQDWGEHRhC(1)E FA(1)IWQDWGEHRhC(1)T IA(1)IWQDWGEHRhC(1)TEGE IA(1)IWQDWGEHRhC(1)TEA IA(1)IWQDWGEHRhC(1)TE IA(1)IWQDWGEHRhC(1)EGE EGSAIA(1)IWQDWGEHRhC(1)[Sar]E EGSAIA(1)IWQDWGEHRhC(1)T EGEIA(1)IWQDWGEHRhC(1)T ESEIA(1)IWQDWGEHRhC(1)T SEIA(1)IWQDWGEHRhC(1)TEA EIA(1)IWQDWGEHRhC(1)TE EIA(1)IWQDWGEHRhC(1)TEGE EGEIA(1)IWQDWGEHRhC(1)EGE ESEIA(1)IWQDWGEHRhC(1)EGE KEKIA(1)IWQDWGEHRhC(1)TEKE EKGIA(1)IWQDWGEHRhC(1)TEKP IA(1)IWQDWGEHRhC(1)TEGK GSAIA(1)IWQDWGEHRhC(1)[Sar]E SAIA(1)IWQDWGEHRhC(1)[Sar]E SAIA(1)IWQDWGEHRhC(1)TEG FA(1)IWQDWGEHRhC(1)TGAE EGSAIA(1)IWQDWGEHRhC(1)[Sar]EGE EGSAFA(1)IWQDWGEHRhC(1)[Sar]E ESSAIA(1)IWQDWGAHRhC(1)T IA(1)IWQDWGAHRhC(1)TGAES {d}YIA(1)I[1-Me-Trp]QDW[Sar]AHRhC(1)-[N-Me-Ile] EGSAIA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAIA(1)I[2-Nal]QDWGEHRhC(1)[Sar]E IA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES IA(1)I[2-Nal]QDWGEHRhC(1)TGAES EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAIA(1)IWQDWGEHRhC(1)TE EGSAFA(1)I[1-Nal]QDWGEHRhC(1)TE EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)TE EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)TE EGSAFA(1)I[2-Nal]QDWGEHRhC(1)TE FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES YA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES FA(1)I[1-Nal]QDWGEHRhC(1)TGAES FA(1)I[2-Nal]QDWGEHRhC(1)TGAES YA(1)I[2-Nal]QDWGEHRhC(1)TGAES YA(1)IWQDWGEHRhC(1)TGAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES YA(1)I[1-Me-Trp]QDWGEHRhC(1)TEAGS YA(1)I[1-Me-Trp]QDWGEHRhC(1)TESGA EGSAYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]E SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES {d}YFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]GAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TEA SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)SEA EFA(1)I[1-Me-Trp]QDWGEHRhC(1)ES SEFA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]EA GEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA GE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA SE[Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA {d}Y[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA Comprising a sequence selected from the following, and the side chains of the residues designated A(1) and hC(1) form cystathionine bridges, the compstatin analog according to item 1. (Item 26) IC(1)IWQDWGAHRA(1)T IC(1)IWQDWGEHRA(1)T ESSAIC(1)IWQDWGEHRA(1)T IC(1)I[1MeTrp]QDWGEHRA(1)T IC(1)IWQDWGKHRA(1)T IC(1)IWQDWGSHRA(1)T IC(1)IWQKWGEHRA(1)T IC(1)IWQKWGAHRA(1)TGAES YC(1)IWQDWGEHRA(1)T ESSAYC(1)IWQDWGEHRA(1)T [Sar]C(1)IWQDWGEHRA(1)T IC(1)IWQDWGAHRA(1)E IC(1)IWQDWGEHRA(1)[Sar] ESSAIC(1)IWQDWGEHRA(1)TGAES IC(1)IWQDWGEHRA(1)TGAES IC(1)IWQEWGEHRA(1)T IC(1)IWQDWGDHRA(1)T IC(1)IWQDWGRHRA(1)T IC(1)IWQDWGAHSA(1)T IC(1)IWQDWGEHSA(1)T IC(1)IWQDWGEHRA(1)S IC(1)IWQDWGEHRA(1)E FC(1)IWQDWGEHRA(1)T IC(1)IWQDWGEHRA(1)TEGE IC(1)IWQDWGEHRA(1)TEA IC(1)IWQDWGEHRA(1)TE IC(1)IWQDWGEHRA(1)EGE EGSAIC(1)IWQDWGEHRA(1)[Sar]E EGSAIC(1)IWQDWGEHRA(1)T EGEIC(1)IWQDWGEHRA(1)T ESEIC(1)IWQDWGEHRA(1)T SEIC(1)IWQDWGEHRA(1)TEA EIC(1)IWQDWGEHRA(1)TE EIC(1)IWQDWGEHRA(1)TEGE EGEIC(1)IWQDWGEHRA(1)EGE ESEIC(1)IWQDWGEHRA(1)EGE KEKIC(1)IWQDWGEHRA(1)TEKE EKGIC(1)IWQDWGEHRA(1)TEKP IC(1)IWQDWGEHRA(1)TEGK GSAIC(1)IWQDWGEHRA(1)[Sar]E SAIC(1)IWQDWGEHRA(1)[Sar]E SAIC(1)IWQDWGEHRA(1)TEG FC(1)IWQDWGEHRA(1)TGAE EGSAIC(1)IWQDWGEHRA(1)[Sar]EGE EGSAFC(1)IWQDWGEHRA(1)[Sar]E ESSAIC(1)IWQDWGAHRA(1)T IC(1)IWQDWGAHRA(1)TGAES {d}YIC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)-[N-Me-Ile] EGSAIC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIC(1)I[2-Nal]QDWGEHRA(1)[Sar]E IC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES IC(1)I[2-Nal]QDWGEHRA(1)TGAES EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIC(1)IWQDWGEHRA(1)TE EGSAFC(1)I[1-Nal]QDWGEHRA(1)TE EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFC(1)I[2-Nal]QDWGEHRA(1)TE FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES FC(1)I[1-Nal]QDWGEHRA(1)TGAES FC(1)I[2-Nal]QDWGEHRA(1)TGAES YC(1)I[2-Nal]QDWGEHRA(1)TGAES YC(1)IWQDWGEHRA(1)TGAES SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS YC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA EGSAYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES {d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAESSEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EASEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EASE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA SEFC(1)I[1-Me-Trp]QDWGEHRA(1)SEA EFC(1)I[1-Me-Trp]QDWGEHRA(1)ES SEFC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA GEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA GE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEASE[Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA{d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA The Compstatin analog according to item 1, comprising a sequence selected from the above, wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge. (Item 27) Ac-IhC(1)IWQDWGAHRA(1)T-NH2 (Analog of Compound 1) Ac-IhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 2) Ac-ESSAIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 3) Ac-IhC(1)I[1-Me-Trp]QDWGEHRA(1)T-NH2 (Analog of Compound 4) Ac-IhC(1)IWQDWGKHRA(1)T-NH2 (Analog of Compound 5) Ac-IhC(1)IWQDWGSHRA(1)T-NH2 (Analog of Compound 6) Ac-IhC(1)IWQKWGEHRA(1)T-NH2 (Analog of Compound 7) Ac-IhC(1)IWQKWGAHRA(1)TGAES-NH2 (Analog of Compound 8) Ac-YhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 9) Ac-ESSAYhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 10) Ac-[Sar]hC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 11) Ac-IhC(1)IWQDWGAHRA(1)E-NH2 (Analog of Compound 12) Ac-IhC(1)IWQDWGEHRA(1)[Sar]-NH2 (Analog of Compound 13) Ac-ESSAIhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 14) Ac-IhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 15) Ac-IhC(1)IWQEWGEHRA(1)T-NH2 (Analog of Compound 16) Ac-IhC(1)IWQDWGDHRA(1)T-NH2 (Analog of Compound 17) Ac-IhC(1)IWQDWGRHRA(1)T-NH2 (Analog of Compound 18) Ac-IhC(1)IWQDWGAHSA(1)T-NH2 (Analog of Compound 19) Ac-IhC(1)IWQDWGEHSA(1)T-NH2 (Analog of Compound 20) Ac-IhC(1)IWQDWGEHRA(1)S-NH2 (Analog of Compound 21) Ac-IhC(1)IWQDWGEHRA(1)E-NH2 (Analog of Compound 22) Ac-FhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 23) Ac-IhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 24) Ac-IhC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 25) Ac-IhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 26) Ac-IhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 29) Ac-EGEIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 30) Ac-ESEIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 31) Ac-SEIhC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 32) Ac-EIhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 33) Ac-EIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIhC(1)IWQDWGEHRA(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIhC(1)IWQDWGEHRA(1)TEKP-NH2 (Analog of Compound 38) Ac-IhC(1)IWQDWGEHRA(1)TEGK-NH2 (Analog of Compound 39) Ac-GSAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 40) Ac-SAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIhC(1)IWQDWGEHRA(1)TEG-NH2 (Analog of Compound 42) Ac-FhC(1)IWQDWGEHRA(1)TGAE-NH2 (Analog of Compound 43) Ac-EGSAIhC(1)IWQDWGEHRA(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 45) Ac-ESSAIhC(1)IWQDWGAHRA(1)T-NH2 (Analog of Compound 46) Ac-IhC(1)IWQDWGAHRA(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIhC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIhC(1)I[2-Nal]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 51) Ac-IhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar] E-NH2 (Analog of Compound 53) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFhC(1)I[1-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFhC(1)I[2-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 60) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 61) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 62) Ac-FhC(1)I[1-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 63) Ac-FhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 64) Ac-YhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 65) Ac-YhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compounds 67 and 151) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS-NH2 (Analog of Compound 68) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E-NH2 (Analog of Compound 70) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 77) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E- NH2 (Analog of Compound 78) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 82) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)SEA-NH2 (Analog of Compound 84) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)ES-NH2 (Analog of Compound 85) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA-NH2 (Analog of Compound 86) Ac-GEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 87) Ac-GE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 88) Ac-SE[Sar]hC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 89) Ac-SE[Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 90) H-{d}Y[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 91) wherein the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge, and it is a complestatin analog as described in Item 1. (Item 28) Ac-IA(1)IWQDWGAHRhC(1)T-NH2 (Analog of Compound 1) Ac-IA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 2) Ac-ESSAIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 3) Ac-IA(1)I[1-Me-Trp]QDWGEHRhC(1)T-NH2 (Analog of Compound 4) Ac-IA(1)IWQDWGKHRhC(1)T-NH2 (Analog of Compound 5) Ac-IA(1)IWQDWGSHRhC(1)T-NH2 (Analog of Compound 6) Ac-IA(1)IWQKWGEHRhC(1)T-NH2 (Analog of Compound 7) Ac-IA(1)IWQKWGAHRhC(1)TGAES-NH2 (Analog of Compound 8) Ac-YA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 9) Ac-ESSAYA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 10) Ac-[Sar]A(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 11) Ac-IA(1)IWQDWGAHRhC(1)E-NH2 (Analog of Compound 12) Ac-IA(1)IWQDWGEHRhC(1)[Sar]-NH2 (Analog of Compound 13) Ac-ESSAIA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 1 4) Ac-IA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 15) Ac-IA(1)IWQEWGEHRhC(1)T-NH2 (Analog of Compound 16) Ac-IA(1)IWQDWGDHRhC(1)T-NH2 (Analog of Compound 17) Ac-IA(1)IWQDWGRHRhC(1)T-NH2 (Analog of Compound 18) Ac-IA(1)IWQDWGAHShC(1)T-NH2 (Analog of Compound 19) Ac-IA(1)IWQDWGEHShC(1)T-NH2 (Analog of Compound 20) Ac-IA(1)IWQDWGEHRhC(1)S-NH2 (Analog of Compound 21) Ac-IA(1)IWQDWGEHRhC(1)E-NH2 (Analog of Compound 22) Ac-FA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 23) Ac-IA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analog of Compound 24) Ac-IA(1)IWQDWGEHRhC(1)TEA-NH2 (Analog of Compound 25) Ac-IA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 26) Ac-IA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 29) Ac-EGEIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 30) Ac-ESEIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 31) Ac-SEIA(1)IWQDWGEHRhC(1)TEA-NH2 (Analog of Compound 32) Ac-EIA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 33), Ac-EIA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIA(1)IWQDWGEHRhC(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIA(1)IWQDWGEHRhC(1)TEKP-NH2 (Analog of Compound 38) Ac-IA(1)IWQDWGEHRhC(1)TEGK-NH2 (Analog of Compound 39) Ac-GSAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 40) Ac-SAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIA(1)IWQDWGEHRhC(1)TEG-NH2 (Analog of Compound 42) Ac-FA(1)IWQDWGEHRhC(1)TGAE-NH2 (Analog of Compound 43) Ac-EGSAIA(1)IWQDWGEHRhC(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Compound Analog of 45) Ac-ESSAIA(1)IWQDWGAHRhC(1)T-NH2 (Analog of Compound 46) Ac-IA(1)IWQDWGAHRhC(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIA(1)I[1-Me-Trp]QDW[Sar]AHRhC(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIA(1)I[2-Nal]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 51) Ac-IA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 53) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFA(1)I[1-Nal]QDWGEHRhC(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFA(1)I[2-Nal]QDWGEHRhC(1)TE-NH2 (Analog of Compound 60) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 61) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 62) Ac-FA(1)I[1-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 63) Ac-FA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 64) Ac-YA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 65) Ac-YA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Compound 151; Analog of Compound 67) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TEAGS-NH2 (Analog of Compound 68) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar] E-NH2 (Analog of Compound 70) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TEA-NH2 (Analog of Compound 77) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 78) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (Analog of Compound 82) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)SEA-NH2 (Analog of Compound 84) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)ES-NH2 (Analog of Compound 85) Ac-SEFA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]EA-NH2 (Analog of Compound 86) Ac-GEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 87) Ac-GE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (Analog of Compound 88) Ac-SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA-NH2 (Analog of Compound 89) Ac-SE[Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (analog of compound 90) H-{d}Y[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (analog of compound 91) which is a compstatin analog according to item 1, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge. (Item 29) Ac-IC(1)IWQDWGAHRA(1)T-NH2 (analog of compound 1) Ac-IC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 2) Ac-ESSAIC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 3) Ac-IC(1)I[1-Me-Trp]QDWGEHRA(1)T-NH2 (analog of compound 4 ) Ac-IC(1)IWQDWGKHRA(1)T-NH2 (analog of compound 5) Ac-IC(1)IWQDWGSHRA(1)T-NH2 (analog of compound 6) Ac-IC(1)IWQKWGEHRA(1)T-NH2 (analog of compound 7) Ac-IC(1)IWQKWGAHRA(1)TGAES-NH2 (analog of compound 8) Ac-YC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 9) Ac-ESSAYC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 10) Ac-[Sar]C(1)IWQDWGEHRA(1)T-NH2 (analog of compound 11) Ac-IC(1)IWQDWGAHRA(1)E-NH2 (analog of compound 12) Ac-IC(1)IWQDWGEHRA(1)[Sar]-NH2 (analog of compound 13) Ac-ESSAIC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 14) Ac-IC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 15) Ac-IC(1)IWQEWGEHRA(1)T-NH2 (analog of compound 16) Ac-IC(1)IWQDWGDHRA(1)T-NH2 (analog of compound 17) Ac-IC(1)IWQDWGRHRA(1)T-NH2 (analog of compound 18) Ac-IC(1)IWQDWGAHSA(1)T-NH2 (analog of compound 19) Ac-IC(1)IWQDWGEHSA(1)T-NH2 (analog of compound 20) Ac-IC(1)IWQDWGEHRA(1)S-NH2 (analog of compound 21) Ac-IC(1)IWQDWGEHRA(1)E-NH2 (Analog of Compound 22) Ac-FC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 23) Ac-IC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 24); Ac-IC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 25) Ac-IC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 26) Ac-IC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 29) Ac-EGEIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 30); Ac-ESEIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 31); Ac-SEIC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 32) Ac-EIC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 33) Ac-EIC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIC(1)IWQDWGEHRA(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIC(1)IWQDWGEHRA(1)TEKP-NH2 (Analog of Compound 38) Ac-IC(1)IWQDWGEHRA(1)TEGK-NH2 (Analog of Compound 39); Ac-GSAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 40 of) Ac-SAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIC(1)IWQDWGEHRA(1)TEG-NH2 (Analog of Compound 42) Ac-FC(1)IWQDWGEHRA(1)TGAE-NH2 (Analog of Compound 43); Ac-EGSAIC(1)IWQDWGEHRA(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 45) Ac-ESSAIC(1)IWQDWGAHRA(1)T-NH2 (Analog of Compound 46) Ac-IC(1)IWQDWGAHRA(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIC(1)I[2-Nal]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 51) Ac-IC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 53) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFC(1)I[1-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFC(1)I[2-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 60) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 61) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 62) Ac-FC(1)I[1-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 63) Ac-FC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 64) Ac-YC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 65) Ac-YC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compounds 67 and 151) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS-NH2 (Analog of Compound 68) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E-NH2 (Analog of Compound 70) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 77) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 78) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 82) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)SEA-NH2 (Analog of Compound 84) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)ES-NH2 (Analog of Compound 85) Ac-SEFC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA-NH2 (Analog of Compound 86) Ac-GEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 87) Ac-GE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 88) Ac-SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 89) Ac-SE[Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 90) H-{d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 91) which are the Compstatin analogs described in Item 1, wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge. (Item 30) [K * GSAIhC(1)IWQDWGEHRA(1)TEGE (Analog of Compound 100) ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 113) EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * (Analogs of Compounds 134 and 161) EGSAIhC(1)IWQDWGEHRA(1)TEG[K * (Analog of Compound 101) EGSAYhC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E (Analog of Compound 103) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * (Analog of Compound 104) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 109) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * (Analog of Compound 110) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * (Analogs of Compounds 111 and 159) FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 102) IhC(1)IWQDWGEHRA(1)TEG-[K * (Analog of Compound 92) IhC(1)IWQDWGEHRA(1)TEGE-[K * (Analog of Compound 94) SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * (Analog of Compound 105) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compounds 119 and 154) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 152; Analog of Compounds 123 and 146) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * (Analog of Compound 129) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * (Analog of Compound 138) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of Compound 140) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 127 and 160) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * (Analog of Compound 139) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * (Analog of Compound 132) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-[K * (Analog of Compound 136) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-[K * (Analog of Compound 137) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * (Analog of Compound 130) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-[K * (Analog of Compound 165; Analog of Compounds 142, 148, and 163) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-[K * (Analog of Compounds 126 and 156) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * (Analog of Compound 133) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 135) SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 120) SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 167; Compounds 124 and 153) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 112) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 117) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 114) SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * (Analog of Compound 121) SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 122) SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 125) EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E (Analog of Compound 107) ESSAIhC(1)IWQDWGEHRA(1)TEGE (Analog of Compound 99) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of Compound 143) SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * (Analog of Compound 164; Compounds 144, 147, and 162) EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of Compound 145) GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * (Analog of Compound 149) SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * (Compound 166; Analogue of Compound 150) GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analogue of Compound 155) EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analogue of Compound 158) A statin analogue according to item 1, comprising a sequence selected from the following, wherein the side chains of the residues designated hC(1) and A(1) form a cystathionine bridge. (Item 31) [K * GSAIA(1)IWQDWGEHRhC(1)TEGE (Analogue of Compound 100) ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analogue of Compound 113) EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-[K * (Compound 161; Analogue of Compound 134) EGSAIA(1)IWQDWGEHRhC(1)TEG[K * (Analogue of Compound 101) EGSAYA(1)I[1-Me-Trp]QDWGEH[K * hC(1)[Sar]E (Analogue of Compound 103) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-[K * (Analogue of Compound 104) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analogue of Compound 109) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-[K * (Analogue of Compound 110) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]-[K * (Compound 159; Analogue of Compound 111) FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * (Analogue of Compound 102) IA(1)IWQDWGEHRhC(1)TEG-[K * (Analogue of Compound 92) IA(1)IWQDWGEHRhC(1)TEGE-[K * (Analogue of Compound 94) SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-[K * (Analogue of Compound 105) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * (Compound 154; Analogue of Compound 119) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K* (Compound 146; analog of Compounds 123 and 152) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-[K * (Analog of Compound 129) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-[K * (Analog of Compound 138) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * (Analog of Compound 140) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 160; analog of Compound 127) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-[K * (Analog of Compound 139) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]GGG-[K * (Analog of Compound 132) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-[K * (Analog of Compound 136) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]E-[K * (Analog of Compound 137) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-[K * (Compound 157; analog of Compound 130) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-[K * (Compounds 148 and 163; analogs of Compounds 142 and 165) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3][Peg3]-[K * (Compound 156; analog of Compound 126) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K * (Analog of Compound 133) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * (Analog of Compound 135) SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * (Analog of Compound 120) SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 153; Analogue of Compounds 124 and 167) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * (Analogue of Compound 112) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Analogue of Compound 117) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analogue of Compound 114) SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K *(Analogue of Compound 121) SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * (Analogue of Compound 122) SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Analogue of Compound 125) EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E(Analogue of Compound 107) ESSAIA(1)IWQDWGEHRhC(1)TEGE(Analogue of Compound 99) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analogue of Compound 143) SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K * (Analogues of Compounds 147 and 162; Analogues of Compounds 144 and 164) EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * (Analogue of Compound 145) GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K * (Compound 149) SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-[K * (Compound 150; Analogue of Compound 166) GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * (Compound 155) EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * (Compound 158) comprising an array selected from, and the side chains of the residues designated A(1) and hC(1) form a cystathionine bridge, the compstatin analog according to item 1. (Item 32) [K * GSAIC(1)IWQDWGEHRA(1)TEGE (analog of compound 100) ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (analog of compound 113) EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * (analogs of compounds 134, 161) EGSAIC(1)IWQDWGEHRA(1)TEG[K * (analog of compound 101) EGSAYC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E (analog of compound 103) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * (analog of compound 104) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE- [K * (analog of compound 109) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K* (analog of compound 110) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * (analogs of compounds 111, 159) FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (analog of compound 102) IC(1)IWQDWGEHRA(1)TEG-[K * (analog of compound 92) IC(1)IWQDWGEHRA(1)TEGE-[K * (analog of compound 94) SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * (analog of compound 105) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (analog of compound 119) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (analogs of compounds 123, 146 and 152) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * (analog of compound 129) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * (analog of compound 138) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of Compound 140) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 127 and 160) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * (Analog of Compound 139) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * (Analog of Compound 132) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]-[K * (Analog of Compound 136) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]E-[K * (Analog of Compound 137) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * (Analog of Compounds 130 and 157) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-[K * (Analog of Compounds 142, 148, 163, and 165) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-[K * (Analog of Compounds 126 and 156) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K *(Analog of Compound 133) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 135) SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 120) SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 124, 153, and 167) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 112) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 117) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 114) SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * (Analog of Compound 121) SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 122) SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 125) EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E (Analog of Compound 107) ESSAIC(1)IWQDWGEHRA(1)TEGE (Analog of Compound 99) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of Compound 143) SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * (Analogs of Compounds 144, 147, 162, 164) EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of Compound 145) GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * (Analog of Compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * (Analogs of Compounds 150, 166) GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of Compound 155) EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of Compound 158) A Compstatin analog as described in Item 1, comprising a sequence selected from the above, wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge. (Item 33) Ac-[K * GSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 100) Ac-ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analog of Compound 113) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * -NH2 (Analogs of Compounds 134, 161) Ac-EGSAIhC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (Analog of Compound 101) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * -NH2 (Analog of Compound 104) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analog of Compound 109) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * -NH2 (Analog of Compound 110) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * -NH2 (Analog of Compounds 111 and 159) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analog of Compound 102) Ac-IhC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (Analog of Compounds 92, 93, 95, 96, 98) Ac-IhC(1)IWQDWGEHRA(1)TEGE-[K * -NH2 (Analog of Compound 9 4, 97) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * -NH2 (Analog of Compounds 105 and 106) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compounds 119 and 154) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 152, 123, and 146) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * -NH2 (Analog of Compound 129) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * -NH2 (Analog of Compound 138) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analog of Compound 140) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 127, 128, and 160) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * -NH2 (Analogues of Compounds 139 and 141) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * -NH2 (Analogue of Compound 132) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]-[K * -NH2 (Analogue of Compound 136) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]E-[K * -NH2 (Analogue of Compound 137) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * -NH2 (Analogues of Compounds 130, 131, and 157) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -NH2 (Compound 165; Analogues of Compounds 142 and 148) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -OH (Analogue of Compound 163) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3][Peg3]-[K * -NH2 (Analogues of Compounds 126 and 156) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * -NH2 (Analogue of Compound 133) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analogue of Compound 135) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogue of Compound 120) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Compound 167; Analogues of Compounds 124 and 153) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogues of Compounds 112 and 118) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 117) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analogues of Compounds 114, 115, 116) Ac-SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * -NH2 (Analogue of Compound 121) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogue of Compound 122) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 125) Φ-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analogues of Compounds 107, 108) Φ-ESSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analogue of Compound 99) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (Analogue of Compound 143) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K *-NH2 (Analogues of Compound 164; Compounds 144 and 147) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -OH (Analogue of Compound 162) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 145) Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 149) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analogues of Compound 166; Compound 150) Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analogue of Compound 155) Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 158) A compstatin analog according to item 30, comprising an array selected from, and the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge. (Item 34) Ac-[K * GSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (analog of compound 100) Ac-ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (analog of compound 113) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-[K * -NH2 (analog of compound 134) Ac-EGSAIA(1)IWQDWGEHRhC(1)TEG-[K * -NH2 (analog of compound 101) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEH[K * hC(1)[Sar]E-NH2 (analog of compound 103) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-[K * -NH2 (analog of compound 104) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (analog of compound 109) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-[K * -NH2 (analog of compound 110) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]-[K * -NH2 (compound 159; analog of compound 111) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * -NH2 (analog of compound 102) Ac-IA(1)IWQDWGEHRhC(1)TEG-[K * -NH2 (analog of compound 92 , 93, 95, 96, 98) Ac-IA(1)IWQDWGEHRhC(1)TEGE-[K * -NH2 (analog of compound 94, 97) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-[K * -NH2 (analog of compound 105, 106) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * -NH2 (compound 154; analog of compound 119) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (compound 146; analog of compound 123, 152) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-[K * -NH2 (analog of compound 129) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-[K * -NH2 (analog of compound 138) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compound 140) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (compound 160; analogs of compounds 127 and 128) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-[K * -NH2 (analogs of compounds 139 and 141) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]GGG-[K * -NH2 (analog of compound 132) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-[K * -NH2 (analog of compound 136) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]E-[K * -NH2 (analog of compound 137) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-[K * -NH2 (compound 157; analogs of compounds 130 and 131) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3]ES-[K * -NH2 (compound 148; analogs of compounds 142 and 165) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3]ES-[K * -OH (compound 163) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3][Peg3]-[K * -NH2 (compound 165; analog of compound 126) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K * -NH2 (analog of compound 133) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * -NH2 (analog of compound 135) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * -NH2 (Analog of Compound 120) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K *-NH2 (Compound 153; Analog of Compounds 124, 167) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * -NH2 (Analog of Compounds 112, 118) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compound 117) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (Analog of Compounds 114, 115, 116) Ac-SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K * -NH2 (Analog of Compound 121) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * -NH2 (Analog of Compound 122) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compound 125) Φ-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compounds 107, 108) Φ-ESSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analog of Compound 99) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (Analog of Compound 143) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K * -NH2 (Compound 147; Analog of Compounds 144, 164) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K * -OH (Compound 162) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (Analog of Compound 145) Ac-GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (Compound 149) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Compound 150; Analogue of Compound 166) Ac-GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Compound 155) Ac-EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (Compound 158) A Compstatin analogue according to item 31, comprising a sequence selected from the above, wherein the side chains of the residues designated A(1) and hC(1) form a cystathionine bridge. (Item 35) Ac-[K * GSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (Analogue of Compound 100) Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analogue of Compound 113) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * -NH2 (Analogue of Compound 134) Ac-EGSAIC(1)IWQDWGEHRA(1)TEG-[K* -NH2 (Analogue of Compound 101) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E-NH2 (Analogue of Compound 103) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * -NH2 (Analogue of Compound 104) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analogue of Compound 109) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * -NH2 (Analogue of Compound 110) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * -NH2 (Analogues of Compounds 111 and 159) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * ] -NH2 (Analogue of Compound 102) Ac-IC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (Analogues of Compounds 92, 93, 95, 96, 98) Ac-IC(1)IWQDWGEHRA(1)TEGE-[K * -NH2 (Analogues of Compounds 94 and 97) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * -NH2 (Analogues of Compounds 105 and 106) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogues of Compounds 119 and 154) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogues of Compounds 123, 146 and 152) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * -NH2 (Analogue of Compound 129) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * -NH2 (Analogue of Compound 138) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analogue of Compound 140) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogues of Compounds 127, 128 and 160) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * -NH2 (Analogues of Compounds 139 and 141) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * -NH2 (Analogue of Compound 132) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]-[K * -NH2 (Analogue of Compound 136) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]E-[K * -NH2 (Analogue of Compound 137) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * -NH2 (Analogues of Compounds 130, 131 and 157) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -NH2 (Analogues of Compounds 142, 148 and 165) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -OH (Analog of Compound 163) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 126 and 156) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * -NH2 (Analog of Compound 133) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analog of Compound 135) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compound 120) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 124, 153, and 167) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compounds 112 and 118) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compound 117) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analog of Compounds 114, 115, and 116) Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * -NH2 (Analog of Compound 121) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compound 122) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compound 125) Φ-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compounds 107 and 108) Φ-ESSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 99) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (Analog of Compound 143) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -NH2 (analog of compounds 144, 147, 164) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -OH (analog of compound 62) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K* -NH2 (analog of compound 145) Ac-GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (analog of compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compounds 150, 166) Ac-GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (compound 155) Ac-EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (compound 158) The Compstatin analog according to item 32, comprising a sequence selected from the above, wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge. (Item 36) Comprising a lipophilic group Φ, wherein the lipophilic group Φ is Z 1 - or Z 1 -Z 2 -; Z 1 is A-C 12~22 alkylene-(CO)-; wherein A is H or -COOH, the alkylene can be linear or branched, and can be saturated or unsaturated, and optionally can incorporate a phenylene moiety or a piperazinylene moiety within its entire length; and Z 2 is a sequence of 1 to 6 residues of a compound selected from γ-Glu, E, K, Orn, S, T, A, β-Ala, G, P, V, L, I, Y, Q, N, Dapa, Gaba or Aib or their corresponding D-forms, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl and 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) and (piperazin-1-yl)-carboxylic acid, the Compstatin analog according to any one of items 1 to 8, 12 to 23 or 30 to 35. (Item 37) Z 1 is dodecanoyl, i.e., H-(CH 2 ) 11 -(CO)-; Myristoyl, i.e., H-(CH 2 ) 13 -(CO)-; Palmitoyl, i.e., H-(CH 2 ) 15 -(CO)-; 13-Carboxytridecanoyl, i.e., HOOC-(CH 2 ) 12 -(CO)-; 15-Carboxypentadecanoyl, i.e., HOOC-(CH 2 ) 14 -(CO)-; 17-Carboxyheptadecanoyl, i.e., HOOC-(CH 2 ) 16 -(CO)-; 19-Carboxynonadecanoyl, i.e., HOOC-(CH 2) 18 -(CO)-; or 21-Carboxyheneicosanoyl, i.e., HOOC-(CH 2 ) 20 -(CO)-, a Compstatin analog as described in item 36. (Item 38) Z 2 is [γGlu]; [γGlu][Peg3][Peg3]-; [(Piperazin-1-yl)-acetyl][Peg3][Peg3]; [γGlu]G[γGlu]; [γGlu]K[γGlu]; [γGlu]KG[γGlu]; or [γGlu]G[Peg3][γGlu][Peg3] , a Compstatin analog as described in item 36 or 37. (Item 39) Z 1 - or Z 1 -Z 2 - is 15-Carboxy-pentadecanoyl; 15-Carboxy-pentadecanoyl[γGlu]-, 15-Carboxy-pentadecanoyl[γGlu][Peg3][Peg3]-; 19-Carboxy-nonadecanoyl[γGlu][Peg3][Peg3]-; 15-Carboxy-pentadecanoyl-[(piperazin-1-yl)-acetyl][Peg3][Peg3]; 17-Carboxy-heptadecanoyl[γGlu]G[γGlu]; 17-Carboxy-heptadecanoyl[γGlu]K[γGlu]; 17-Carboxy-heptadecanoyl[γGlu]KG[γGlu]; 17-Carboxy-heptadecanoyl[γGlu]G[Peg3][γGlu]-[Peg3]; 15-Carboxy-hexadecanoyl[γGlu]G[γGlu]; 17-Carboxy-heptadecanoyl; 17-Carboxy-heptadecanoyl[γGlu]; 19-Carboxy-nonadecanoyl[γGlu]G[γGlu]; and 17-Carboxy-heptadecanoyl[γGlu][Peg3][Peg3] , a Compstatin analog as described in any one of items 36 to 38. (Item 40) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([15-Carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 92) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 93) Ac-IhC(1)IWQDWGEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 94) Ac-IhC(1)IWQDWGEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (Analog of Compound 95) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 96 ) Ac-IhC(1)IWQDWGEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 97) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 98)[15-carboxy-pentadecanoyl]-ESSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 99) Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 100) Ac-EGSAIhC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (Analog of Compound 101) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 102) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 104) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (analog of compound 105) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 106) [15-carboxy-pentadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analog of compound 107) [17-carboxy-heptadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analog of compound 108) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 109) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 110) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2 (analogs of compounds 111, 159) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 112) Ac-ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 113) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 114) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 115) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2 (Analog of Compound 116) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 117) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 118) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compounds 119 and 154) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 120) Ac-SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 121) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 122) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 152; analog of Compounds 123 and 146) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 167; analog of Compounds 124, 153) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 125) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (analog of Compounds 126, 156) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compounds 127, 160) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 128) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of Compound 129) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of Compounds 130, 157) Ac-SEFhC(1)I[1-Me-Trp]-QDWGEHRA(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-N H2 (analog of Compound 131) Ac-SEFhC(1)I[1-Me-Trp]-QDWGEHRA(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analogue of compound 132) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analogue of compound 133) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogues of compounds 134, 161) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 135) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analogue of compound 136) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2 (analogue of compound 137) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 138) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 139) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 140) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analogue of compound 141) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (Compound 165; analog of Compounds 142 and 148) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (analog of Compound 163) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 143) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 164; analog of Compounds 144 and 147) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH (analog of Compound 162) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 145) Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sa r]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 149) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 166; analog of Compound 150) Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 155) Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(Analog of Compound 158) It is a compstatin analog as described in Item 1, where the side chains of the residues called hC(1) and A(1) form a cystathionine bridge. (Item 41) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2(Analog of Compound 92) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2(Analog of Compound 93) Ac-IA(1)IWQDWGEHRhC(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2(Analog of Compound 94) Ac-IA(1)IWQDWGEHRhC(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2(Analog of Compound 95) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2(Analog of Compound 96) Ac-IA(1)IWQDWGEHRhC(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2(Analog of Compound 97) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2(Analog of Compound 98)[15-carboxy-pentadecanoyl]-ESSAIA(1)IWQDWGEHRhC(1)TEGE-NH2(Analog of Compound 99) Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIA(1)IWQDWGEHRhC(1)TEGE-NH2(Analog of Compound 100) Ac-EGSAIA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2(Analog of Compound 101) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 102) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-hC(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 104) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E- K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (Analog of Compound 105) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 106) [15-carboxy-pentadecanoyl]-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 107) [17-carboxy-heptadecanoyl]-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 108) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 109) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 110) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2 (Compound 159; Analog of Compound 111) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 112) Ac-ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 113) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 114) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 115) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2 (analog of compound 116) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 117) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 118) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2 (compound 154; analog of compound 119) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 120) Ac-SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 121) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γG lu][Peg3])-NH2 (analog of compound 122) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (compound 146; analog of compounds 123 and 152) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compounds 153, 124, and 167) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 125) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (compound 156; analog of compound 126) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (compound 160; analog of compound 127) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 128) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 129) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 157; analog of Compound 130) Ac-SEFA(1)I[1-Me-Trp]-QDWGEHRhC(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 131) Ac-SEFA(1)I[1-Me-Trp]-QDWGEHRhC(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 132) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 133) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 161; analog of Compound 134) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 135) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 136) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2 (analog of Compound 137) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of Compound 138) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG ESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of Compound 139) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 140) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analog of compound 141) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (compound 148; analog of compounds 142, 165) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (compound 163) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 143) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (compound 147; analog of compounds 144, 164) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH (compound 162) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 145) Ac-GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (compound 149) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 150; Analogue of Compound 166) Ac-GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 155) Ac-EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 158) which are compstatin analogues according to Item 1, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge. (Item 42) Ac-IC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (Analogue of Compound 92) Ac-IC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analogue of Compound 93) Ac-IC(1)IWQDWGEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analogue of Compound 94) Ac-IC(1)IWQDWGEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])- NH2 (Analogue of Compound 95) Ac-IC(1)IWQDWGEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analogue of Compound 96) Ac-IC(1)IWQDWGEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analogue of Compound 97) Ac-IC(1)IWQDWGEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analogue of Compound 98) [15-carboxy-pentadecanoyl]-ESSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (Analogue of Compound 99) Ac-[K([15-carboxypentadecanoyl][γGlu][Peg3][Peg3])]-GSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (analogue of compound 100) Ac-EGSAIC(1)IWQDWGEHRA(1)TEG-K([15-carboxypentadecanoyl][γGlu])-NH2 (analogue of compound 101) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxypentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 102) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH-K([15-carboxypentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (analogue of compound 103) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-K([15-carboxypentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 104) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxyheptadecanoyl][γGlu]KG[γGlu])-NH2 (analogue of compound 105) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxyheptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 106) [15-carboxypentadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analogue of compound 107) [17-carboxyheptadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analogue of compound 108) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxyheptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 109) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxyheptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 110) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2(Analog of Compound 111, 159) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 112) Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 113) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE -K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 114) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 115) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2(Analog of Compound 116) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 117) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(Analog of Compound 118) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2(Analog of Compound 119, 154) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(Analog of Compound 120) Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 121) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 122) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compounds 123, 146 and 152) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compounds 124, 153, 167) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 125) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (analog of compounds 126, 156) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 127) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 128) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 129) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compounds 130 and 157) Ac-SEFC(1)I[1-Me-Trp]-QDWGEHRA(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 131) Ac-SEFC(1)I[1-Me-Trp]-QDWGEHRA(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 132) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 133) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compounds 134 and 161) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 135) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 136) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2 (Analog of Compound 137) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compound 138) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compound 139) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compound 140) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (Analog of Compound 141) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (Analogs of Compounds 142, 148, 165) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (Analog of Compound 163) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 143) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analogs of Compounds 144, 147, 164) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH (Analog of Compound 162) Ac-EF[C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G [γGlu])-NH2 (Analog of Compound 145) Ac-GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compounds 150 and 166) Ac-GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 155) Ac-EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 158) which is a compstatin analog according to Item 1, wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge. (Item 43) A composition comprising a compstatin analog according to any one of Items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, in a mixture with a carrier. (Item 44) The composition according to Item 43, which is a pharmaceutical composition, and wherein the carrier is a pharmaceutically acceptable carrier. (Item 45) A pharmaceutical composition comprising a compstatin analog according to any one of Items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, in a mixture with a pharmaceutically acceptable carrier, excipient or vehicle. (Item 46) A compstatin analog according to any one of Items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy. (Item 47) A compstatin analog according to any one of Items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of inhibiting complement activation. (Item 48) The inhibition of complement activation comprises one or more biological activities selected from (1) inhibition of binding to C3 protein, (2) inhibition of binding to C3b protein, and / or (3) inhibition of cleavage of native C3 by C3 convertase. A compstatin analog or a pharmaceutically acceptable salt or solvate thereof for use according to Item 47. (Item 49) For use in a method of preventing or treating age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer, and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis, and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis, or antiphospholipid syndrome, a Compstatin analog according to any one of items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof. (Item 50) For use in a method of inhibiting complement activation occurring during cell transplantation or organ transplantation, an item 1 to 42 of a Compstatin analog according to any one of the described, or a pharmaceutically acceptable salt or solvate thereof. (Item 51) A method of inhibiting complement activation for treating a subject in need thereof, the method comprising administering to the subject a Compstatin analog according to any one of items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, thereby inhibiting complement activation in the subject. (Item 52) The subject has age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer, and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis, and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis, or antiphospholipid syndrome, and the method comprises administering to the subject a compstatin analog according to any one of items 1 to 30, the method according to item 51. (Item 53) An ex vivo method of inhibiting complement activation in an extracorporeal shunt of a physiological fluid, the method comprising contacting the physiological fluid with a compstatin analog according to any one of items 1 to 42 or a pharmaceutically acceptable salt or solvate thereof, thereby inhibiting complement activation. (Item 54) Use of a compstatin analog according to any one of items 1 to 42 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for inhibiting complement activation. (Item 55) Use of a Compstatin analog according to any one of items 1 to 42, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis or antiphospholipid syndrome.

Brief Description of the Drawings

[0095]

Figure 1-1

Figure 1-2

Figure 1-3

Figure 1-4

Figure 2

Figure 3

Mode for Carrying Out the Invention

[0096] As used herein, "and / or" is to be taken as a specific disclosure of each of two specified components or constituents, either or both of which may be present. For example, "A and / or B" is to be taken as a specific disclosure of (i) A, (ii) B, and (iii) both A and B, as if each were individually recited herein.

[0097] Unless the context states otherwise, the descriptions and definitions of the configurations described above are not limited to any particular embodiment or aspect of the invention, but apply equally to all embodiments and aspects described.

[0098] Various publications, including patents, published applications, technical papers, and academic papers, are cited throughout this specification. Each of these cited publications is hereby incorporated by reference in its entirety.

[0099] Unless defined otherwise herein, scientific and technical terms used in this application shall have the meanings commonly understood by one of ordinary skill in the art. Generally, the nomenclature and techniques associated with chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry as described herein are well known and commonly used in the art.

[0100] Each embodiment of the invention described herein may be taken alone or in combination with one or more other embodiments of the invention.

[0101] Unless otherwise specified, the following definitions apply to the specific terms used herein.

[0102] Definitions Throughout this specification, the term "comprise" and its grammatical variations such as "comprises" or "comprising" are meant to include the recited integer or component or group of integers or components, but not to the exclusion of any other integer or component or group of integers or components.

[0103] The singular forms "a", "an" and "the" include the plural unless the context clearly dictates otherwise.

[0104] The term "including" is used to mean "including but not limited to". "Including" and "including but not limited to" may be used interchangeably.

[0105] The terms "patient", "subject" and "individual" may be used interchangeably. The subject may be a mammal, including a human or non-human mammal such as a non-human primate (e.g., ape, Old World monkey or New World monkey), livestock (e.g., cow or pig), pet (e.g., dog or cat) or laboratory animal such as a rodent (e.g., mouse or rat).

[0106] Throughout this specification and the claims, the conventional three-letter and one-letter codes for the naturally occurring amino acids, namely A (Ala), G (Gly), L (Leu), I (Ile), V (Val), F (Phe), W (Trp), S (Ser), T (Thr), Y (Tyr), N (Asn), Q (Gln), D (Asp), E (Glu), K (Lys), R (Arg), H (His), M (Met), C (Cys) and P (Pro); and other α-amino acids such as norleucine (Nle), sarcosine (Sar), homocysteine (hCys; hC), α-aminoisobutyric acid (Aib), 2,3-diaminopropanoic acid (Dap), 2,4-diaminobutyric acid (Dab) and 2,5-diaminopentanoic acid (ornithine; Orn), 1-methyl-tryptophan (1-Me-Trp, 1Me-Trp or 1MeTrp), 1-formyl-tryptophan (1-For-Trp or 1For-Trp or 1ForTrp), 1-naphthylalanine (1-Nal or 1Nal), 2-naphthylalanine (2-Nal or 2Nal), 5-methyltryptophan (5-Me-Trp or 5Me-Trp or 5MeTrp), p-benzoyl-phenylalanine (Bpa) 2-indanylglycine (2Igl or 2-Igl) are used. Other α-amino acids, when used in a general formula or sequence in this specification, especially when the remaining formula or sequence is shown using the one-letter code, may be shown within square brackets "[]" (e.g., "[Nle]"). The 20 "naturally occurring" amino acids described above are those encoded by the standard genetic code and may also be referred to as "proteinogenic" amino acids.

[0107] Gamma-Glu and beta-Asp (also referred to as γGlu(γ-Glu) and βAsp(β-Asp)) (or isoGlu and isoAsp) each refer to glutamate or aspartate that participates in a peptide bond via a γ- or β-carboxylic acid (usually regarded as a side-chain carboxyl group) rather than the conventional configuration. Similarly, εLys or isoLys refers to lysine that participates in a peptide bond via an epsilon amino group (usually regarded as a side-chain amino group) rather than an alpha amino group.

[0108] Beta Ala (also referred to as β-Ala or βAla) refers to 3-aminopropanoic acid.

[0109] Peg3 refers to the residue of 8-amino-3,6-dioxaoctanoic acid (also known as {2-[2-aminoethoxy]ethoxy}acetic acid), and Peg4 refers to the residue of 11-amino-3,6,9-trioxaundecanoic acid. Also, the Peg3 residue can be represented as [8-amino-3,6-dioxaoctanoyl].

Chemical formula

[0110] Unless otherwise specified, the amino acid residues in the peptides of the present invention are in the L-configuration. However, in some cases, D-configuration amino acids can be incorporated. In this regard, amino acid codes written in lowercase represent the D-configuration of the amino acids. For example, "k" represents the D-configuration of lysine (K), or D-configuration amino acids may be written as (d)X or {d}X, where X is an amino acid. For example, (d)Y or {d}Y represents the D-configuration of tyrosine (Y).

[0111] In the compounds of the present invention, the side chains of the residues at positions X2 and X12 (corresponding to the cysteine residues at positions 2 and 12 of compstatin) are linked by a thioether bond.

[0112] Thus, the side chains of the residues of X2 and X12 can together represent a cystathionine bridge. In relation to the peptides of the invention, the cystathionine bridge can have two orientations:

Chemical formula

Chemical formula

[0113] For ease of reference, it may be convenient to refer to the residues that nominally exist at positions X2 and X12 "before" the formation of the thioether.

[0114] The cystathionine bridge can be considered to consist of the sulfur atom of the homocysteine side chain covalently bonded to the beta-carbon atom (i.e., the side chain carbon atom) of the alanine residue. Thus, the residues of X2 and X12 can be considered to be homocysteine and alanine in either order.

[0115] Alternatively, the cystathionine bridge can be considered to be the product of a condensation reaction between homocysteine and serine that forms a thioether bond. Thus, the residues of X2 and X12 can be considered to be homocysteine and serine in either order.

[0116] Thus, in some embodiments, X2 is homocysteine (hC) and X12 is alanine (A) (represented as cystathionine 1 (Ctt1) or gamma-cystathionine), or X2 is alanine (A) and X12 is homocysteine (hC) (represented as cystathionine 2 (Ctt2) or delta-cystathionine).

[0117] The notation used should not be taken to imply any particular synthetic method.

[0118] Instead, the side chains of the residues of X2 and X12 may together represent a lanthionine (3,3-thiodialanine) bridge.

Chemical formula

[0119] The lanthionine bridge may be considered to consist of the sulfur atom of the cysteine side chain covalently bonded to the beta-carbon atom (i.e., the side chain carbon atom) of the alanine residue. Alternatively, the lanthionine bridge can be considered to be the product of a condensation reaction between cysteine and serine.

[0120] Therefore, it may be convenient to refer to the residues nominally present at X2 and X12 as cysteine and alanine, respectively.

[0121] In connection with the peptides of the present invention, the lanthionine bridge is symmetric and can have only one orientation, so it is not important to consider which residue is present at each position.

[0122] (Alternatively still, since the lanthionine bridge can be considered to be a thioether dimer of cysteine, the residues of X2 and X12 can each be represented as cysteine. However, it will be understood that these residues are linked by a thioether bond rather than a disulfide bond.)

[0123] Therefore, in some embodiments, X2 is homocysteine and X12 is alanine (Ctt1; gamma-cystathionine); X2 is alanine and X12 is homocysteine (Ctt2; delta-cystathionine); or X2 is cysteine and X12 is alanine.

[0124] In addition to compounds having a thioether bond between residues at positions X2 and X12, the examples describe molecules having a peptide backbone sequence and acylation similar to the compounds of the invention, but containing cysteine residues at positions X2 and X12 linked by a disulfide bond.

[0125] In formulas using single-letter amino acid notation herein, residues whose side chains are involved in covalent bonds are indicated by "(1)".

[0126] Thus, for example, the sequence IC(1)IWQDWGAHRC(1)T contains a disulfide bond; the sequence IhC(1)IWQDWGAHRA(1)T contains a Ctt1 (gamma-cystathionine) bridge; the sequence IA(1)IWQDWGAHRhC(1)T contains a Ctt2 (delta-cystathionine) bridge; the sequences IC(1)IWQDWGAHRA(1)T and IA(1)IWQDWGAHRC(1)T both contain a lanthionine bridge and represent the same compound.

[0127] The terminal groups present at the N-terminus and C-terminus of the peptide backbone are referred to as Y1 and Y2, respectively. Thus, Y1 is attached to the nitrogen atom of the N-terminal amino group and Y2 is attached to the carbonyl carbon atom of the C-terminus.

[0128] Y1 = hydrogen (also denoted as "H-" or "Hy-") represents a hydrogen atom corresponding to the presence of a free primary or secondary amino group at the N-terminus. Y1 = acetyl ("Ac") indicates the presence of a secondary acetylamide group at the N-terminus.

[0129] Y2 = "OH" or "NH2" indicates the presence of a carboxy (COOH) group or an amide (CONH2) group at the C-terminus of the molecule.

[0130] Either or both of Y1 and Y2 may alternatively be a lipophilic group Φ. Typically, only one of Y1 or Y2 will be the lipophilic group Φ.

[0131] In some embodiments, regardless of whether the molecule contains a lipophilic group elsewhere, Y2 is NH2 or OH. In some embodiments, Y1 is hydrogen or acetyl, and Y2 is OH or NH2.

[0132] In some embodiments, regardless of whether the molecule contains a lipophilic group elsewhere, Y2 is NH2. In some embodiments, Y1 is hydrogen or acetyl, and Y2 is NH2.

[0133] In some embodiments, regardless of whether the molecule contains a lipophilic group elsewhere, Y2 is NH2 and Y1 is acetyl.

[0134] Various terms related to the methods and other aspects of the present invention are used throughout this specification and the claims. Such terms should be given their ordinary meaning in the art, unless otherwise specified. Other specifically defined terms should be interpreted in accordance with the definitions provided herein. As used herein, the term "about" when referring to measurable values, such as amounts and time periods, means a variation of ±20%, ±10% in some embodiments, ±5% in some embodiments, ±1% in some embodiments, and ±0.1% in some embodiments from the specified value. This is because such variations are appropriate for manufacturing and using the disclosed compounds and compositions.

[0135] As used herein, the term "full-length compstatin" refers to a 27-amino acid peptide having the sequence IC(1)VVQDWGHHRC(1)TAGHMANLTSHASAI, where C(1) represents a cysteine residue linked by a disulfide bond. As described above, a truncated form of full-length compstatin, the tridecapeptide Ile linked by a disulfide bond between the cysteine residues at positions 2 and 12 1 -Cys 2 -Val 3 -Val 4-Gln 5 -Asp 6 -Trp 7 -Gly 8 -His 9 -His 10 -Arg 11 -Cys 12 -Thr 13 -NH2 retains the activity of the full-length peptide. The N-terminal acetylated version of this tridecapeptide is referred to herein as "Ac-compstatin".

[0136] The term "compstatin analog" refers to a modified Ac-compstatin that contains one or more substitutions of natural or non-natural amino acids or amino acid analogs and various modifications within or between various amino acids, as described in more detail herein. A compstatin analog may contain about one, two, three, four, or five amino acid modifications compared to Ac-compstatin. A compstatin analog may contain five, six, seven, or eight or more amino acid modifications compared to Ac-compstatin. A compstatin analog may contain about five, six, seven, or eight amino acid modifications compared to Ac-compstatin.

[0137] The term "analog" is frequently used for the protein or peptide in question prior to undergoing further chemical modification (derivatization), particularly acylation. Products resulting from such chemical modification (derivatization) are sometimes referred to as "derivatives" or "acylated analogs". However, in the context of this application, the term "analog" refers to analogs of Ac-compstatin and (acylated) derivatives of such Ac-compstatin analogs.

[0138] When referring to the position of an amino acid or analog within Ac-compstatin or a compstatin analog, the positions are numbered from 1 (Ile within compstatin) to 13 (Thr within compstatin). For example, the Gly residue occupies the "8th position". "C(1)", used to describe the compstatin analog peptide of the present invention, represents a disulfide bond between each cysteine residue within the compstatin analog.

[0139] The terms "pharmaceutically active" and "biologically active" refer to the ability of the compounds of the invention to bind to C3 or a fragment thereof and inhibit complement activation. The biological activity of the compstatin analogs can be measured by one or more of several assays recognized in the art, as described in more detail herein.

[0140] As used herein, "L-amino acid" refers to either a naturally occurring left-handed alpha-amino acid that is normally present in proteins or an alkyl ester of such an alpha-amino acid. The term "D-amino acid" refers to a right-handed alpha-amino acid. Unless otherwise specified, all amino acids referred to herein are L-amino acids.

[0141] "Hydrophobic" or "nonpolar" are used synonymously herein and refer to either intermolecular or intramolecular interactions that are not characterized by dipoles.

[0142] As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds, where the parent compound is modified by formation of its acidic or basic salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids. Accordingly, the term "acid addition salt" refers to the corresponding salt derivatives of the parent compound prepared by addition of an acid. Pharmaceutically acceptable salts include, for example, conventional salts or quaternary ammonium salts of the parent compound formed from inorganic or organic acids. For example, such conventional salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid; and organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid and isethionic acid, but are not limited thereto. Certain acidic or basic compounds of the invention may exist as zwitterions. All forms of the compounds including the free acid, free base and zwitterions are intended to be within the scope of the invention.

[0143] Compstatin analog Ac-Compstatin (N-terminal acetylated 13 amino acid peptide) is known to bind to C3 and prevent C3 convertase-mediated cleavage. Since its discovery by phage display, modifications to the 13 amino acid Ac-Compstatin sequence have been carried out in an attempt to find analogs with increased biological activity. However, in the core sequence between the two cysteine residues at positions 2 and 12, alanine scanning experiments have previously generated analogs showing only a modest improvement in biological activity, with only a few modifications being tolerated. Modifications include changing the valine at position 4 to tryptophan or a tryptophan analog (which leads to an increase in biological activity) and changing the histidine at position 9 to alanine or an analog thereof.

[0144] In particular, previous attempts to introduce modifications to the valine residue at position 3 and substitute it with glycine, alanine, D-valine or leucine have been shown to lead to a decrease in biological activity. In contrast to these prior art findings, the inventors have surprisingly found that, as shown in the following examples, the change of valine to isoleucine is quite tolerant and results in an improvement in biological activity.

[0145] While not wishing to be bound by any particular theory, the inventors have discussed that this modification can be combined with the introduction of one or more polar or charged amino acids within the core sequence and can be used as an approach to increase the ability of the solubilized compstatin peptide. First, glutamic acid or serine at position 9, when combined with valine 3, led to a decrease in activity as compared to the reference sequence 4W9A. However, when these changes were combined with the introduction of isoleucine at position 3, a surprising increase in biological activity was observed, particularly for the combination of isoleucine at position 3 and glutamic acid at position 9. This observation correlates with an improvement in binding to C3 as measured by surface plasmon resonance (SPR). See Tables 7 and 8.

[0146] In a further series of experiments to confirm these findings, compstatin peptides having glutamic acid at position 9, when combined at position 3 with various substitutions that are normally considered to be "conservative" substitutions to isoleucine, again show that the peptide having isoleucine at position 3 is the most active.

[0147] In summary, these experiments show that substitution of the valine residue at position 3 with isoleucine surprisingly provides a compstatin peptide with increased biological activity and improved binding to C3. Further, the experiments surprisingly demonstrate that these changes can be readily combined with other modifications within the core sequence of compstatin analogs and the addition of N-terminal and C-terminal sequences, for example, to improve the solubility of the compstatin peptide at, for example, higher concentrations.

[0148] In addition, when isoleucine is introduced in place of valine at the 3-position of a compound of a previous art (also referred to as "peptide 14" in this paper: Qu et al., Immunobiology 2013, 281(4):496-505), which is designated as "Cp40", the binding affinity to C3 was increased as measured by SPR.

[0149] In any embodiment, X1 can be Y, I or F. In any embodiment, X4 can be W, V, 1-Nal, 2-Nal or 1-Me-Trp. In any embodiment, X6 can be E or D. In any embodiment, X9 can be A, E, D, K or S. In any embodiment, X13 can be T, S, E, I, Sar, K or G. In any embodiment, X13 can be T, I, S, E, K or Sar. In any embodiment, X13 can be T, S, E or Sar.

[0150] Lipophilic substituent Compstatin analogs can have a lipophilic group designated as Φ.

[0151] The lipophilic group can be covalently attached to the N-terminus and / or C-terminus of the molecule, i.e., Y1 can be Φ (instead of H or Ac), and / or Y2 can be Φ (instead of OH or NH2).

[0152] In addition or alternatively, the lipophilic group can be covalently attached to the side chain of an amino acid residue within the analog. The residue can be part of R1, R2 of the molecule or part of the compstatin analog portion X1-X13.

[0153] The lipophilic group Φ is typically attached via an acyl group. Thus, the modification can be referred to as acylation, but can also be referred to as lipidation.

[0154] The lipophilic group is designated as Z herein 1It is referred to as a long-chain alkylene group derived from a fatty acid and is called a lipophilic substituent. Without wishing to be bound by theory, the lipophilic substituent binds to plasma proteins (e.g., albumin) in the bloodstream and is thought to enhance the half-life of the compounds used in connection with the present invention by shielding the compounds from enzymatic degradation. In addition, the lipophilic substituent can modulate the potency of the compound.

[0155] Z 1 As defined herein, can be directly attached to an amino acid sequence (including the R1 and R2 extensions or as Y1), or via a spacer Z 2 can be attached.

[0156] In other words, Φ is Z 1 - or Z 1 -Z 2 can be.

[0157] When Y1 is Φ, Φ is preferably Z 1 -.

[0158] When the lipophilic group Φ is linked to an amino acid side chain (i.e., when Y1 is hydrogen or Ac), Φ is preferably Z 1 -Z 2 can be.

[0159] In certain embodiments, only one amino acid side chain is conjugated to the lipophilic substituent. In other embodiments, two amino acid side chains are each conjugated to the lipophilic substituent. In further embodiments, three or more amino acid side chains are each conjugated to the lipophilic substituent. When the compound contains two or more lipophilic substituents, these can be the same or different substituents.

[0160] In certain embodiments, only one lipophilic group Φ is present within the molecule.

[0161] The term "conjugated" is used herein to describe the covalent attachment of one distinguishable chemical moiety to another distinguishable chemical moiety and the structural relationship between those moieties. It should not be taken to encompass any particular synthetic method. When present, one or more spacers Z 2 are used to provide a spacing between the compound and the lipophilic substituent Z 1 .

[0162] The lipophilic substituent can be attached to the N-terminal nitrogen or amino acid side chain, or to the spacer via an ester, sulfonyl ester, thioester, amide or sulfonamide. Thus, it will be understood that the lipophilic substituent can contain an acyl group, sulfonyl group, N atom, O atom or S atom that forms part of an ester, sulfonyl ester, thioester, amide or sulfonamide.

[0163] Suitably, the acyl group within the lipophilic substituent forms part of an amide or ester together with the N-terminal nitrogen, or amino acid side chain, or spacer. The lipophilic substituent can contain a hydrocarbon chain having from 10 to 24 carbon (C) atoms, such as from 10 to 22 C atoms, such as from 10 to 20 C atoms. Preferably, the hydrocarbon chain has at least 11 C atoms and preferably has 18 or fewer C atoms. For example, the hydrocarbon chain can contain 12, 13, 14, 15, 16, 17 or 18 carbon atoms. The hydrocarbon chain can be straight-chain or branched and can be saturated or unsaturated.

[0164] The hydrocarbon chain can incorporate a phenylene moiety or a piperazinylene moiety within its total length, as shown, for example, below (wherein --- represents a point of attachment within the chain). These groups should be "counted" as four carbon atoms within the chain length.

Chemical formula

[0165] From the foregoing discussion, it will be understood that the hydrocarbon chain can be substituted with a moiety that forms a bond to the amino acid side chain or spacer, such as an acyl group, a sulfonyl group, an N atom, an O atom, or an S atom. Most preferably, the hydrocarbon chain is substituted with an acyl group, and thus the hydrocarbon chain can be part of an alkanoyl group, such as a dodecanoyl, 2-butyloctanoyl, tetradecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, or eicosanoyl group. Alternatively, the Z 1 group is derived from a long-chain saturated α,ω-dicarboxylic acid of the formula HOOC-(CH2) 12~22 -COOH, preferably a long-chain saturated α,ω-dicarboxylic acid having an even number of carbon atoms in the aliphatic chain.

[0166] In other words, Z 1 can be A-C 12~22 alkylene-(CO)-, where A is H or -COOH, the alkylene can be straight-chain or branched, and can be saturated or unsaturated, and optionally can incorporate a phenylene moiety or a piperazinylene moiety within its entire length.

[0167] For example, Z 1 can be as follows: Dodecanoyl, i.e., H-(CH2) 11 -(CO)-; Tetradecanoyl, i.e., H-(CH2) 13 -(CO)-; Hexadecanoyl, i.e., H-(CH2) 15 -(CO)-; 13-Carboxytridecanoyl, i.e., HOOC-(CH2) 12 -(CO)-; 15-Carboxypentadecanoyl, i.e., HOOC-(CH2) 14 -(CO)-; 17-Carboxyheptadecanoyl, i.e., HOOC-(CH2) 16 -(CO)-; 19-Carboxynonadecanoyl, i.e., HOOC-(CH2) 18 -(CO)-; or 21-Carboxyheneicosanoyl, i.e., HOOC-(CH2) 20 -(CO)-.

[0168] When present, the carboxylic acid may be replaced by a bioisostere, phosphate or sulfonate. Suitable bioisosteres for carboxylic acids are known in the art and include tetrazoles, acylsulfonamides, acylhydroxylamines and squaric acid derivatives.

[0169] As described above, the lipophilic substituent Z 1 is one or more spacers Z 2 It can be conjugated to an amino acid side chain or the N-terminal nitrogen by

[0170] When present, the spacer is attached to the lipophilic substituent and the amino acid side chain or the N-terminal nitrogen. The spacer is attached to the lipophilic substituent and the amino acid side chain independently by an ester, a sulfonyl ester, a thioester, an amide, or a sulfonamide. Thus, the spacer may comprise two moieties independently selected from acyl, sulfonyl, an N atom, an O atom, or an S atom. The spacer may be a linear C 1~10 Hydrocarbon chains, more preferably linear C 1~5 The spacer may further comprise a C 1~6 Alkyl, C 1~6 Alkylamines, C 1~6 Alkyl hydroxy and C 1~6 It may be substituted with one or more substituents selected from alkyl, carboxy.

[0171] The spacer can be, for example, a residue of any amino acid, whether naturally occurring or non-natural. For example, the spacer can be a residue of Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, Glu, Asp, γ-Glu, β-Asp, ε-Lys, Asp, Ser, Thr, Dapa, Gaba, Aib, β-Ala (i.e., 3-aminopropanoyl), 4-aminobutanoyl, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoyl. In certain embodiments, the spacer is a residue of Glu, γ-Glu, ε-Lys, β-Ala (i.e., 3-aminopropanoyl), 4-aminobutanoyl, 8-aminooctanoyl or 8-amino-3,6-dioxaoctanoyl (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) or (piperazin-1-yl)-carboxylic acid. In the present invention, γGlu and isoGlu are used interchangeably.

[0172] Z 2 is suitably a sequence of 1 to 6 residues of a compound selected from γGlu, βAsp, D, E, K, Orn, S, T, A, βAla, G, P, V, L, I, Y, Q, N, Dapa, Gaba or Aib or their corresponding D-forms, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl and 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) or (piperazin-1-yl)-carboxylic acid.

[0173] For example, Z 2 can be or can include the following: [γGlu]; [γGlu][Peg3][Peg3]-; [(piperazin-1-yl)-acetyl][Peg3][Peg3]; [γGlu]-G-[γGlu]; [γGlu]-K-[γGlu]; [γGlu]-KG-[γGlu]; or [γGlu]-G-[Peg3][γGlu][Peg3].

[0174] Z 2 is suitably linked by amide bonds on both sides. Other suitable linkages can be used for the same degree of atomic substitution; for example, sulfinamide, sulfonamide or ester linkages or amino, ether or thioether linkages are envisaged.

[0175] In other words, in some embodiments, the lipophilic group Φ is Z 1 - or Z 1 -Z 2 -; wherein, Z 1 is A-C 12~22 alkylene-(CO)-; A is H or -COOH, alkylene can be linear or branched, and can be saturated or unsaturated, and optionally can incorporate a phenylene moiety or a piperazinylene moiety within its entire length; and Z 2 is a sequence of 1 to 6 residues of a compound selected from γ-Glu, βAsp, D, E, K, Orn, S, T, A, β-Ala, G, P, V, L, I, Y, Q, N, Dapa, Gaba or Aib or its corresponding D form, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl and 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) or (piperazin-1-yl)-carboxylic acid, for example, [Glu], [γGlu][Peg3][Peg3]-; [(piperazin-1-yl)-acetyl][Peg3][Peg3]; [γGlu]-G-[γGlu]; [γGlu)-K-[γGlu]; [γGlu]-KG-[γGlu]; and [γGlu]-G-[Peg3][γGlu][Peg3] is a linker selected from the following.

[0176] The amino acid side chain conjugated with the lipophilic substituent typically contains a carboxy, hydroxyl, thiol, amide or amine group for forming an ester, sulfonyl ester, thioester, amide or sulfonamide together with a spacer or a lipophilic substituent. Since an amide bond may be particularly preferred, the amino acid can be any amino acid having an amine group within its side chain, but it will also be apparent that side chains having other functional groups are contemplated. Accordingly, the amino acid side chain can be the side chain of a Glu, Lys, Ser, Cys, Dbu, Dpr or Orn residue. For example, the amino acid side chain can be the side chain of a Lys, Glu or Cys residue. When two or more side chains have lipophilic substituents, the lipophilic substituents can be independently selected from their residues.

[0177] Typically, the amino acid side chain is the side chain of a Lys residue.

[0178] Lipophilic moiety Z 1 and spacer Z 2 Examples of lipophilic substituents containing are shown in the following formula.

Chemical formula

[0179] Alternative Z 1 groups are derived from long-chain saturated α,ω-dicarboxylic acids of the formula HOOC-(CH2) 12~22 -COOH. [Chemical formula] Here, the side chain of the Lys residue is covalently linked via an amide bond to the γGlu spacer (Z 2 ). The 15-carboxypentadecanoyl group (Z 1 ) is covalently linked via an amide bond to the γGlu spacer. This combination of a lipophilic moiety and a spacer conjugated to a Lys residue can be denoted, for example, by the shorthand notation K(15-carboxypentadecanoyl-γ-Glu) when shown in the formula of a specific compound. Also, γGlu can be referred to as isoGlu.

[0180] Specific preferred Φ groups (Z 1 - and Z 1 -Z 2 -) include the following: [15-carboxy-pentadecanoyl]; [15-carboxy-pentadecanoyl][γGlu], [15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3]; [19-Carboxy-nonadecanoyl][γGlu][Peg3][Peg3]; [15-Carboxy-pentadecanoyl][(piperazin-1-yl)-acetyl][Peg3][Peg3]; [17-Carboxy-heptadecanoyl][γGlu]G[γGlu]; [17-Carboxy-heptadecanoyl][γGlu]K[γGlu]; [17-Carboxy-heptadecanoyl][γGlu]KG[γGlu]; [17-Carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3]; [15-Carboxy-pentadecanoyl][γGlu]G[γGlu]; [17-Carboxy-heptadecanoyl]; [17-Carboxy-heptadecanoyl][γGlu] [19-Carboxy-nonadecanoyl][γGlu]G[γGlu]; and [17-Carboxy-heptadecanoyl][γGlu][Peg3][Peg3].

[0181] Examples of the Φ group (Z 1 - and Z 1 -Z 2 -) are shown below, where the wavy line indicates the bond to the peptide (to the amino acid side chain, N-terminal nitrogen, or C-terminal carbon). [19-Carboxy-nonadecanoyl][γGlu]G[γGlu]:

Chemical Structure

Chemical Structure

Chemical Structure

Chem.

Chem.

Chem.

Chem.

Chem.

Chem.

Chem.

[0182] One of ordinary skill in the art will be fully aware of the techniques suitable for preparing the compounds used in connection with the present invention. For examples of suitable chemistry, see WO 98 / 08871, WO 00 / 55184, WO 00 / 55119, Madsen et al., J. Med. Chem. 50:6126-32 (2007), and Knudsen et al., J. Med Chem. 43:1664-1669 (2000), which are incorporated herein by reference.

[0183] In some embodiments, the comstatine analog has the lipophilic group Φ described above conjugated to one or more amino acids at positions corresponding to positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 13 of the comstatine-like sequence, i.e., positions X1-X13.

[0184] In certain embodiments, the comstatine analog has the lipophilic substituent described above conjugated to one or more amino acids at positions corresponding to position X1, X11, or X13, or to amino acids within R1 or R2, or at the N-terminus as group Y1.

[0185] Well-established conjugation strategies have been developed for C-terminal acylation or lipidation of peptides. For example, such conjugation can be carried out by click chemistry (i.e., a copper(I)-catalyzed biorthogonal azide-alkyne conjugation reaction) or other conjugation strategies known to those of skill in peptide chemistry.

[0186] The comstatine analog may comprise one of the following sequences: I-X2-IWQDWGAHR-X12-T I-X2-IWQDWGEHR-X12-T ESSAI-X2-IWQDWGEHR-X12-T I-X2-I[1MeTrp]QDWGEHR-X12-T I-X2-IWQDWGKHR-X12-T I-X2-IWQDWGSHR-X12-T I-X2-IWQKWGEHR-X12-T I-X2-IWQKWGAHR-X12-TGAES Y-X2-IWQDWGEHR-X12-T ESSAY-X2-IWQDWGEHR-X12-T [Sar]-X2-IWQDWGEHR-X12-T I-X2-IWQDWGAHR-X12-E I-X2-IWQDWGEHR-X12-[Sar] ESSAI-X2-IWQDWGEHR-X12-TGAES I-X2-IWQDWGEHR-X12-TGAES I-X2-IWQEWGEHR-X12-T I-X2-IWQDWGDHR-X12-T I-X2-IWQDWGRHR-X12-T I-X2-IWQDWGAHS-X12-T I-X2-IWQDWGEHS-X12-T I-X2-IWQDWGEHR-X12-S I-X2-IWQDWGEHR-X12-E F-X2-IWQDWGEHR-X12-T I-X2-IWQDWGEHR-X12-TEGE I-X2-IWQDWGEHR-X12-TEA I-X2-IWQDWGEHR-X12-TE I-X2-IWQDWGEHR-X12-EGE EGSAI-X2-IWQDWGEHR-X12-[Sar]E EGSAI-X2-IWQDWGEHR-X12-T EGEI-X2-IWQDWGEHR-X12-T ESEI-X2-IWQDWGEHR-X12-T SEI-X2-IWQDWGEHR-X12-TEA EI-X2-IWQDWGEHR-X12-TE EI-X2-IWQDWGEHR-X12-TEGE EGEI-X2-IWQDWGEHR-X12-EGE ESEI-X2-IWQDWGEHR-X12-EGE KEKI-X2-IWQDWGEHR-X12-TEKE EKGI-X2-IWQDWGEHR-X12-TEKP I-X2-IWQDWGEHR-X12-TEGK GSAI-X2-IWQDWGEHR-X12-[Sar]E SAI-X2-IWQDWGEHR-X12-[Sar]E SAI-X2-IWQDWGEHR-X12-TEG F-X2-IWQDWGEHR-X12-TGAE EGSAI-X2-IWQDWGEHR-X12-[Sar]EGE EGSAF-X2-IWQDWGEHR-X12-[Sar]E ESSAI-X2-IWQDWGAHR-X12-T I-X2-IWQDWGAHR-X12-TGAES {d}YI-X2-I[1-Me-Trp]QDW[Sar]AHR-X12-[N-Me-Ile] EGSAI-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E EGSAI-X2-I[2-Nal]QDWGEHR-X12-[Sar]E I-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES I-X2-I[2-Nal]QDWGEHR-X12-TGAES EGSAF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E EGSAI-X2-IWQDWGEHR-X12-TE EGSAF-X2-I[1-Nal]QDWGEHR-X12-TE EGSAF-X2-I[1-Me-Trp]QDWGEHR-X12-TE EGSAF-X2-I[1-Me-Trp]QDWGEHR-X12-EGE EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-TE EGSAF-X2-I[2-Nal]QDWGEHR-X12-TE F-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES Y-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES F-X2-I[1-Nal]QDWGEHR-X12-TGAES F-X2-I[2-Nal]QDWGEHR-X12-TGAES Y-X2-I[2-Nal]QDWGEHR-X12-TGAES Y-X2-IWQDWGEHR-X12-TGAES SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES Y-X2-I[1-Me-Trp]QDWGEHR-X12-TEAGS Y-X2-I[1-Me-Trp]QDWGEHR-X12-TESGA EGSAY-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]E SEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA F-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-TGAES {d}YF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-TGAES SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]GAES SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA SEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]EA SEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-TEA SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E SEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]E EF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA SE[Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA SE[Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-TEA SEF-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EA SEF-X2-I[1-Me-Trp]QDWGEHR-X12-SEA EF-X2-I[1-Me-Trp]QDWGEHR-X12-ES SEF-X2-I[1-Me-Trp]QDWGEHK-X12-[Sar]EA GEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA GE[Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-TEA SE[Sar]-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-TEA SE[Sar]-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EA {d}Y[Sar]-X2-I[1-Me-Trp]QDWGEHR-X12-TEA。 In the formula, X2 and X12 are residues, and the side chains thereof are residues linked by a thioether bond.

[0187] For example, a compstatin analog may include one of the following sequences: IhC(1)IWQDWGAHRA(1)T IhC(1)IWQDWGEHRA(1)T ESSAIhC(1)IWQDWGEHRA(1)T IhC(1)I[1MeTrp]QDWGEHRA(1)T IhC(1)IWQDWGKHRA(1)T IhC(1)IWQDWGSHRA(1)T IhC(1)IWQKWGEHRA(1)T IhC(1)IWQKWGAHRA(1)TGAES YhC(1)IWQDWGEHRA(1)T ESSAYhC(1)IWQDWGEHRA(1)T [Sar]hC(1)IWQDWGEHRA(1)T IhC(1)IWQDWGAHRA(1)E IhC(1)IWQDWGEHRA(1)[Sar] ESSAIhC(1)IWQDWGEHRA(1)TGAES IhC(1)IWQDWGEHRA(1)TGAES IhC(1)IWQEWGEHRA(1)T IhC(1)IWQDWGDHRA(1)T IhC(1)IWQDWGRHRA(1)T IhC(1)IWQDWGAHSA(1)T IhC(1)IWQDWGEHSA(1)T IhC(1)IWQDWGEHRA(1)S IhC(1)IWQDWGEHRA(1)E FhC(1)IWQDWGEHRA(1)T IhC(1)IWQDWGEHRA(1)TEGE IhC(1)IWQDWGEHRA(1)TEA IhC(1)IWQDWGEHRA(1)TE IhC(1)IWQDWGEHRA(1)EGE EGSAIhC(1)IWQDWGEHRA(1)[Sar]E EGSAIhC(1)IWQDWGEHRA(1)T EGEIhC(1)IWQDWGEHRA(1)T ESEIhC(1)IWQDWGEHRA(1)T SEIhC(1)IWQDWGEHRA(1)TEA EIhC(1)IWQDWGEHRA(1)TE EIhC(1)IWQDWGEHRA(1)TEGE EGEIhC(1)IWQDWGEHRA(1)EGE ESEIhC(1)IWQDWGEHRA(1)EGE KEKIhC(1)IWQDWGEHRA(1)TEKE EKGIhC(1)IWQDWGEHRA(1)TEKP IhC(1)IWQDWGEHRA(1)TEGK GSAIhC(1)IWQDWGEHRA(1)[Sar]E SAIhC(1)IWQDWGEHRA(1)[Sar]E SAIhC(1)IWQDWGEHRA(1)TEG FhC(1)IWQDWGEHRA(1)TGAE EGSAIhC(1)IWQDWGEHRA(1)[Sar]EGE EGSAFhC(1)IWQDWGEHRA(1)[Sar]E ESSAIhC(1)IWQDWGAHRA(1)T IhC(1)IWQDWGAHRA(1)TGAES {d}YIhC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)-[N-Me-Ile] EGSAIhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIhC(1)I[2-Nal]QDWGEHRA(1)[Sar]E IhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES IhC(1)I[2-Nal]QDWGEHRA(1)TGAES EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIhC(1)IWQDWGEHRA(1)TE EGSAFhC(1)I[1-Nal]QDWGEHRA(1)TE EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFhC(1)I[2-Nal]QDWGEHRA(1)TE FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES FhC(1)I[1-Nal]QDWGEHRA(1)TGAES FhC(1)I[2-Nal]QDWGEHRA(1)TGAES YhC(1)I[2-Nal]QDWGEHRA(1)TGAES YhC(1)IWQDWGEHRA(1)TGAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YhC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS YhC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA EGSAYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES {d}YFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA SEFhC(1)I[1-Me-Trp]QDWGEHRa(1)[Sar]E SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)SEA EFhC(1)I[1-Me-Trp]QDWGEHRA(1)ES SEFhC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA GEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA GE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA SE[Sar]hC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA SE[Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA {d}Y[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA. In the formula, the side chains of the residues called hC(1) and A(1) form a cystathionine bridge.

[0188] The compstatin analog may include one of the following sequences: IA(1)IWQDWGAHRhC(1)T IA(1)IWQDWGEHRhC(1)T ESSAIA(1)IWQDWGEHRhC(1)T IA(1)I[1MeTrp]QDWGEHRhC(1)T IA(1)IWQDWGKHRhC(1)T IA(1)IWQDWGSHRhC(1)T IA(1)IWQKWGEHRhC(1)T IA(1)IWQKWGAHRhC(1)TGAES YA(1)IWQDWGEHRhC(1)T ESSAYA(1)IWQDWGEHRhC(1)T [Sar]A(1)IWQDWGEHRhC(1)T IA(1)IWQDWGAHRhC(1)E IA(1)IWQDWGEHRhC(1)[Sar] ESSAIA(1)IWQDWGEHRhC(1)TGAES IA(1)IWQDWGEHRhC(1)TGAES IA(1)IWQEWGEHRhC(1)T IA(1)IWQDWGDHRhC(1)T IA(1)IWQDWGRHRhC(1)T IA(1)IWQDWGAHShC(1)T IA(1)IWQDWGEHShC(1)T IA(1)IWQDWGEHRhC(1)S IA(1)IWQDWGEHRhC(1)E FA(1)IWQDWGEHRhC(1)T IA(1)IWQDWGEHRhC(1)TEGE IA(1)IWQDWGEHRhC(1)TEA IA(1)IWQDWGEHRhC(1)TE IA(1)IWQDWGEHRhC(1)EGE EGSAIA(1)IWQDWGEHRhC(1)[Sar]E EGSAIA(1)IWQDWGEHRhC(1)T EGEIA(1)IWQDWGEHRhC(1)T ESEIA(1)IWQDWGEHRhC(1)T SEIA(1)IWQDWGEHRhC(1)TEA EIA(1)IWQDWGEHRhC(1)TE EIA(1)IWQDWGEHRhC(1)TEGE EGEIA(1)IWQDWGEHRhC(1)EGE ESEIA(1)IWQDWGEHRhC(1)EGE KEKIA(1)IWQDWGEHRhC(1)TEKE EKGIA(1)IWQDWGEHRhC(1)TEKP IA(1)IWQDWGEHRhC(1)TEGK GSAIA(1)IWQDWGEHRhC(1)[Sar]E SAIA(1)IWQDWGEHRhC(1)[Sar]E SAIA(1)IWQDWGEHRhC(1)TEG FA(1)IWQDWGEHRhC(1)TGAE EGSAIA(1)IWQDWGEHRhC(1)[Sar]EGE EGSAFA(1)IWQDWGEHRhC(1)[Sar]E ESSAIA(1)IWQDWGAHRhC(1)T IA(1)IWQDWGAHRhC(1)TGAES {d}YIA(1)I[1-Me-Trp]QDW[Sar]AHRhC(1)-[N-Me-Ile] EGSAIA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAIA(1)I[2-Nal]QDWGEHRhC(1)[Sar]E IA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES IA(1)I[2-Nal]QDWGEHRhC(1)TGAES EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E EGSAIA(1)IWQDWGEHRhC(1)TE EGSAFA(1)I[1-Nal]QDWGEHRhC(1)TE EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)TE EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)TE EGSAFA(1)I[2-Nal]QDWGEHRhC(1)TE FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES YA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES FA(1)I[1-Nal]QDWGEHRhC(1)TGAES FA(1)I[2-Nal]QDWGEHRhC(1)TGAES YA(1)I[2-Nal]QDWGEHRhC(1)TGAES YA(1)IWQDWGEHRhC(1)TGAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES YA(1)I[1-Me-Trp]QDWGEHRhC(1)TEAGS YA(1)I[1-Me-Trp]QDWGEHRhC(1)TESGA EGSAYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]E SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES {d}YFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]GAES SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TEA SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)SEA EFA(1)I[1-Me-Trp]QDWGEHRhC(1)ES SEFA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]EA GEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA GE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA SE[Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA {d}Y[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA。 In the formula, the side chains of the residues called A(1) and hC(1) form a cystathionine bridge.

[0189] The compstatin analog may contain one of the following sequences: IC(1)IWQDWGAHRA(1)T IC(1)IWQDWGEHRA(1)T ESSAIC(1)IWQDWGEHRA(1)T IC(1)I[1MeTrp]QDWGEHRA(1)T IC(1)IWQDWGKHRA(1)T IC(1)IWQDWGSHRA(1)T IC(1)IWQKWGEHRA(1)T IC(1)IWQKWGAHRA(1)TGAES YC(1)IWQDWGEHRA(1)T ESSAYC(1)IWQDWGEHRA(1)T [Sar]C(1)IWQDWGEHRA(1)T IC(1)IWQDWGAHRA(1)E IC(1)IWQDWGEHRA(1)[Sar] ESSAIC(1)IWQDWGEHRA(1)TGAES IC(1)IWQDWGEHRA(1)TGAES IC(1)IWQEWGEHRA(1)T IC(1)IWQDWGDHRA(1)T IC(1)IWQDWGRHRA(1)T IC(1)IWQDWGAHSA(1)T IC(1)IWQDWGEHSA(1)T IC(1)IWQDWGEHRA(1)S IC(1)IWQDWGEHRA(1)E FC(1)IWQDWGEHRA(1)T IC(1)IWQDWGEHRA(1)TEGE IC(1)IWQDWGEHRA(1)TEA IC(1)IWQDWGEHRA(1)TE IC(1)IWQDWGEHRA(1)EGE EGSAIC(1)IWQDWGEHRA(1)[Sar]E EGSAIC(1)IWQDWGEHRA(1)T EGEIC(1)IWQDWGEHRA(1)T ESEIC(1)IWQDWGEHRA(1)T SEIC(1)IWQDWGEHRA(1)TEA EIC(1)IWQDWGEHRA(1)TE EIC(1)IWQDWGEHRA(1)TEGE EGEIC(1)IWQDWGEHRA(1)EGE ESEIC(1)IWQDWGEHRA(1)EGE KEKIC(1)IWQDWGEHRA(1)TEKE EKGIC(1)IWQDWGEHRA(1)TEKP IC(1)IWQDWGEHRA(1)TEGK GSAIC(1)IWQDWGEHRA(1)[Sar]E SAIC(1)IWQDWGEHRA(1)[Sar]E SAIC(1)IWQDWGEHRA(1)TEG FC(1)IWQDWGEHRA(1)TGAE EGSAIC(1)IWQDWGEHRA(1)[Sar]EGE EGSAFC(1)IWQDWGEHRA(1)[Sar]E ESSAIC(1)IWQDWGAHRA(1)T IC(1)IWQDWGAHRA(1)TGAES {d}YIC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)-[N-Me-Ile] EGSAIC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIC(1)I[2-Nal]QDWGEHRA(1)[Sar]E IC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES IC(1)I[2-Nal]QDWGEHRA(1)TGAES EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E EGSAIC(1)IWQDWGEHRA(1)TE EGSAFC(1)I[1-Nal]QDWGEHRA(1)TE EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)TE EGSAFC(1)I[2-Nal]QDWGEHRA(1)TE FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES FC(1)I[1-Nal]QDWGEHRA(1)TGAES FC(1)I[2-Nal]QDWGEHRA(1)TGAES YC(1)I[2-Nal]QDWGEHRA(1)TGAES YC(1)IWQDWGEHRA(1)TGAES SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES YC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS YC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA EGSAYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES {d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA SEFC(1)I[1-Me-Trp]QDWGEHRA(1)SEA EFC(1)I[1-Me-Trp]QDWGEHRA(1)ES SEFC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA GEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA GE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA SE[Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA {d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA. In the formula, the side chains of the residues called C(1) and A(1) form a lanthionine bridge.

[0190] For example, the compstatin analogs can be the following: Ac-IhC(1)IWQDWGAHRA(1)T-NH2 (analog of compound 1) Ac-IhC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 2) Ac-ESSAIhC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 3) Ac-IhC(1)I[1-Me-Trp]QDWGEHRA(1)T-NH2 (analog of compound 4) Ac-IhC(1)IWQDWGKHRA(1)T-NH2 (analog of compound 5) Ac-IhC(1)IWQDWGSHRA(1)T-NH2 (Analog of Compound 6) Ac-IhC(1)IWQKWGEHRA(1)T-NH2 (Analog of Compound 7) Ac-IhC(1)IWQKWGAHRA(1)TGAES-NH2 (Analog of Compound 8) Ac-YhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 9) Ac-ESSAYhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 10) Ac-[Sar]hC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 11) Ac-IhC(1)IWQDWGAHRA(1)E-NH2 (Analog of Compound 12) Ac-IhC(1)IWQDWGEHRA(1)[Sar]-NH2 (Analog of Compound 13) Ac-ESSAIhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 14) Ac-IhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 15) Ac-IhC(1)IWQEWGEHRA(1)T-NH2 (Analog of Compound 16) Ac-IhC(1)IWQDWGDHRA(1)T-NH2 (Analog of Compound 17) Ac-IhC(1)IWQDWGRHRA(1)T-NH2 (Analog of Compound 18) Ac-IhC(1)IWQDWGAHSA(1)T-NH2 (Analog of Compound 19) Ac-IhC(1)IWQDWGEHSA(1)T-NH2 (Analog of Compound 20) Ac-IhC(1)IWQDWGEHRA(1)S-NH2 (Analog of Compound 21) Ac-IhC(1)IWQDWGEHRA(1)E-NH2 (Analog of Compound 22) Ac-FhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 23) Ac-IhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 24) Ac-IhC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 25) Ac-IhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 26) Ac-IhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 29) Ac-EGEIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 30) Ac-ESEIhC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 31) Ac-SEIhC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 32) Ac-EIhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 33) Ac-EIhC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIhC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIhC(1)IWQDWGEHRA(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIhC(1)IWQDWGEHRA(1)TEKP-NH2 (Analog of Compound 38) Ac-IhC(1)IWQDWGEHRA(1)TEGK-NH2 (Analog of Compound 39) Ac-GSAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 40) Ac-SAIhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIhC(1)IWQDWGEHRA(1)TEG-NH2 (Analog of Compound 42) Ac-FhC(1)IWQDWGEHRA(1)TGAE-NH2 (Analog of Compound 43) Ac-EGSAIhC(1)IWQDWGEHRA(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFhC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 45) Ac-ESSAIhC(1)IWQDWGAHRA(1)T-NH2 (Analog of Compound 46) Ac-IhC(1)IWQDWGAHRA(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIhC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIhC(1)I[2-Nal]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 51) Ac-IhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 53) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIhC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFhC(1)I[1-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFhC(1)I[2-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 60) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 61) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 62) Ac-FhC(1)I[1-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 63) Ac-FhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 64) Ac-YhC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 65) Ac-YhC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analogs of Compounds 67 and 151) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS-NH2 (Analog of Compound 68) Ac-YhC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E-NH2 (Analog of Compound 70) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 77) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 78) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 82) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)SEA-NH2 (Analog of Compound 84) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)ES-NH2 (Analog of Compound 85) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA-NH2 (Analog of Compound 86) Ac-GEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 87) Ac-GE[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 88) Ac-SE[Sar]hC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 89) Ac-SE[Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 90) H-{d}Y[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 91). In the formula, the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge.

[0191] For example, the compstatin analogs can be as follows: Ac-IA(1)IWQDWGAHRhC(1)T-NH2 (Analog of Compound 1) Ac-IA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 2) Ac-ESSAIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 3) Ac-IA(1)I[1-Me-Trp]QDWGEHRhC(1)T-NH2 (Analog of Compound 4) Ac-IA(1)IWQDWGKHRhC(1)T-NH2 (Analog of Compound 5) Ac-IA(1)IWQDWGSHRhC(1)T-NH2 (Analog of Compound 6) Ac-IA(1)IWQKWGEHRhC(1)T-NH2 (Analog of Compound 7) Ac-IA(1)IWQKWGAHRhC(1)TGAES-NH2 (Analog of Compound 8) Ac-YA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 9) Ac-ESSAYA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 10) Ac-[Sar]A(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 11) Ac-IA(1)IWQDWGAHRhC(1)E-NH2 (Analog of Compound 12) Ac-IA(1)IWQDWGEHRhC(1)[Sar]-NH2 (Analog of Compound 13) Ac-ESSAIA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 14) Ac-IA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 15) Ac-IA(1)IWQEWGEHRhC(1)T-NH2 (Analog of Compound 16) Ac-IA(1)IWQDWGDHRhC(1)T-NH2 (Analog of Compound 17) Ac-IA(1)IWQDWGRHRhC(1)T-NH2 (Analog of Compound 18) Ac-IA(1)IWQDWGAHShC(1)T-NH2 (Analog of Compound 19) Ac-IA(1)IWQDWGEHShC(1)T-NH2 (Analog of Compound 20) Ac-IA(1)IWQDWGEHRhC(1)S-NH2 (Analog of Compound 21) Ac-IA(1)IWQDWGEHRhC(1)E-NH2 (Analog of Compound 22) Ac-FA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 23) Ac-IA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analog of Compound 24) Ac-IA(1)IWQDWGEHRhC(1)TEA-NH2 (Analog of Compound 25) Ac-IA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 26) Ac-IA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 29) Ac-EGEIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 30) Ac-ESEIA(1)IWQDWGEHRhC(1)T-NH2 (Analog of Compound 31) Ac-SEIA(1)IWQDWGEHRhC(1)TEA-NH2 (Analog of Compound 32) Ac-EIA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 33) Ac-EIA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIA(1)IWQDWGEHRhC(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIA(1)IWQDWGEHRhC(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIA(1)IWQDWGEHRhC(1)TEKP-NH2 (Analog of Compound 38) Ac-IA(1)IWQDWGEHRhC(1)TEGK-NH2 (Analog of Compound 39) Ac-GSAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 40) Ac-SAIA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIA(1)IWQDWGEHRhC(1)TEG-NH2 (Analog of Compound 42) Ac-FA(1)IWQDWGEHRhC(1)TGAE-NH2 (Analog of Compound 43) Ac-EGSAIA(1)IWQDWGEHRhC(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFA(1)IWQDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 45) Ac-ESSAIA(1)IWQDWGAHRhC(1)T-NH2 (Analog of Compound 46) Ac-IA(1)IWQDWGAHRhC(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIA(1)I[1-Me-Trp]QDW[Sar]AHRhC(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIA(1)I[2-Nal]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 51) Ac-IA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 53) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIA(1)IWQDWGEHRhC(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFA(1)I[1-Nal]QDWGEHRhC(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFA(1)I[2-Nal]QDWGEHRhC(1)TE-NH2 (Analog of Compound 60) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 61) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 62) Ac-FA(1)I[1-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 63) Ac-FA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 64) Ac-YA(1)I[2-Nal]QDWGEHRhC(1)TGAES-NH2 (Analog of Compound 65) Ac-YA(1)IWQDWGEHRhC(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-NH2 (Compound 151; Analog of Compound 67) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TEAGS-NH2 (Analog of Compound 68) Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 70) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TEA-NH2 (Analog of Compound 77) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analog of Compound 78) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (Analog of Compound 82) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)SEA-NH2 (Analog of Compound 84) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)ES-NH2 (Analog of Compound 85) Ac-SEFA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]EA-NH2 (Analog of Compound 86) Ac-GEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 87) Ac-GE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (Analog of Compound 88) Ac-SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA-NH2 (Analog of Compound 89) Ac-SE[Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (Analog of Compound 90) H-{d}Y[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (Analog of Compound 91). In the formula, the side chains of the residues called A(1) and hC(1) form a cystathionine bridge.

[0192] For example, the compstatin analogs can be as follows: Ac-IC(1)IWQDWGAHRA(1)T-NH2 (analog of compound 1) Ac-IC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 2) Ac-ESSAIC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 3) Ac-IC(1)I[1-Me-Trp]QDWGEHRA(1)T-NH2 (analog of compound 4) Ac-IC(1)IWQDWGKHRA(1)T-NH2 (analog of compound 5) Ac-IC(1)IWQDWGSHRA(1)T-NH2 (analog of compound 6) Ac-IC(1)IWQKWGEHRA(1)T-NH2 (analog of compound 7) Ac-IC(1)IWQKWGAHRA(1)TGAES-NH2 (analog of compound 8) Ac-YC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 9) Ac-ESSAYC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 10) Ac-[Sar]C(1)IWQDWGEHRA(1)T-NH2 (analog of compound 11) Ac-IC(1)IWQDWGAHRA(1)E-NH2 (analog of compound 12) Ac-IC(1)IWQDWGEHRA(1)[Sar]-NH2 (analog of compound 13) Ac-ESSAIC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 14) Ac-IC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 15) Ac-IC(1)IWQEWGEHRA(1)T-NH2 (analog of compound 16) Ac-IC(1)IWQDWGDHRA(1)T-NH2 (analog of compound 17) Ac-IC(1)IWQDWGRHRA(1)T-NH2 (analog of compound 18) Ac-IC(1)IWQDWGAHSA(1)T-NH2 (Analog of Compound 19) Ac-IC(1)IWQDWGEHSA(1)T-NH2 (Analog of Compound 20) Ac-IC(1)IWQDWGEHRA(1)S-NH2 (Analog of Compound 21) Ac-IC(1)IWQDWGEHRA(1)E-NH2 (Analog of Compound 22) Ac-FC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 23) Ac-IC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 24) Ac-IC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 25) Ac-IC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 26) Ac-IC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 27) Ac-EGSAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 28) Ac-EGSAIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 29) Ac-EGEIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 30) Ac-ESEIC(1)IWQDWGEHRA(1)T-NH2 (Analog of Compound 31) Ac-SEIC(1)IWQDWGEHRA(1)TEA-NH2 (Analog of Compound 32) Ac-EIC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 33) Ac-EIC(1)IWQDWGEHRA(1)TEGE-NH2 (Analog of Compound 34) Ac-EGEIC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 35) Ac-ESEIC(1)IWQDWGEHRA(1)EGE-NH2 (Analog of Compound 36) Ac-KEKIC(1)IWQDWGEHRA(1)TEKE-NH2 (Analog of Compound 37) Ac-EKGIC(1)IWQDWGEHRA(1)TEKP-NH2 (Analog of Compound 38) Ac-IC(1)IWQDWGEHRA(1)TEGK-NH2 (Analog of Compound 39) Ac-GSAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 40) Ac-SAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 41) Ac-SAIC(1)IWQDWGEHRA(1)TEG-NH2 (Analog of Compound 42) Ac-FC(1)IWQDWGEHRA(1)TGAE-NH2 (Analog of Compound 43) Ac-EGSAIC(1)IWQDWGEHRA(1)[Sar]EGE-NH2 (Analog of Compound 44) Ac-EGSAFC(1)IWQDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 45) Ac-ESSAIC(1)IWQDWGAHRA(1)T-NH2 (Analog of Compound 46) Ac-IC(1)IWQDWGAHRA(1)TGAES-NH2 (Analog of Compound 47) H-{d}YIC(1)I[1-Me-Trp]QDW[Sar]AHRA(1)[N-Me-Ile]-NH2 (Analog of Compound 48) Ac-EGSAIC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 49) Ac-EGSAIC(1)I[2-Nal]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 50) Ac-IC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 51) Ac-IC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 52) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 53) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 54) Ac-EGSAIC(1)IWQDWGEHRA(1)TE-NH2 (Analog of Compound 55) Ac-EGSAFC(1)I[1-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 56) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 57) Ac-EGSAFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-NH2 (Analog of Compound 58) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)TE-NH2 (Analog of Compound 59) Ac-EGSAFC(1)I[2-Nal]QDWGEHRA(1)TE-NH2 (Analog of Compound 60) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 61) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 62) Ac-FC(1)I[1-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 63) Ac-FC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 64) Ac-YC(1)I[2-Nal]QDWGEHRA(1)TGAES-NH2 (Analog of Compound 65) Ac-YC(1)IWQDWGEHRA(1)TGAES-NH2 (Analog of Compound 66) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-NH2 (Analog of Compounds 67 and 151) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TEAGS-NH2 (Analog of Compound 68) Ac-YC(1)I[1-Me-Trp]QDWGEHRA(1)TESGA-NH2 (Analog of Compound 69) Ac-EGSAYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E-NH2 (Analog of Compound 70) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 71) Ac-FC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 72) H-{d}YFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TGAES-NH2 (Analog of Compound 73) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]GAES-NH2 (Analog of Compound 74) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 75) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EA-NH2 (Analog of Compound 76) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)TEA-NH2 (Analog of Compound 77) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 78) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E-NH2 (Analog of Compound 79) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 80) Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 81) Ac-SE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analog of Compound 82) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analog of Compound 83) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)SEA-NH2 (Analogue of Compound 84) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)ES-NH2 (Analogue of Compound 85) Ac-SEFC(1)I[1-Me-Trp]QDWGEHKA(1)[Sar]EA-NH2 (Analogue of Compound 86) Ac-GEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA-NH2 (Analogue of Compound 87) Ac-GE[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analogue of Compound 88) Ac-SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA-NH2 (Analogue of Compound 89) Ac-SE[Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA-NH2 (Analogue of Compound 90) H-{d}Y[Sar]C(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (Analogue of Compound 91). In the formula, the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge.

[0193] Alternatively, the compstatin analogues may contain one of the following sequences: [K * GSAI-X2-IWQDWGEHR-X12-TEGE (Analogue of Compound 100) ASGEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE-[K * (Analogue of Compound 113) EF-X2-I[1-Me-Trp]QDWGEHR-X12-EGE-[K * (Analogues of Compounds 134 and 161) EGSAI-X2-IWQDWGEHR-X12-TEG[K * (Analogue of Compound 101) EGSAY-X2-I[1-Me-Trp]QDWGEH[K *-X12-[Sar]E (Analog of Compound 103) EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EG-[K * (Analog of Compound 104) EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE-[K * (Analog of Compound 109) EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGK-[K * (Analog of Compound 110) EGSAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EK[γGlu]-[K * (Analog of Compounds 111 and 159) F-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES-[K * (Analog of Compound 102) I-X2-IWQDWGEHR-X12-TEG-[K * (Analog of Compound 92) I-X2-IWQDWGEHR-X12-TEGE-[K * (Analog of Compound 94) SAY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E-[K * (Analog of Compound 105) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGA-[K * (Analog of Compounds 119 and 154) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 123, 146 and 152) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGEGGG-[K * (Analog of Compound 129) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3]-[K * (Analog of Compound 138) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3]ES-[K * (Analog of compound 140) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3][Peg3]-[K * (Analogs of compounds 127 and 160) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGESES-[K * (Analog of compound 139) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EK[γGlu]GGG-[K * (Analog of compound 132) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEGE[8-aminooctanoyl]-[K * (Analog of compound 136) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEGE[8-aminooctanoyl]E-[K * (Analog of compound 137) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEGEGGG-[K * (Analogs of compounds 130 and 157) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEGE[Peg3]ES-[K * (Analogs of compounds 142, 148, 163 and 165) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEGE[Peg3][Peg3]-[K * (Analogs of compounds 126 and 156) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TEK[γGlu]GGG-[K * (Analog of compound 133) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-TGAES-[K * (Analog of compound 135) SEF-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EGA-[K * (Analog of compound 120) SEF-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EGE[Peg3][Peg3]-[K * (Analogs of compounds 124, 153, and 167) SEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGA-[K * (Analog of compound 112) SEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 117) SEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE-[K * (Analog of compound 114) SEY-X2-I[1-Me-Trp]QEW[Sar]EHR-X12-[Sar]EK[γGlu]A-[K * (Analog of compound 121) SEY-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EGA-[K * (Analog of compound 122) SEY-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 125) EGSEY-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]E (Analog of compound 107) ESSAI-X2-IWQDWGEHR-X12-TEGE (Analog of compound 99) SEF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of compound 143) SEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]E[Peg3][Peg3]-[K * (Analogs of compounds 144, 147, 162, and 164) EF-X2-I[1-Me-Trp]QDWGEHR-X12-[Sar]EA[Peg3][Peg3]-[K * (Analog of compound 145) GEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]EAE[Peg3][Peg3]-[K * (Analog of compound 149) SEF-X2-I[1-Me-Trp]QDW[Sar]EHR-X12-[Sar]EGE[Peg3]ES-[K * (Analog of compounds 150 and 166) GEF-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EGE[Peg3]ES-[K * (Analog of compound 155) EF-X2-I[1-Me-Trp]QEWGEHR-X12-[Sar]EA[Peg3][Peg3]-[K * (Analog of compound 158). In the formula, X2 and X12 are residues whose side chains are linked by a thioether bond; * indicates that the amino acid residue has a lipophilic group Φ covalently bonded to its side chain.

[0194] Alternatively, the compstatin analog may contain one of the following sequences: [K * GSAIhC(1)IWQDWGEHRA(1)TEGE (Analog of compound 100) ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of compound 113) EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * (Analogs of compounds 134 and 161) EGSAIhC(1)IWQDWGEHRA(1)TEG[K * (Analog of compound 101) EGSAYhC(1)I[1-Me-Trp]QDWGEH[K* A(1)[Sar]E (Analog of Compound 103) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * (Analog of Compound 104) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 109) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * (Analog of Compound 110) EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * (Analog of Compounds 111 and 159) FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 102) IhC(1)IWQDWGEHRA(1)TEG-[K * (Analog of Compound 92) IhC(1)IWQDWGEHRA(1)TEGE-[K * (Analog of Compound 94) SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * (Analog of Compound 105) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compounds 119 and 154) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 152; Compounds 123 and 146) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * (Analog of Compound 129) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K *(Analog of Compound 138) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of Compound 140) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 127 and 160) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * (Analog of Compound 139) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * (Analog of Compound 132) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]-[K * (Analog of Compound 136) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]E-[K * (Analog of Compound 137) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * (Analog of Compounds 130 and 157) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-[K * (Analog of Compound 165; Analogs of Compounds 142, 148 and 163) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-[K * (Analog of Compounds 126 and 156) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * (Analog of Compound 133) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 135) SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of compound 120) SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 167; Analog of compounds 124 and 153) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of compound 112) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 117) SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of compound 114) SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * (Analog of compound 121) SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of compound 122) SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 125) EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E(Analog of compound 107) ESSAIhC(1)IWQDWGEHRA(1)TEGE(Analog of compound 99) SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of compound 143) SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K *(Compound 164; Analogue of Compounds 144, 147, and 162) EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analogue of Compound 145) GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * (Analogue of Compound 149) SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * (Compound 166; Analogue of Compound 150) GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analogue of Compound 155) EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analogue of Compound 158). In the formula, the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge.

[0195] Alternatively, the compstatin analogue may include one of the following sequences: [K * GSAIA(1)IWQDWGEHRhC(1)TEGE (Analogue of Compound 100) ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analogue of Compound 113) EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-[K * (Compound 161; Analogue of Compound 134) EGSAIA(1)IWQDWGEHRhC(1)TEG[K * (Analogue of Compound 101) EGSAYA(1)I[1-Me-Trp]QDWGEH[K * hC(1)[Sar]E (Analogue of Compound 103) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-[K * (Analog of compound 104) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analog of compound 109) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-[K * (Analog of compound 110) EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]-[K * (Compound 159; Analog of compound 111) FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * (Analog of compound 102) IA(1)IWQDWGEHRhC(1)TEG-[K * (Analog of compound 92) IA(1)IWQDWGEHRhC(1)TEGE-[K * (Analog of compound 94) SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-[K * (Analog of compound 105) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * (Compound 154; Analog of compound 119) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 146; Analog of compounds 123 and 152) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-[K * (Analog of compound 129) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-[K * (Analog of compound 138) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * (Analog of compound 140) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 160; analog of compound 127) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-[K * (Analog of compound 139) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]GGG-[K * (Analog of compound 132) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-Aminooctanoyl]-[K * (Analog of compound 136) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-Aminooctanoyl]E-[K * (Analog of compound 137) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-[K * (Compound 157; analog of compound 130) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-[K * (Analogs of compounds 148 and 163; analogs of compounds 142 and 165) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3][Peg3]-[K * (Compound 156; analog of compound 126) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K * (Analog of compound 133) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * (Analog of compound 135) SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * (Analog of compound 120) SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Compound 153; Analog of compounds 124 and 167) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * (Analog of compound 112) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 117) SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * (Analog of compound 114) SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K * (Analog of compound 121) SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * (Analog of compound 122) SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of compound 125) EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E(Analog of compound 107) ESSAIA(1)IWQDWGEHRhC(1)TEGE(Analog of compound 99) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of compound 143) SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K *(Analogs of Compounds 147 and 162; Compounds 144 and 164) EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of Compound 145) GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K * (Compound 149) SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-[K * (Compound 150; Analog of Compound 166) GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * (Compound 155) EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * (Compound 158). In the formula, the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge.

[0196] Alternatively, the compstatin analogs may include one of the following sequences: [K * GSAIC(1)IWQDWGEHRA(1)TEGE (Analog of Compound 100) ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 113) EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * (Analogs of Compounds 134 and 161) EGSAIC(1)IWQDWGEHRA(1)TEG[K * (Analog of Compound 101) EGSAYC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E (Analog of Compound 103) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * (Analog of Compound 104) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 109) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * (Analog of Compound 110) EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * (Analog of Compounds 111 and 159) FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of Compound 102) IC(1)IWQDWGEHRA(1)TEG-[K * (Analog of Compound 92) IC(1)IWQDWGEHRA(1)TEGE-[K * (Analog of Compound 94) SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * (Analog of Compound 105) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compounds 119 and 154) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compounds 123, 146 and 152) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * (Analog of Compound 129) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * (Analog of Compound 138) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of compound 140) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analogs of compounds 127, 160) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * (Analog of compound 139) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * (Analog of compound 132) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-[K * (Analog of compound 136) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-[K * (Analog of compound 137) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * (Analogs of compounds 130, 157) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-[K * (Analogs of compounds 142, 148, 163, 165) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-[K * (Analogs of compounds 126, 156) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * (Analog of compound 133) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * (Analog of compound 135) SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K* (Analog of Compound 120) SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analogs of Compounds 124, 153, 157) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 112) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 117) SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * (Analog of Compound 114) SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * (Analog of Compound 121) SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * (Analog of Compound 122) SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * (Analog of Compound 125) EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E(Analog of Compound 107) ESSAIC(1)IWQDWGEHRA(1)TEGE(Analog of Compound 99) SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * (Analog of Compound 143) SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * (Analogs of Compounds 144, 147, 162, 164) EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of compound 145) GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * (Analog of compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * (Analogs of compounds 150 and 166) GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * (Analog of compound 155) EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * (Analog of compound 158). In the formula, the side chains of the residues called C(1) and A(1) form a lanthionine bridge.

[0197] For example, a compstatin analog may include one of the following sequences: Ac-[K * GSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 100) Ac-ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (analog of compound 113) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * -NH2 (analogs of compounds 134 and 161) Ac-EGSAIhC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (analog of compound 101) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEH[K * A(1)[Sar]E-NH2 (analog of compound 103) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * -NH2 (Analog of Compound 104) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analog of Compound 109) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * -NH2 (Analog of Compound 110) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * -NH2 (Analog of Compounds 111, 159) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analog of Compound 102) Ac-IhC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (Analog of Compounds 92, 93, 95, 96, 98) Ac-IhC(1)IWQDWGEHRA(1)TEGE-[K * -NH2 (Analog of Compounds 94, 97) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * -NH2 (Analog of Compounds 105, 106) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compounds 119, 154) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Compound 152; Analog of Compounds 123, 146) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * -NH2 (Analog of Compound 129) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * -NH2 (Analog of Compound 138) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analog of Compound 140) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 127, 128, 160) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * -NH2 (Analog of Compounds 139, 141) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * -NH2 (Analog of Compound 132) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]-[K * -NH2 (Analog of Compound 136) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-Aminooctanoyl]E-[K * -NH2 (Analog of Compound 137) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * -NH2 (Analog of Compounds 130, 131, 157) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -NH2 (Compound 165; Analog of Compounds 142, 148) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -OH (Analog of Compound 163) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3][Peg3]-[K * -NH2 (Analogues of Compounds 126 and 156) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * -NH2 (Analogue of Compound 133) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analogue of Compound 135) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogue of Compound 120) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Compound 167; Analogues of Compounds 124 and 153) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogues of Compounds 112 and 118) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 117) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analogues of Compounds 114, 115, and 116) Ac-SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * -NH2 (Analogue of Compound 121) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (Analogue of Compound 122) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K* -NH2 (analog of compound 125) Φ-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analogs of compounds 107 and 108) Φ-ESSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 99) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (analog of compound 143) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -NH2 (analogs of compounds 164; 144 and 147) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -OH (analog of compound 162) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (analog of compound 145) Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (analog of compound 149) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analogs of compounds 166; 150) Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compound 155) Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (analog of compound 158). In the formula, the side chains of the residues designated as hC(1) and A(1) form cystathionine crosslinks.

[0198] For example, a compstatin analog may comprise one of the following sequences: Ac-[K * GSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (analog of compound 100) Ac-ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (analog of compound 113) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-[K * -NH2 (compound 161; analog of compound 134) Ac-EGSAIA(1)IWQDWGEHRhC(1)TEG-[K * -NH2 (analog of compound 101) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEH[K * hC(1)[Sar]E-NH2 (analog of compound 103) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-[K * -NH2 (analog of compound 104) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (analog of compound 109) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-[K * -NH2 (analog of compound 110) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]-[K * -NH2 (compound 159; analog of compound 111) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * -NH2 (analog of compound 102) Ac-IA(1)IWQDWGEHRhC(1)TEG-[K * -NH2 (Analogs of Compounds 92, 93, 95, 96, 98) Ac-IA(1)IWQDWGEHRhC(1)TEGE-[K * -NH2 (Analogs of Compounds 94, 97) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-[K * -NH2 (Analogs of Compounds 105, 106) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * -NH2 (Compound 154; Analogs of Compound 119) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Compound 146; Analogs of Compounds 123, 152) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-[K * -NH2 (Analog of Compound 129) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-[K * -NH2 (Analog of Compound 138) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (Analog of Compound 140) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Compound 160; Analogs of Compounds 127, 128) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-[K * -NH2 (Analogs of Compounds 139, 141) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK[γGlu]GGG-[K *-NH2 (analog of compound 132) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-[K * -NH2 (analog of compound 136) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]E-[K * -NH2 (analog of compound 137) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-[K * -NH2 (compound 157; analogs of compounds 130 and 131) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3]ES-[K * -NH2 (compound 148; analogs of compounds 142 and 165) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3]ES-[K * -OH (compound 163) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE-[Peg3][Peg3]-[K * -NH2 (compound 156; analog of compound 126) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K * -NH2 (analog of compound 133) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-[K * -NH2 (analog of compound 135) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * -NH2 (analog of compound 120) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (compound 153; analogs of compounds 124 and 167) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-[K * -NH2 (Analogues of Compounds 112 and 118) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 117) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K * -NH2 (Analogues of Compounds 114, 115, and 116) Ac-SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K * -NH2 (Analogue of Compound 121) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K * -NH2 (Analogue of Compound 122) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analogue of Compound 125) Φ-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (Analogues of Compounds 107 and 108) Φ-ESSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (Analogue of Compound 99) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (Analogue of Compound 143) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K * -NH2 (Compound 147; Analogues of Compounds 144 and 164) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K * -OH (Compound 162) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (analogue of compound 145) Ac-GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (compound 149) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (compound 150; analogue of compound 166) Ac-GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K * -NH2 (compound 155) Ac-EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (compound 158). In the formula, the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge.

[0199] For example, a compstatin analogue may contain one of the following sequences: Ac-[K * GSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (analogue of compound 100) Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (analogue of compound 113) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-[K * -NH2 (analogues of compounds 134, 161) Ac-EGSAIC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (analogue of compound 101) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH[K *A(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-[K * -NH2 (Analog of Compound 104) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (Analog of Compound 109) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K * -NH2 (Analog of Compound 110) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]-[K * -NH2 (Analog of Compounds 111 and 159) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (Analog of Compound 102) Ac-IC(1)IWQDWGEHRA(1)TEG-[K * -NH2 (Analog of Compounds 92, 93, 95, 96, and 98) Ac-IC(1)IWQDWGEHRA(1)TEGE-[K * -NH2 (Analog of Compounds 94 and 97) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K * -NH2 (Analog of Compounds 105 and 106) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (Analog of Compounds 119 and 154) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (Analog of Compounds 123, 146, and 152) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K * -NH2 (Analog of Compound 129) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-[K * -NH2 (analog of compound 138) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compound 140) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (analog of compounds 127, 128, 160) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-[K * -NH2 (analog of compounds 139, 141) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK[γGlu]GGG-[K * -NH2 (analog of compound 132) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-[K * -NH2 (analog of compound 136) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-[K * -NH2 (analog of compound 137) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K * -NH2 (analog of compounds 130, 131, 157) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -NH2 (analog of compounds 142, 148, 165) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3]ES-[K * -NH2 (analog of compound 163) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE-[Peg3][Peg3]-[K * -NH2 (analogues of compounds 126 and 156) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-[K * -NH2 (analogue of compound 133) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-[K * -NH2 (analogue of compound 135) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (analogue of compound 120) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (analogues of compounds 124, 153, and 167) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-[K * -NH2 (analogues of compounds 112 and 118) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K * -NH2 (analogue of compound 117) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-[K * -NH2 (analogues of compounds 114, 115, and 116) Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K * -NH2 (analogue of compound 121) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K * -NH2 (analogue of compound 122) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K *-NH2 (analog of compound 125) Φ-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analog of compounds 107 and 108) Φ-ESSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 99) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K * -NH2 (analog of compound 143) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -NH2 (analog of compounds 144, 147, and 164) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K * -OH (analog of compound 162) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (analog of compound 145) Ac-GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-[K * -NH2 (analog of compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compounds 150 and 166) Ac-GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K * -NH2 (analog of compound 155) Ac-EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K * -NH2 (analog of compound 158). In the formula, the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge.

[0200] For example, the compstatin analogs can be as follows: Ac-IhC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 92) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 93) Ac-IhC(1)IWQDWGEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 94) Ac-IhC(1)IWQDWGEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (analog of compound 95) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 96) Ac-IhC(1)IWQDWGEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 97) Ac-IhC(1)IWQDWGEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 98) [15-carboxy-pentadecanoyl]-ESSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 99) Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIhC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 100) Ac-EGSAIhC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 101) Ac-FhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 102) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 104) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (Analog of Compound 105) Ac-SAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 106) [15-carboxy-pentadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 107) [17-carboxy-heptadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 108) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 109) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 110) Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2 (analog of compounds 111, 159) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 112) Ac-ASGEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 113) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 114) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 115) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2 (analog of compound 116) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 117) Ac-SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of compound 118) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compounds 119, 154) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 120) Ac-SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 121) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analog of Compound 122) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 152; Analog of Compounds 123 and 146) Ac-SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 167; Analog of Compounds 124, 153) Ac-SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 125) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (Analog of Compounds 126, 156) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compounds 127 and 160) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 128) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compound 129) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compounds 130 and 157) Ac-SEFhC(1)I[1-Me-Trp]-QDWGEHRA(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 131) Ac-SEFhC(1)I[1-Me-Trp]-QDWGEHRA(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 132) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 133) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compounds 134 and 161) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 135) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 136) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2 (analog of compound 137) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 138) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 139) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 140) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analog of compound 141) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (compound 165; analogs of compounds 142 and 148) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (analog of compound 163) Ac-SEFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 143) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 164; analog of Compounds 144 and 147) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH (analog of Compound 162) Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 145) Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 149) Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 166; analog of Compound 150) Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 155) Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 158). In the formula, the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge.

[0201] For example, a compstatin analog can be as follows: Ac-IA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analogue of compound 92) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 93) Ac-IA(1)IWQDWGEHRhC(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 94) Ac-IA(1)IWQDWGEHRhC(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (analogue of compound 95) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 96) Ac-IA(1)IWQDWGEHRhC(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 97) Ac-IA(1)IWQDWGEHRhC(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 98) [15-carboxy-pentadecanoyl]-ESSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (analogue of compound 99) Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIA(1)IWQDWGEHRhC(1)TEGE-NH2 (analogue of compound 100) Ac-EGSAIA(1)IWQDWGEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analogue of compound 101) Ac-FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 102) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-hC(1)[Sar]E-NH2 (analogue of compound 103) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 104) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (analogue of compound 105) Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 106) [15-carboxy-pentadecanoyl]-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (analogue of compound 107) [17-carboxy-heptadecanoyl]-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (analogue of compound 108) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 109) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 110) Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2 (Compound 159; analog of Compound 111) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 112) Ac-ASGEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 113) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 114) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 115) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2 (analog of Compound 116) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 117) Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analog of Compound 118) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2 (Compound 154; Analogue of Compound 119) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analogue of Compound 120) Ac-SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analogue of Compound 121) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (Analogue of Compound 122) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 146; Analogue of Compounds 123 and 152) Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 153; Analogue of Compounds 124 and 167) Ac-SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analogue of Compound 125) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (Compound 156; Analogue of Compound 126) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (Compound 160; analog of Compound 127) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 128) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of Compound 129) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Compound 157; analog of Compound 130) Ac-SEFA(1)I[1-Me-Trp]-QDWGEHRhC(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 131) Ac-SEFA(1)I[1-Me-Trp]-QDWGEHRhC(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 132) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of Compound 133) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 161; analog of Compound 134) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 135) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (analog of compound 136) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2 (analog of compound 137) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 138) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 139) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analog of compound 140) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analog of compound 141) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (compound 148; analog of compounds 142, 165) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (compound 163) Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 143) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 147; Analog of Compounds 144, 164) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH (Compound 162) Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 145) Ac-GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 149) Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 150; Analog of Compound 166) Ac-GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 155) Ac-EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Compound 158). In the formula, the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge.

[0202] For example, the compstatin analogs can be the following: Ac-IC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 92) Ac-IC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 93) Ac-IC(1)IWQDWGEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 94) Ac-IC(1)IWQDWGEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (analog of compound 95) Ac-IC(1)IWQDWGEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 96) Ac-IC(1)IWQDWGEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 97) Ac-IC(1)IWQDWGEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 98) [15-carboxy-pentadecanoyl]-ESSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 99) Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 100) Ac-EGSAIC(1)IWQDWGEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 101) Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 102) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (Analog of Compound 103) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (Analog of Compound 104) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (Analog of Compound 105) Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 106) [15-carboxy-pentadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 107) [17-carboxy-heptadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (Analog of Compound 108) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 109) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 110) Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2(Analog of Compound 111, 159) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 112) Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 113) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 114) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 115) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2(Analog of Compound 116) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(Analog of Compound 117) Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(Analog of Compound 118) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2(Analog of Compound 119, 154) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analogue of compound 120) Ac-SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analogue of compound 121) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2 (analogue of compound 122) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogues of compounds 123, 146 and 152) Ac-SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogues of compounds 124, 153, 167) Ac-SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 125) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2 (analogues of compounds 126, 156) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2 (analogues of compounds 127, 160) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 128) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analog of Compound 129) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (Analogs of Compounds 130 and 157) Ac-SEFC(1)I[1-Me-Trp]-QDWGEHRA(1)TEGEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 131) Ac-SEFC(1)I[1-Me-Trp]-QDWGEHRA(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 132) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 133) Ac-EFC(1)I[1-Me-Trp]QDWGEHRA(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (Analogs of Compounds 134 and 161) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2 (Analog of Compound 135) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2 (Analog of Compound 136) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 137) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 138) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 139) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2 (analogue of compound 140) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analogue of compound 141) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2 (analogues of compounds 142, 148, 165) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH (analogue of compound 163) Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 143) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogues of compounds 144, 147, 164) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 162) Ac-EF[C(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 145) Ac-GEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 149) Ac-SEFC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compounds 150 and 166) Ac-GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 155) Ac-EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of Compound 158). In the formula, the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge.

[0203] Compstatine analogs formed in the prior art have been shown to have improved activity (i.e., up to about 99-fold (Mallik, B. et al, 2005, supra; WO 2004 / 026328 pamphlet) and up to about 264-fold (Katragadda et al., 2006, supra; WO 2007 / 062249 pamphlet)) compared to the parent peptide.

[0204] In accordance with the present invention, using information on the biological and physicochemical characteristics of the binding of Ac-compstatin to C3, a compstatin analog with significantly improved activity compared to the parent compstatin analog was designed.

[0205] Preferably, the compstatin analog has greater activity than Ac-compstatin, for example, at least 10 times greater activity than Ac-compstatin, at least 20 times greater activity, at least 30 times greater activity. In other embodiments, the analog has at least 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, 110 times, 120 times, 130 times, 140 times or 150 times or more the activity of Ac-compstatin when compared using the assays described in the examples.

[0206] The compounds of the present invention typically have greater activity than the same compound except that they have valine instead of isoleucine at the position corresponding to Val3 of compstatin.

[0207] The compstatin analog can bind to C3 and / or C3b and can inhibit the activation of the complement cascade, particularly downstream of C3, for example, by inhibiting the cleavage of C3 by the C3 convertase.

[0208] Also, the compstatin analog can typically inhibit complement-driven hemolysis. Complement-driven hemolysis is typically evaluated by contacting serum from a first mammalian species (e.g., human serum) with erythrocytes (red blood cells; RBCs) from a second mammalian species (e.g., sheep or any other suitable species), typically in the presence of a mammalian immunoglobulin that can bind to the erythrocytes. Complement in the serum is activated by the cell-bound immunoglobulin, leading to lysis of the erythrocytes, i.e., hemolysis. The immunoglobulin can be derived from the first species or from a third mammalian species as long as it can activate the complement derived from the first species.

[0209] In such an assay, the test compound will typically be pre-incubated with the serum before the serum contacts the erythrocytes. Also, the erythrocytes can be pre-incubated with an immunoglobulin before contacting the serum.

[0210] In the following example, human serum is pre-incubated with a test compound before the serum and erythrocytes are combined, and the sheep erythrocytes are pre-incubated with rabbit anti-serum against sheep erythrocytes.

[0211] Thus, the activity of a Compstatin analog can be determined with reference to one or more biological activities selected from (1) binding to C3 protein, (2) binding to C3b protein, (3) inhibition of cleavage of native C3 by C3 convertase, and (4) inhibition of activation of the complement system.

[0212] Thus, the Compstatin analogs of the present invention can bind to C3 or C3b with a higher affinity than Compstatin. For example, the Compstatin analogs of the present invention can have a Kd that is at least 10-fold, at least 20-fold, or at least 30-fold lower than that of Ac-Compstatin, and for example, at least 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, or 150-fold lower than that of Ac-Compstatin. The Kd can be determined, for example, by surface plasmon resonance (SPR) using the assay described in Example 4.

[0213] The Compstatin analogs of the present invention typically bind to C3 or C3b with a greater affinity (i.e., a lower Kd) than the same compound except that they have a valine instead of an isoleucine at the position corresponding to Val3 of Compstatin.

[0214] The Compstatin analogs of the present invention can have a greater ability to inhibit hemolysis than Ac-Compstatin. For example, the Compstatin analogs of the present invention can have an IC that is at least 10-fold, at least 20-fold, or at least 30-fold lower than that of Ac-Compstatin.50 、 for example, at least 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250, 300, 350, 400, 450, 500 times lower in IC than, for example, Ac-compstatin 50 can inhibit hemolysis.

[0215] The compstatin analogs of the present invention typically have a greater ability to inhibit hemolysis than the same compound except that they have valine instead of isoleucine at the position corresponding to Val3 of compstatin (i.e., IC 50 is lower).

[0216] Preferably, the in vitro effect of the compounds of the present invention is evaluated by measuring the inhibitory effect on the classical complement pathway in a hemolysis assay, for example, using the assay described in Example 2.

[0217] Compstatin analogs with acylation may have a lower absolute activity than the same compound except for the lack of acylation, but have additional benefits such as an extended in vivo half-life that can offset any apparent decrease in absolute activity.

[0218] Synthesis of Compstatin Analogs It is preferred to synthesize the compstatin analogs of the present invention by solid-phase peptide synthesis methodology or liquid-phase peptide synthesis methodology. In this regard, reference may be made to WO 98 / 11125 pamphlet and especially Fields, G.B. et al., 2002, “Principles and practice of solid-phase peptide synthesis”. In: Synthetic Peptides (2nd Edition) as well as the examples herein.

[0219] Details regarding the synthesis and structure of a compstatin analog containing cystathionine and lanthionine bridges between residues at positions X2 and X12 are provided in WO 2012 / 040259 pamphlet and Knerr et al., ACS Chem Biol. 2011 July 15;6(7):753-760 (DOI:10.1021 / cb2000378). Further relevant details regarding cystathionine and lanthionine chemistry can be found in de Araujo et al., 2014, Nature Communications;5:3165 (DOI:10.1038 / ncomms4165) and Muttenthaler et al., J. Med. Chem. 2010, 53, 8585-8596 (DOI:10.1021 / jm100989w).

[0220] According to the present invention, the compstatin analogs of the present invention can be synthesized or produced in several ways, including, for example, (a) synthesizing the compstatin analog by solid-phase peptide synthesis methodology or liquid-phase peptide synthesis methodology and recovering the thus-obtained synthesized compstatin analog; or (b) expressing the precursor peptide sequence from a nucleic acid construct encoding the precursor peptide, recovering the expression product, and modifying the precursor peptide to obtain the compounds of the present invention by methods including.

[0221] The precursor peptide can be modified by the introduction of one or more non-proteinogenic amino acids, such as Aib, Orn, Dap, 1-Me-Trp, 1-Nal, 2-Nal, Sar, γGlu or Dab, or the introduction of suitable terminal groups Y1 and / or Y2.

[0222] Expression is typically carried out from a nucleic acid encoding the precursor peptide, which can be carried out in a cell or cell-free expression system containing such nucleic acid.

[0223] It is preferred to synthesize the analogs of the present invention by solid-phase peptide synthesis or liquid-phase peptide synthesis. In this regard, reference is made to WO 98 / 11125 pamphlet and in particular Fields, G.B. et al., 2002, “Principles and practice of solid-phase peptide synthesis”. In: Synthetic Peptides (2nd Edition) as well as the examples in this specification.

[0224] For recombinant expression, the nucleic acid fragment encoding the precursor peptide will typically be inserted into a vector suitable for forming a cloning or expression vector. The vector can be in the form of a plasmid, phage, cosmid, mini-chromosome or virus, depending on the purpose and type of use, but naked DNA that is only transiently expressed in a particular cell is also an important vector. Preferred cloning vectors and expression vectors (plasmid vectors) can replicate autonomously, thereby allowing a high copy number for high-level expression or high-level replication for subsequent cloning.

[0225] In general outline, an expression vector comprises, operably linked in the 5'→3' direction, the following components: a promoter for driving the expression of the nucleic acid fragment, a nucleic acid sequence encoding a leader peptide that optionally enables secretion (into the extracellular phase or, where appropriate, into the periplasm), the nucleic acid fragment encoding the precursor peptide, and optionally a nucleic acid sequence encoding a terminus. These can include additional components, such as selection markers and origins of replication. When operating with an expression vector in a producer strain or cell line, the vector may preferably be integratable into the host cell genome. Those skilled in the art are very familiar with suitable vectors and can design those that comply with their specific requirements.

[0226] The vector of the present invention is used to transform host cells to produce precursor peptides. Such transformed cells can be cultured cells or cell lines used for the propagation of nucleic acid fragments and vectors and / or for the recombinant production of precursor peptides.

[0227] Preferred transformed cells are microorganisms such as bacteria [e.g., species of the genus Escherichia (e.g., Escherichia coli), species of the genus Bacillus (e.g., Bacillus subtilis), species of the genus Salmonella or species of the genus Mycobacterium (preferably non-pathogenic, e.g., Mycobacterium bovis BCG), yeasts (e.g., Saccharomyces cerevisiae and Pichia pastoris) and protozoa. Alternatively, the transformed cells can be derived from multicellular organisms, i.e., fungal cells, insect cells, algal cells, plant cells or animal cells, such as mammalian cells. For the purpose of cloning and / or optimizing expression, it is preferred that the transformed cells can replicate the nucleic acid fragment of the present invention. Cells expressing fragments of the nucleus can be used for small-scale or large-scale preparation of the peptides of the present invention.

[0228] When producing precursor peptides by transformed cells, although not absolutely essential, it is convenient for the expression product to be secreted into the medium.

[0229] Medical situations In a broad aspect, the present invention provides the Compstatin analogs of the present invention for use as a medicament or in therapy.

[0230] The Compstatin analogs described herein have biological activity that binds to C3 protein and / or inhibits complement activation. Generally, the Compstatin analogs of the present invention can be used in treatment or prophylactic situations associated with excessive or unwanted activation of the complement system. Complement can be activated via three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. The major activation event shared by all three pathways is the proteolytic cleavage of the central protein C3 of the complement system by C3 convertase into its activation products C3a and C3b. The generation of these fragments leads to opsonization of pathogenic cells by C3b and iC3b (the process of making pathogenic cells sensitive to phagocytosis or clearance) and activation of immune cells through interaction with complement receptors (Markiewski & Lambris, 2007, Am. J. Pathol., 171:715 - 727). Also, deposition of C3b on target cells induces the formation of new convertase complexes, thereby initiating an auto - amplification loop. An ensemble of plasma and cell - surface - bound proteins carefully regulates complement activation so as to protect host cells from self - attack by the complement cascade. The 13 - amino - acid cyclic tridecapeptide used as a reference point for the design of the Compstatin analogs of the present invention inhibits complement activation by binding to C3 and / or C3b, preventing the cleavage of native C3 by C3 convertase. Without wishing to be bound by any particular theory, the inventors believe that the Compstatin analogs of the present invention may also function in this way and share one or more biological activities selected from (1) binding to C3 protein, (2) binding to C3b protein, (3) inhibition of the cleavage of native C3 by C3 convertase, and / or (4) inhibition of the activation of the complement system. The biological activity of the Compstatin analogs of the present invention can be determined in vitro, for example, by measuring the inhibitory effect on the classical complement pathway in a hemolysis assay using the protocol described in the following examples.

[0231] Excessive activation or inappropriate regulation of the complement can lead to several pathological conditions ranging from autoimmune diseases to inflammatory diseases (Holers, 2003, Clin. Immunol., 107:140-51; Markiewski & Lambris, 2007, supra; Ricklin & Lambris, 2007, Nat. Biotechnol., 25:1265-75; Sahu et al., 2000, J. Immunol., 165:2491-9). These situations include (1) inhibition of complement activation to facilitate the treatment of diseases or conditions (age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis, antiphospholipid syndrome); (2) inhibition of complement activation occurring during cell transplantation or solid organ transplantation or during the use of artificial organs or grafts (e.g., by coating or otherwise treating cells, organs, artificial organs or grafts with the peptides of the present invention); or (3) inhibition of complement activation occurring during extracorporeal shunting of physiological fluids (blood, urine) (e.g., by coating the tubes through which the fluid is shunted with the compstatin analogs of the present invention).

[0232] Pharmaceutical Compositions and Administration In a further aspect, the present invention relates to a composition comprising a compstatin analog according to the present invention or a pharmaceutically acceptable salt or solvate thereof, together with a carrier. In one embodiment of the present invention, the composition is a pharmaceutical composition, and the carrier is a pharmaceutically acceptable carrier. The present invention also relates to a pharmaceutical composition comprising a compstatin analog according to the present invention or a salt and / or solvate thereof, together with a carrier, excipient or vehicle. Accordingly, the compstatin analog of the present invention or a salt or solvate thereof, particularly a pharmaceutically acceptable salt and / or solvate thereof, can be formulated as a composition or pharmaceutical composition prepared for storage or administration and containing a therapeutically effective amount of the compstatin analog of the present invention or a salt or solvate thereof.

[0233] Suitable salts formed with bases include metal salts, such as alkali metal salts or alkaline earth metal salts.

[0234] In one embodiment, the pharmaceutical composition of the present invention is one in which the compstatin analog is in the form of a pharmaceutically acceptable acid addition salt.

[0235] As will be apparent to those skilled in the medical art, the "therapeutically effective amount" of the compstatin analog compound of the present invention or its pharmaceutical composition will vary, inter alia, depending on the age, weight and / or sex of the subject (patient) to be treated. Other factors that may be relevant include the physical characteristics of the particular patient under consideration, the patient's diet, the nature of any concurrent medications, the particular compound used, the particular mode of administration, the desired pharmacological effect and the particular therapeutic indication. These factors and their relationships in determining this amount are well known in the medical art, and thus the determination of the therapeutically effective dosage levels, the amounts necessary to achieve the desired results of treating and / or preventing and / or ameliorating the malabsorption and / or low-grade inflammation described herein, and other medical indicators disclosed herein will be within the scope of those skilled in the art.

[0236] As used herein, the term "therapeutically effective amount" refers to an amount that alleviates the symptoms or manifestations of a given condition or pathology and preferably normalizes the physiological response in an individual having that condition or pathology. Alleviation of symptoms or normalization of physiological response can be determined using routine methods in the art and may vary depending on the given condition or pathology. In one embodiment, a therapeutically effective amount of one or more Compstatin analogs or pharmaceutical compositions thereof restores a measurable physiological parameter to a value substantially the same (preferably within 30%, more preferably within 20%, even more preferably within 10%) as the parameter in an individual not having the condition or pathology in question.

[0237] In one embodiment of the invention, administration of the compounds or pharmaceutical compositions of the invention is initiated at a lower dosage level, which is increased until the desired effect of preventing / treating the relevant medical indicators is achieved. This will define the therapeutically effective amount. For the Compstatin analogs of the invention, such human dosages of the active Compstatin analogs, alone or as part of a pharmaceutical composition, can be from about 0.01 pmol / kg body weight to 500 μmol / kg, from about 0.01 pmol / kg body weight to 300 μmol / kg, 0.01 pmol / kg body weight to 100 μmol / kg, 0.1 pmol / kg body weight to 50 μmol / kg, 1 pmol / kg body weight to 10 μmol / kg, 5 pmol / kg body weight to 5 μmol / kg, 10 pmol / kg body weight to 1 μmol / kg, 50 pmol / kg body weight to 0.1 μmol / kg, 100 pmol / kg body weight to 0.01 μmol / kg, 0.001 μmol / kg body weight to 0.5 μmol / kg, 0.05 μmol / kg body weight to 0.1 μmol / kg.

[0238] The most appropriate therapeutic administration and regimen for treating a patient will, of course, vary depending on the disease or condition to be treated and according to the patient's weight and other parameters. While not wishing to be bound by any particular theory, it is expected that dosages in the mg / kg range and shorter or longer periods or frequencies of treatment may result in therapeutically useful outcomes, such as a statistically significant inhibition of the alternative and classical complement pathways. The most appropriate dosage size and administration regimen for human use can be guided by the results obtained according to the present invention and can be confirmed in appropriately designed clinical trials.

[0239] Effective dosages and treatment protocols can likewise be determined by conventional means of starting at low dosages in laboratory animals and increasing the dosage while monitoring the effects and systematically varying the dosing schedule. When determining the optimal dosage for a given subject, a number of factors can be considered by the clinician.

[0240] For topical delivery to the eye, the pharmaceutically acceptable composition can be formulated in an isotonic pH-adjusted sterile saline solution with or without a preservative, such as benzalkonium chloride, or in water. Alternatively, for ophthalmic use, the pharmaceutically acceptable composition can be formulated as an ointment, such as in petrolatum, or as an eye drop. Examples of methods of topical administration to the eye include choroidal injection, transscleral injection or scleral patch placement, selective arterial catheterization, eye drops or eye ointments, intravitreal administration (including retinal injection, subconjunctival injection, intravitreal injection, suprachoroidal injection, subtenon injection, scleral pocket and scleral cut-down injection (such as by an osmotic pump)), etc. Also, the agent can alternatively be administered intravascularly, such as intravenously (IV) or intraarterially. In choroidal injection and scleral patching, the clinician uses a topical approach to the eye after initiation of appropriate anesthesia, which may include analgesics and ophthalmic muscle relaxants. The needle containing the therapeutic compound is introduced and inserted into the choroid or sclera of the subject under sterile conditions. Once the needle is properly positioned, the compound is injected into either or both the choroid and sclera. In any of these methods, the clinician can select a sustained release or longer acting dosage form. Thus, the procedure may only be repeated every few months or years, depending on the tolerance of the subject to the treatment and response.

[0241] The following examples are provided to illustrate the invention in more detail. These are not intended to limit the invention, but rather are intended to be examples of the invention. The compounds described have particularly advantageous properties as a result of their specific amino acid sequences and / or acylation. In addition to compounds having residues linked by thioether bonds at positions corresponding to positions 2 and 12 of compstatin, some of the compounds described below have cysteine residues linked by disulfide bonds at those positions. Similar or otherwise identical compounds containing thioether bonds are expected to have similar advantageous properties and / or to exhibit improved stability, such as chemical stability (resistance to degradation) or physical stability (resistance to aggregation).

Examples

[0242] Example 1: Synthesis of Compstatin Analogs General Peptide Synthesis

[0243] [Table 1]

[0244] [Table 2]

[0245] Apparatus and Synthetic Strategy Using 9-fluorenylmethyloxycarbonyl (Fmoc) as the N-α-amino protecting group and appropriate general protecting groups for side-chain functional groups, peptides were synthesized manually in batch or using a peptide synthesizer, such as a CEM Liberty Peptide Synthesizer or a Symphony X Synthesizer, according to solid-phase peptide synthesis procedures.

[0246] A polymer support-based resin, such as TentaGel™, was used. The resin was swollen in DMF and then solid-phase synthesis was initiated.

[0247] Standard Amino Acid Coupling Procedures Manual Peptide Coupling Manual coupling was carried out with 2 - 3 equivalents of Fmoc-protected amino acid and either HATU:NMM (2 - 3:4 - 6 equivalents), HBTU:NMM (2 - 3:4 - 6 equivalents), DIC:Oxyma (2 - 3:2 - 3), or DIC:Oxyma:DIPEA (2 - 3:2 - 3:0.3 - 6). After an amino acid coupling time of 45 minutes to 1 hour with shaking, thorough washing was continued.

[0248] CEM Liberty Peptide Synthesizer A solution of Fmoc-protected amino acid (4 equivalents), coupling reagent (4 equivalents), and base (8 equivalents) was added to the resin. The mixture was heated to 70 - 75 °C for 5 minutes by a microwave apparatus or coupled without heating for 60 minutes. During coupling, nitrogen was passed through the mixture to agitate it.

[0249] Symphony X Synthesizer The amino acid coupling reagents were transferred to the reaction vessel in the following order: Fmoc-protected amino acid (4 equivalents), HATU (4 equivalents), and DIPEA (8 equivalents). The coupling time was 10 minutes at room temperature (rt.) unless otherwise specified. The resin was washed with DMF (5 × 0.5 minutes). In the case of repeated coupling, the coupling time was 45 minutes at rt. in all cases.

[0250] Fmoc Deprotection Manual Fmoc Deprotection After thorough washing of the resin, a DMF solution of 20 v / v / % piperazine was added and the mixture was left to react for 30 minutes with shaking. After coupling, the resin was washed appropriately.

[0251] CEM Liberty Peptide Synthesizer The Fmoc group was deprotected using piperidine in DMF or other suitable solvent. The deprotection solution was added to the reactor and the mixture was heated for 30 seconds until it reached approximately 40 °C. The reactor was drained, fresh deprotection solution was added, and then heated to 70 - 75 °C for 3 minutes. After draining the reactor, the resin was washed with DMF or other suitable solvent.

[0252] Symphony X Synthesizer Fmoc deprotection was carried out using 40% piperidine in DMF for 2.5 minutes and repeated using the same conditions. The resin was washed with DMF (5 × 0.5 minutes).

[0253] Side Chain Acylation An amino acid having Fmoc-Lys(Dde)-OH or an alternative orthogonal side-chain protecting group was introduced at the acylation position (side-chain lipidation). The N-terminus of the linear peptide was acetylated or Boc-protected. While the peptide was still attached to the resin, the protecting group of the lysine ε -amine side-chain was selectively cleaved using freshly prepared hydrazine hydrate (2 - 4%) in NMP for 2 x 15 minutes. Subsequently, the unprotected lysine side-chain was extended with the desired building blocks according to a specific sequence using standard coupling conditions and Fmoc-deprotection. The lipid moiety was coupled as the final step.

[0254] Alternatively, the side-chain acylation was assembled and then the linear peptide was assembled. Dde-Lys(Fmoc)-OH or alternatively another orthogonal protecting group was introduced at the C-terminus at the position of acylation (side-chain lipidation). Subsequently, the Fmoc group was removed as described in the deprotection section, and the unprotected lysine side-chain was extended with the desired building blocks using standard amino acid coupling conditions and Fmoc-deprotection. The lipidated moiety was coupled as the final step. The branched lysine was still attached to the resin, while the orthogonal N-terminal protecting group (Dde) was selectively cleaved using freshly prepared hydrazine hydrate (2 - 4%) in NMP for 2 x 15 minutes to continue with standard peptide synthesis.

[0255] Incorporation of Dde-hCys(Fmoc-Ala-OAllyl)-OH (#1) or Dde-Ala(Fmoc-hCys-OAllyl)-OH (#2) 1.5 - 3.0 equivalents of #1 or #2 (Scheme 1a) were used. Also, the building blocks were incorporated using standard coupling reagents and an extended coupling time of 2.5 hours to 12 hours.

[0256] Allyl deprotection and lactam formation: After the assembly of the branched peptide on the resin, the resin after thorough washing with DMF was treated with a CHCl3 / AcOH / NMM solution of Pd(P(C6H5)3)4 for 3 hours to remove the OAll group. The Fmoc group was removed using standard deprotection conditions. Amide bonds formed between the free amine and carboxylic acid were formed using PyAOP, HOBt, and DIPEA (3:5:5) in DMF overnight.

[0257] Release of the peptide from the solid support The dried peptide resin was treated with TFA and appropriate scavengers for approximately 2 hours. The volume of the filtrate was reduced, and the crude peptide was precipitated after the addition of diethyl ether. The crude peptide precipitate was washed several times with diethyl ether and finally dried.

[0258] HPLC purification of the crude peptide The crude peptide was purified by preparative reverse-phase HPLC using a conventional HPLC apparatus equipped with a column, e.g., a 5×25 cm Gemini NX 5u C18 110A column or a Phenomenex Luna C18 250×21 mm 100A, and a fraction collector, e.g., a Gilson GX-281 having a 331 / 332 pump combination, with an appropriate gradient of buffer A (0.1% formic acid, aq.) or A (0.1% TFA, aq.) and buffer B (0.1% formic acid, 90% MeCN, aq.) or B (0.1% TFA, 90% MeCN, aq.) at a flow rate of 20 - 40 ml / min. The fractions were analyzed by analytical HPLC and MS, the selected fractions were pooled, and lyophilized. The final product was characterized by HPLC and MS.

[0259] Formation of disulfide bonds After purification and lyophilization of the linear peptide, the peptide was redissolved in 0.1% TFA in water, acetonitrile and acetic acid. The concentration of the peptide solution was maintained at approximately 1 - 2 mg / ml. A methanol solution of iodine (approximately 1.5 equivalents) was added dropwise with stirring until the peptide solution turned orange. After 10 - 15 minutes, the reaction was complete and the excess iodine was quenched with an aqueous solution of ascorbic acid (1 equivalent) until the peptide solution turned colorless. The peptide solution was diluted with water and then purified by preparative HPLC.

[0260] Analytical HPLC The final purity was determined by analytical HPLC (Agilent 1100 / 1200 series) equipped with an autosampler, a degasser, a 20 μl flow cell and Chromeleon software. Using an analytical column, for example, a Kinetex 2.6 μm XB - C18 100A 100×8.6 mm column, HPLC was operated at a flow rate of 1.2 ml / min at 40 °C. The compound was detected and quantified at 215 nm. Buffer A (0.1% TFA, aq.) and Buffer B (0.1% TFA, 90% MeCN, aq.).

[0261] Mass spectrometry The final MS analysis value was determined using a conventional mass spectrometry, for example, Waters Xevo G2 TOF equipped with an electrospray detector and MassLynx software by lock - mass calibration. This was operated in positive mode using cone voltages of 15 V (1TOF), 30 V (2TOF) or 45 V (3TOF) specified in the direct injection and chromatogram. The accuracy was 5 ppm at a typical resolution of 15,000 - 20,000.

[0262] Synthesis of Compound No24: Ac - IC(1)IWQDWGEHRC(1)TEGE - NH2 Solid-phase peptide synthesis was carried out on a Symphony X Synthesizer using standard Fmoc chemistry. TentaGel S RAM (2.51 g; 0.23 mmol / g) was swollen in DMF (20 ml), and the Fmoc-group was deprotected according to the procedure described above.

[0263] Amino acid coupling The appropriate Fmoc-amino acid protected according to the sequence was coupled as described above using HATU as the coupling reagent. All amino acid couplings were carried out at rt.

[0264] Fmoc deprotection Fmoc deprotection was carried out according to the procedure described above.

[0265] Cleavage of the peptide from the solid support The peptide-resin was washed with EtOH (3×10 ml) and Et2O (3×10 ml) and dried to a constant weight at room temperature (rt). The peptide was released from the resin by treatment with TFA / DODT (95 / 5; 60 ml, 2 h; rt). The volume of the filtrate was reduced, and the crude peptide was precipitated by the addition of diethyl ether. The crude peptide precipitate was washed several times with diethyl ether and finally dried to give 760 mg of crude peptide product (purity about 30%).

[0266] HPLC purification of the crude linear peptide Using a Gilson GX-281 with a 331 / 332 pump combination for binary gradient applications equipped with a 5×25 cm Gemini NX 5u C18 110A column and a fraction collector, the crude peptide was purified by preparative reverse-phase HPLC with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.) from 20% B to 45% B at a flow rate of 35 ml / min for 47 minutes. The fractions were analyzed by analytical HPLC and MS, the relevant fractions were pooled and lyophilized to obtain 190 mg. The purity was characterized by HPLC and MS as described above to be 85%. Calculated monoisotopic MW 2001.58 m / z, measured 2001.81 m / z.

[0267] Formation of disulfide bonds 190 mg of the purified linear peptide was dissolved in 220 ml of water / acetonitrile (65% / 35%) containing 0.1% TFA. A methanol solution of iodine (2.2 mL, approximately 1.5 equivalents of iodine) was added dropwise with stirring until the peptide solution turned orange. Analytical HPLC was continued after the reaction, and the reaction was found to be complete after 10 - 15 minutes. The excess iodine was reduced with an aqueous solution of ascorbic acid (220 μL, approximately 1 equivalent) until the peptide solution became colorless. The volume of the peptide solution was slightly reduced by rotary evaporation and then purified by preparative HPLC.

[0268] HPLC purification of the oxidized peptide The crude peptide was purified by preparative reversed-phase HPLC using a Gilson GX-281 with a 331 / 332 pump combination for binary gradient applications, equipped with a 5×25 cm Gemini NX 5u C18 110A column and a fraction collector, with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.) from 20% B to 45% B at 35 ml / min for 47 min. The fractions were analyzed by analytical HPLC and MS, the relevant fractions were pooled and lyophilized to obtain 138 mg. It was characterized by HPLC and MS as described above with a purity of 92%. Calculated monoisotopic MW 1999.83 m / z, measured 1999.54 m / z.

[0269] Synthesis of Compound No119 Ac-SEFC(1)I[1-Me-Trp]QDWGEHRC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2

[0270] Solid-phase peptide synthesis was performed on a Symphony X Synthesizer using standard Fmoc chemistry. TentaGel S RAM (3× ca. 1.3 g; 0.22 mmol / g) was swollen in DMF (3×10 ml) before use and the Fmoc-group was deprotected according to the procedure described above.

[0271] Amino acid coupling The appropriate Fmoc-amino acids protected according to the sequence were coupled as described above using HATU as the coupling reagent. All couplings were performed at rt. Lysine used for the incorporation of the branched part was incorporated as Fmoc-Lys(Dde)-OH for orthogonal coupling of the side chain.

[0272] Fmoc deprotection Fmoc deprotection was carried out according to the procedure described above.

[0273] Side chain acylation While the peptide was still bound to the resin, the orthogonal side chain protecting group (Dde) was selectively cleaved using freshly prepared hydrazine hydrate (4%) in NMP for 2×15 minutes. The unprotected lysine side chains were double-coupled with Fmoc-Peg3-OH using standard coupling conditions, followed by single couplings with Fmoc-Glu-OtBu, Fmoc-Peg3-OH, Fmoc-Gly-OH, Fmoc-Glu-OtBu and finally the fatty acid moiety 17-carboxy-heptadecanoic acid mono tert-butyl ester.

[0274] Cleavage of the peptide from the solid support The peptide-resin was washed with EtOH (3×15 ml) and Et2O (3×150 ml) and dried to a constant weight at room temperature (rt). The peptide was cleaved from the resin by treatment with TFA / DODT (95 / 5; 120 ml, 2 hours; rt). The volume of the filtrate was reduced and the crude peptide was precipitated by the addition of diethyl ether. The crude peptide precipitate was washed several times with diethyl ether and finally dried to give 2.36 g of crude peptide product (purity about 41 - 48%).

[0275] HPLC purification of the crude linear peptide The crude peptide was purified by preparative reverse-phase HPLC using a Gilson GX-281 with a 331 / 332 pump combination for binary gradient applications, equipped with a 5×25 cm Gemini NX 5u C18 110A column and a fraction collector, with a gradient from buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.) from 30% B to 60% B at 35 ml / min for 47 minutes. The fractions were analyzed by analytical HPLC and MS, the relevant fractions were pooled and lyophilized to give 744 mg. The purity was characterized as 84% by HPLC and MS as described above. Calculated monoisotopic MW 3207.47 m / z, measured 3207.32 m / z.

[0276] Formation of disulfide bonds 744 mg of the purified linear peptide was dissolved in 350 mL of 0.1% TFA in water, 150 mL of acetonitrile, and 100 mL of acetic acid to obtain a clear solution. An iodine methanol solution (4.7 mL, approximately 1.5 equivalents of iodine) was added dropwise with stirring until the peptide solution turned orange. Analytical HPLC was continued after the reaction. The reaction was completed after 10 - 15 minutes, and the excess iodine was quenched with an aqueous solution of ascorbic acid (150 μL, approximately 1 equivalent) to obtain a colorless solution. The volume of the peptide solution was slightly reduced by rotary evaporation and then purified by preparative HPLC.

[0277] HPLC Purification of the Oxidized Peptide The crude peptide was purified by preparative reverse-phase HPLC using a Gilson GX-281 with a 331 / 332 pump combination for binary gradient applications, equipped with a 5×25 cm Gemini NX 5u C18 110A column and a fraction collector, with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.) from 30% B to 60% B at a flow rate of 35 mL / min for 47 minutes. The fractions were analyzed by analytical HPLC and MS, the relevant fractions were pooled and lyophilized to obtain 510 mg. The purity was characterized by 91% by the HPLC and MS described above. Calculated monoisotopic MW 3205.47 m / z, measured 3205.23 m / z.

[0278] Synthesis of Compound No146 Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2

Chemical Structure

[0279] A schematic of the synthetic route for Compound 146 (Scheme 1b) is shown in Figure 3.

[0280] Overall Solid-phase peptide synthesis was performed manually using standard Fmoc chemistry. Link amide-MBHA (0.5 mmol, 0.214 mmol / g, ca. 2.3 g) was swollen overnight in DMF:DCM before use and the Fmoc-group was deprotected according to the procedure described above.

[0281] Amino acid coupling The appropriate Fmoc-amino acids protected according to the sequence were coupled as described above using HBTU:NMM or HATU:NMM with 2 - 3 equivalents of amino acid as coupling reagent. All couplings were carried out for 1 - 3 h at room temperature (rt.), unless stated otherwise. Lysine used for the incorporation of the branched part was incorporated as Dde-Lys(Fmoc)-OH for orthogonal coupling.

[0282] Fmoc deprotection Fmoc deprotection was carried out according to the procedure described above.

[0283] Steps 1 and 2 (Scheme 1b) After the coupling of Dde-Lys(Fmoc)-OH to the resin and Fmoc deprotection, the following amino acids were coupled to the lysine ε-amino using HATU:NMM as coupling reagent: Fmoc-Glu-OtBu, Fmoc-Peg3-OH, Fmoc-Gly-OH, Fmoc-Glu-OtBu and finally the fatty acid moiety 17-carboxy-heptadecanoic acid monoter-butyl ester. The peptide was still bound to the resin while the protecting group (Dde) was selectively cleaved using freshly prepared hydrazine hydrate (2 - 4%) in NMP for 2 × 15 min. After thorough washing with NMP, the C-terminal amino acid was coupled using standard conditions (mostly HATU:NMM) and ended with the coupling of sarcosine.

[0284] Steps 3 and 4 (Scheme 1b) After standard Fmoc deprotection, the building block Dde-hCys(Fmoc-Ala-OAllyl)-OH (#1, Scheme 1a) was incorporated using 3 equivalents of #1 and HATU:NMM (3:6) at rt for 2.5 h. The N-terminal amino acid was coupled using 3 equivalents of amino acid and HBTU:NMM (3:6) at rt for 1 h and finished with N-terminal acetylation using Ac2O:DCM (1:2) for 2 h.

[0285] Step 5 (Scheme 1b) The synthesis was continued by removing the Dde protecting group from the N-terminal amine using freshly prepared hydrazine hydrate (4%) in NMP for 2 × 15 min. After thorough washing with NMP, the free amine and carboxylic acid were coupled to form the lactam using 3 equivalents of amino acid and HATU:NMM (3:6) at rt for 1 h.

[0286] Step 6 (Scheme 1b) After assembly of the branched peptide on the resin, the resin was treated with a CHCl3 / AcOH / NMM solution of Pd(P(C6H5)3)4 for 3 h to remove the allyl group. The resin was thoroughly washed and the Fmoc group was removed using standard deprotection conditions. The lactam was formed using PyAOP, HOBt and DIPEA (3:5:5) in DMF overnight.

[0287] Cleavage of the peptide from the solid support (Step 7, Scheme 1b) The peptide-resin was washed with EtOH (3 × 15 ml) and Et2O (3 × 150 ml) and dried. The peptide was released from the resin by treatment with TFA / EDT / thioanisole / phenol / H2O (87.5 / 2.5 / 5 / 2.5 / 2.5; 35 ml, 2 h; rt.). The volume of the filtrate was reduced and the crude peptide was precipitated by addition of diethyl ether. The crude peptide precipitate was washed several times with diethyl ether and finally dried to give 1.4 g of crude peptide product (purity 23%).

[0288] HPLC Purification of the Final Peptide The crude peptide was purified by preparative reverse-phase HPLC using a 5×25 cm Phenomenex Luna C18 110A column and a fraction collector, running at 35 ml / min for 47 min with a gradient from 30% B to 60% B of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.). The fractions were analyzed by analytical HPLC and MS, the relevant fractions were pooled, lyophilized, and 125.5 mg was obtained. The purity was characterized as 90.3% by HPLC and MS as described above. Calculated monoisotopic MW 3245.52 m / z, measured 3245.32 m / z.

[0289] [Table 3]

[0290] [Table 4]

[0291] [Table 5]

[0292] [Table 6]

[0293] [Table 7]

[0294] [Table 8]

[0295] [Table 9]

[0296]

Table 10

[0297] Example 2: In vitro hemolysis assay Method The in vitro effect of the test compound was evaluated by measuring the inhibitory effect on the classical complement pathway in a hemolysis assay.

[0298] Briefly, the test compound and the reference compound were dissolved in DMSO and diluted as 9-point serial dilutions in 96-well plates in Tris / casein assay buffer (10 mM Tris, 145 mM NaCl, 0.5 mM MgCl2, 0.15 mM CaCl2 and 0.1 W / V% casein, adjusted to pH 7.4). Sensitized sheep red blood cells (RBC) (Complement Technology, Inc., TX, USA) coated with rabbit anti-sheep red blood cell antiserum were washed in Tris / casein assay buffer. 50 μL from the diluted compound of each well was added to a 96-well plate containing 50 μL of diluted human serum (Complement Technology, Inc., TX, USA) and incubated at room temperature for 15 minutes. The serum dilution factor was optimized for each serum batch to obtain 70 - 90% maximum hemolysis using the protocol. Next, 50 μL of sensitized sheep red blood cells was added to all wells (10 7 per well).

[0299] After 30 minutes of incubation at 37 °C with gentle stirring, the reaction was stopped by the addition of 50 μL of Tris STOP buffer (10 mM EDTA, 10 mM Tris, 145 mM NaCl, adjusted to pH 7.4) per well. Next, the RBC were removed by centrifugation and the resulting supernatant was measured for hemolysis by absorbance at 405 nm.

[0300] The responses were normalized by comparison with positive and negative controls (vehicle), and the IC50 was calculated from the concentration-response curves using a 4-parameter logistic (4PL) non-linear model for curve fitting. All values were based on independent determinations with n => 2.

[0301]

Table 11

[0302] Additional compounds were tested as shown below.

[0303]

Table 12

[0304]

Table 13

[0305]

Table 14

[0306]

Table 15

[0307] The following pairs of compounds (differing only at the 3-position) show that the effect of substituting valine with isoleucine is seen in compounds with various peptide backbone sequences.

[0308]

Table 16

[0309] Also, isoleucine at the 3-position was demonstrated to be superior compared to other residues that are often considered to be "conservative" substitutions with isoleucine.

[0310]

Table 17

[0311] Due to the high concentration of C3 found in serum, it may be difficult to distinguish compounds with very high affinity for C3 using a hemolysis assay.

[0312] In such situations, it may be possible to determine a more accurate hierarchy of binding affinities for C3 by SPR measurements using immobilized C3, as described below.

[0313] Example 3: Solubility Test Materials and Methods Compound Solubility at 10 mg / mL The solubility of the compounds was evaluated by measuring light scattering over a pH range from pH 4 to pH 7.5.

[0314] The compounds were dissolved in a stock solution of 20 mg / mL in H2O at pH 2.5 or pH 10. These stock solutions were diluted 1:1 with 200 mM buffer solution to reach a final solution of 10 mg / mL compound in 100 mM buffer. The five conditions investigated were (1) acetic ac...

Claims

1. Formula: Y1 - P - Y2 A compstatin analog represented by the formula, wherein in the formula, Y1 is hydrogen, acetyl or a lipophilic group Φ; Y2 is NH ２ , OH or a lipophilic group Φ; P is as follows: (I) IhC(1)IWQDWDGAHRA(1)T, IhC(1)IWQDWDGEHRA(1)T, ESSAIhC(1)IWQDWDGEHRA(1)T, IhC(1)I[1MeTrp]QDWDGEHRA(1)T, IhC(1)IWQDWDGKHRA(1)T, IhC(1)IWQDWDGSHRA(1)T, IhC(1)IWQKWGEHRA(1)T, IhC(1)IWQKWGAHRA(1)TGES, YhC(1)IWQDWDGEHRA(1)T, ESSAYhC(1)IWQDWDGEHRA(1)T, [Sar]hC(1)IWQDWDGEHRA(1)T, IhC(1)IWQDWDGAHRA(1)E, IhC(1)IWQDWDGEHRA(1)[Sar], ESSAIhC(1)IWQDWDGEHRA(1)TGES, IhC(1)IWQDWDGEHRA(1)TGES, IhC(1)IWQEWGEHRA(1)T, IhC(1)IWQDWDGDRHA(1)T, IhC(1)IWQDWDGRHA(1)T, IhC(1)IWQDWDGAHSA(1)T, IhC(1)IWQDWDGEHSA(1)T, IhC(1)IWQDWDGEHRA(1)S, IhC(1)IWQDWDGEHRA(1)E, FhC(1)IWQDWDGEHRA(1)T, IhC(1)IWQDWDGEHRA(1)TEGE, IhC(1)IWQDWDGEHRA(1)TEA, IhC(1)IWQDWDGEHRA(1)TE, IhC(1)IWQDWDGEHRA(1)EGE, EGSAIhC(1)IWQDWDGEHRA(1)[Sar]E, EGSAIhC(1)IWQDWDGEHRA(1)T, EGEIhC(1)IWQDWDGEHRA(1)T, ESEIhC(1)IWQDWDGEHRA(1)T, SEIhC(1)IWQDWDGEHRA(1)TEA, EIhC(1)IWQDWDGEHRA(1)TE, EIhC(1)IWQDWDGEHRA(1)TEGE, EGEIhC(1)IWQDWDGEHRA(1)EGE, ESEIhC(1)IWQDWDGEHRA(1)EGE, KEKIhC(1)IWQDWDGEHRA(1)TEKE, EKGIhC(1)IWQDWDGEHRA(1)TEKP, IhC(1)IWQDWDGEHRA(1)TEGK, GSAIhC(1)IWQDWEHRA(1)[Sar]E、 SAIhC(1)IWQDWEHRA(1)[Sar]E、 SAIhC(1)IWQDWEHRA(1)TEG、 FhC(1)IWQDWEHRA(1)TGAE、 EGSAIhC(1)IWQDWEHRA(1)[Sar]EGE、 EGSAFhC(1)IWQDWEHRA(1)[Sar]E、 ESSAIhC(1)IWQDWAHRA(1)T、 IhC(1)IWQDWAHRA(1)TGES、 {d}YIhC(1)I[1-Me-Trp]QDWAHRA(1)-[N-Me-Ile]、 EGSAIhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E、 EGSAIhC(1)I[2-Nal]QDWEHRA(1)[Sar]E、 IhC(1)I[1-Me-Trp]QDWEHRA(1)TGES、 IhC(1)I[2-Nal]QDWEHRA(1)TGES、 EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E、 EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E、 EGSAIhC(1)IWQDWEHRA(1)TE、 EGSAFhC(1)I[1-Nal]QDWEHRA(1)TE、 EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)TE、 EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)EGE、 EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)TE、 EGSAFhC(1)I[2-Nal]QDWEHRA(1)TE、 FhC(1)I[1-Me-Trp]QDWEHRA(1)TGES、 YhC(1)I[1-Me-Trp]QDWEHRA(1)TGES、 FhC(1)I[1-Nal]QDWEHRA(1)TGES、 FhC(1)I[2-Nal]QDWEHRA(1)TGES、 YhC(1)I[2-Nal]QDWEHRA(1)TGES、 YhC(1)IWQDWEHRA(1)TGES、 SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TGES、 YhC(1)I[1-Me-Trp]QDWEHRA(1)TEAGS、 YhC(1)I[1-Me-Trp]QDWEHRA(1)TESGA、 EGSAYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E, SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, FhC(1)I[1-Me-Trp]QDWSar]EHRA(1)TGAES, {d}YFhC(1)I[1-Me-Trp]QDWSar]EHRA(1)TGAES, SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]GAES, SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SEFhC(1)I[1-Me-Trp]QDWSar]EHRA(1)[Sar]EA, SEFhC(1)I[1-Me-Trp]QDWSar]EHRA(1)TEA, SEFhC(1)I[1-Me-Trp]QDWEHRa(1)[Sar]E, SEFhC(1)I[1-Me-Trp]QDWSar]EHRA(1)[Sar]E, EFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)TEA, SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA, SEFhC(1)I[1-Me-Trp]QDWEHRA(1)SEA, EFhC(1)I[1-Me-Trp]QDWEHRA(1)ES, SEFhC(1)I[1-Me-Trp]QDWEHK A(1)[Sar]EA, GEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, GE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)TEA, SE[Sar]hC(1)I[1-Me-Trp]QEWSar]EHRA(1)TEA, SE[Sar]hC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA, and {d}Y[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)TEA is a sequence selected from, and the side chains of the residues designated as hC(1) and A(1) form cystathionine bridges or (II) IA(1)IWQDWEAHRhC(1)T, IA(1)IWQDWEHRhC(1)T, ESS AIA(1)IWQDWEHRhC(1)T, IA(1)I[1MeTrp]QDWEHRhC(1)T, IA(1)IWQDWGKHRhC(1)T, IA(1)IWQDWGSHRhC(1)T, IA(1)IWQKWGEHRhC(1)T, IA(1)IWQKWGAHRhC(1)TGAES, YA(1)IWQDWEHRhC(1)T, ESSAYA(1)IWQDWEHRhC(1)T, [Sar]A(1)IWQDWEHRhC(1)T, IA(1)IWQDWAHRhC(1)E, IA(1)IWQDWEHRhC(1)[Sar], ESSIA(1)IWQDWEHRhC(1)TGES, IA(1)IWQDWEHRhC(1)TGES, IA(1)IWQEWGEHRhC(1)T, IA(1)IWQDWDHRhC(1)T, IA(1)IWQDWRHRhC(1)T, IA(1)IWQDWAHShC(1)T, IA(1)IWQDWEHShC(1)T, IA(1)IWQDWEHRhC(1)S, IA(1)IWQDWEHRhC(1)E, FA(1)IWQDWEHRhC(1)T, IA(1)IWQDWEHRhC(1)TEGE, IA(1)IWQDWEHRhC(1)TEA, IA(1)IWQDWEHRhC(1)TE, IA(1)IWQDWEHRhC(1)EGE, EGSAIA(1)IWQDWEHRhC(1)[Sar]E, EGSAIA(1)IWQDWEHRhC(1)T, EGEIA(1)IWQDWEHRhC(1)T, ESEIA(1)IWQDWEHRhC(1)T, SEIA(1)IWQDWEHRhC(1)TEA, EIA(1)IWQDWEHRhC(1)TE, EIA(1)IWQDWEHRhC(1)TEGE, EGEIA(1)IWQDWEHRhC(1)EGE, ESEIA(1)IWQDWEHRhC(1)EGE, KEKIA(1)IWQDWEHRhC(1)TEKE, EKGAIA(1)IWQDWEHRhC(1)TEKP, IA(1)IWQDWEHRhC(1)TEGK, GSAIA(1)IWQDWEHRhC(1)[Sar]E, SAIA(1)IWQDWEHRhC(1)[Sar]E, SAIA(1)IWQDWEHRhC(1)TEG, FA(1)IWQDWEHRhC(1)TGAE, EGSAIA(1)IWQDWEHRhC(1)[Sar]EGE, EGSAFA(1)IWQDWGHRhC(1)[Sar]E, ESSAI A(1)IWQDWGHRhC(1)T, IA(1)IWQDWGHRhC(1)TGES, {d}YIA(1)I[1 - Me - Trp]QDWSarAHRC(1)-[N - Me - Ile], EGSAIA(1)I[1 - Me - Trp]QDWGHRhC(1)[Sar]E, EGSAIA(1)I[2 - Nal]QDWGHRhC(1)[Sar]E, IA(1)I[1 - Me - Trp]QDWGHRhC(1)TGES, IA(1)I[2 - Nal]QDWGHRhC(1)TGES, EGSAFA(1)I[1 - Me - Trp]QDWGHRhC(1)[Sar]E, EGSAYA(1)I[1 - Me - Trp]QDWGHRhC(1)[Sar]E, EGSAIA(1)IWQDWGHRhC(1)TE, EGSAFA(1)I[1 - Nal]QDWGHRhC(1)TE, EGSAFA(1)I[1 - Me - Trp]QDWGHRhC(1)TE, EGSAFA(1)I[1 - Me - Trp]QDWGHRhC(1)EGE, EGSAYA(1)I[1 - Me - Trp]QDWGHRhC(1)TE, EGSAFA(1)I[2 - Nal]QDWGHRhC(1)TE, FA(1)I[1 - Me - Trp]QDWGHRhC(1)TGES, YA(1)I[1 - Me - Trp]QDWGHRhC(1)TGES, FA(1)I[1 - Nal]QDWGHRhC(1)TGES, FA(1)I[2 - Nal]QDWGHRhC(1)TGES, YA(1)I[2 - Nal]QDWGHRhC(1)TGES, YA(1)IWQDWGHRhC(1)TGES, SEFA(1)I[1 - Me - Trp]QDWGHRhC(1)TGES, YA(1)I[1 - Me - Trp]QDWGHRhC(1)TEAGS, YA(1)I[1 - Me - Trp]QDWGHRhC(1)TESGA, EGSAYA(1)I[1 - Me - Trp]QEWGHRhC(1)[Sar]E, SEYA(1)I[1 - Me - Trp]QDWGHRhC(1)[Sar]EA, FA(1)I[1 - Me - Trp]QDWSarEHRhC(1)TGES, {d}YFA(1)I[1 - Me - Trp]QDWSarEHRhC(1)TGES, SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]GAES, SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA, SEFA(1)I[1-Me-Trp]QD[Sar]EHRhC(1)[Sar]EA, SEFA(1)I[1-Me-Trp]QD[Sar]EHRhC(1)TEA, SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E, SEFA(1)I[1-Me-Trp]QD[Sar]EHRhC(1)[Sar]E, EFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA, SE[Sar]A(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA, SE[Sar]A(1)I[1-Me-Trp]QDWEHRhC(1)TEA, SEFA(1)I[1-Me-Trp]QEWEHRhC(1)[Sar]EA, SEFA(1)I[1-Me-Trp]QDWEHRhC(1)SEA, EFA(1)I[1-Me-Trp]QDWEHRhC(1)ES, SEFA(1)I[1-Me-Trp]QDWEHKhC(1)[Sar]EA, GEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA, GE[Sar]A(1)I[1-Me-Trp]QDWEHRhC(1)TEA, SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA, SE[Sar]A(1)I[1-Me-Trp]QEWEHRhC(1)[Sar]EA, and {d}Y[Sar]A(1)I[1-Me-Trp]QDWEHRhC(1)TEA is an array selected from, and the side chains of the residues designated as A(1) and hC(1) form cystathionine bridges or, (III) IC(1)IWQDWAHRA(1)T, IC(1)IWQDWEHRA(1)T, ESS AIC(1)IWQDWEHRA(1)T, IC(1)I[1MeTrp]QDWEHRA(1)T, IC(1)IWQDWGKHRA(1)T, IC(1)IWQDWGSHRA(1)T, IC(1)IWQKWGEHRA(1)T, IC(1)IWQKWGAHRA(1)TG AES, YC(1)IWQDWEHRA(1)T, ESSAYC(1)IWQDWEHRA(1)T, [Sar]C(1)IWQDWEHRA(1)T, IC(1)IWQDWEAHRA(1)E, IC(1)IWQDWEHRA(1)[Sar], ESSAC(1)IWQDWEHRA(1)TGES, IC(1)IWQDWEHRA(1)TGES, IC(1)IWQEWGEHRA(1)T, IC(1)IWQDWDHRA(1)T, IC(1)IWQDWRHRA(1)T, IC(1)IWQDWAHSA(1)T, IC(1)IWQDWEHSA(1)T, IC(1)IWQDWEHRA(1)S, IC(1)IWQDWEHRA(1)E, FC(1)IWQDWEHRA(1)T, IC(1)IWQDWEHRA(1)TEGE, IC(1)IWQDWEHRA(1)TEA, IC(1)IWQDWEHRA(1)TE, IC(1)IWQDWEHRA(1)EGE, EGSAIC(1)IWQDWEHRA(1)[Sar]E, EGSAIC(1)IWQDWEHRA(1)T, EGEIC(1)IWQDWEHRA(1)T, ESEIC(1)IWQDWEHRA(1)T, SEIC(1)IWQDWEHRA(1)TEA, EIC(1)IWQDWEHRA(1)TE, EIC(1)IWQDWEHRA(1)TEGE, EGEIC(1)IWQDWEHRA(1)EGE, ESEIC(1)IWQDWEHRA(1)EGE, KEKIC(1)IWQDWEHRA(1)TEKE, EKGC(1)IWQDWEHRA(1)TEKP, IC(1)IWQDWEHRA(1)TEGK, GSAIC(1)IWQDWEHRA(1)[Sar]E, SAIC(1)IWQDWEHRA(1)[Sar]E, SAIC(1)IWQDWEHRA(1)TEG, FC(1)IWQDWEHRA(1)TGAE, EGSAIC(1)IWQDWEHRA(1)[Sar]EGE, EGSAFC(1)IWQDWEHRA(1)[Sar]E, ESSAC(1)IWQDWAHRA(1)T, IC(1)IWQDWAHRA(1)TGES, {d}YIC(1)I[1 - Me - Trp]QDWA[Sar]HRA(1)-[N - Me - Ile], EGSAIC(1)I[1 - Me - Trp]QDWEHRA(1)[Sar]E, EGSAIC(1)I[2 - Nal]QDWEHRA(1)[Sar]E, IC(1)I[1-Me-Trp]QDWEHRA(1)TGES, IC(1)I[2-Nal]QDWEHRA(1)TGES, EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E, EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E, EGSAIC(1)IWQDWEHRA(1)TE, EGSAFC(1)I[1-Nal]QDWEHRA(1)TE, EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)TE, EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)EGE, EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)TE, EGSAFC(1)I[2-Nal]QDWEHRA(1)TE, FC(1)I[1-Me-Trp]QDWEHRA(1)TGES, YC(1)I[1-Me-Trp]QDWEHRA(1)TGES, FC(1)I[1-Nal]QDWEHRA(1)TGES, FC(1)I[2-Nal]QDWEHRA(1)TGES, YC(1)I[2-Nal]QDWEHRA(1)TGES, YC(1)IWQDWEHRA(1)TGES, SEFC(1)I[1-Me-Trp]QDWEHRA(1)TGES, YC(1)I[1-Me-Trp]QDWEHRA(1)TEAGS, YC(1)I[1-Me-Trp]QDWEHRA(1)TESGA, EGSAYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]E, SEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, FC(1)I[1-Me-Trp]QDWSarEHRA(1)TGES, {d}YFC(1)I[1-Me-Trp]QDWSarEHRA(1)TGES, SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]GAES, SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SEFC(1)I[1-Me-Trp]QDWSarEHRA(1)[Sar]EA, SEFC(1)I[1-Me-Trp]QDWSarEHRA(1)TEA, SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E, SEFC(1)I[1-Me-Trp]QDWSarEHRA(1)[Sar]E, EFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SE[Sar]C(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, SE[Sar]C(1)I[1-Me-Trp]QDWEHRA(1)TEA, SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA, SEFC(1)I[1-Me-Trp]QDWEHRA(1)SEA, EFC(1)I[1-Me-Trp]QDWEHRA(1)ES, SEFC(1)I[1-Me-Trp]QDWEHKRA(1)[Sar]EA, GEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA, GE[Sar]C(1)I[1-Me-Trp]QDWEHRA(1)TEA, SE[Sar]C(1)I[1-Me-Trp]QEW[Sar]EHRA(1)TEA, SE[Sar]C(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA, and {d}Y[Sar]C(1)I[1-Me-Trp]QDWEHRA(1)TEA is a sequence selected from, and the side chains of the residues designated C(1) and A(1) form a lanthionine bridge; Here, when Φ exists, Z １ −, or Z １ −Z ２ − (wherein, Z １ is A-C １２～２２ alkylene-(CO)-; wherein A is H or -COOH, Z ２ is a sequence of 1 to 6 residues of a compound selected from γ-Glu, E, K, Orn, S, T, A, β-Ala, G, P, V, L, I, Y, Q, N, Dapa, GABA or Aib or their corresponding D-forms, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4) and (piperazin-1-yl)-carboxylic acid), a compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof. **Claim 2** Ac-IhC(1)IWQDWAHRA(1)T-NH2 (analog of compound 1), Ac-IhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 2), Ac-ESSAIhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 3), Ac-IhC(1)I[1-Me-Trp]QDWEHRA(1)T-NH2 (analog of compound 4), Ac-IhC(1)IWQDWGKRA(1)T-NH2 (analog of compound 5), Ac-IhC(1)IWQDWGSHRA(1)T-NH2 (analog of compound 6), Ac-IhC(1)IWQKWGEHRA(1)T-NH2 (analog of compound 7), Ac-IhC(1)IWQKWGAHRA(1)TGAES-NH2 (analog of compound 8), Ac-YhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 9), Ac-ESSAYhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 10), Ac-[Sar]hC(1)IWQDWEHRA(1)T-NH2 (analog of compound 11), Ac-IhC(1)IWQDWAHRA(1)E-NH2 (analog of compound 12), Ac-IhC(1)IWQDWEHRA(1)[Sar]-NH2 (analog of compound 13), Ac-ESSAIhC(1)IWQDWEHRA(1)TGES-NH2 (analog of compound 14), Ac-IhC(1)IWQDWEHRA(1)TGES-NH2 (analog of compound 15), Ac-IhC(1)IWQEWGEHRA(1)T-NH2 (analog of compound 16), Ac-IhC(1)IWQDWDHRA(1)T-NH2 (analog of compound 17), Ac-IhC(1)IWQDWRHRA(1)T-NH2 (analog of compound 18), Ac-IhC(1)IWQDWAHSA(1)T-NH2 (analog of compound 19), Ac-IhC(1)IWQDWEHSA(1)T-NH2 (analog of compound 20), Ac-IhC(1)IWQDWEHRA(1)S-NH2 (analog of compound 21), Ac-IhC(1)IWQDWEHRA(1)E-NH2 (analog of compound 22), Ac-FhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 23), Ac-IhC(1)IWQDWEHRA(1)TEGE-NH2 (analog of compound 24), Ac-IhC(1)IWQDWEHRA(1)TEA-NH2 (analog of compound 25), Ac-IhC(1)IWQDWEHRA(1)TE-NH2 (analog of compound 26), Ac-IhC(1)IWQDWEHRA(1)EGE-NH2 (analog of compound 27), Ac-EGSA IhC(1)IWQDWEHRA(1)[Sar]E-NH2 (analog of compound 28), Ac-EGSA IhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 29), Ac-EGE IhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 30), Ac-ESE IhC(1)IWQDWEHRA(1)T-NH2 (analog of compound 31), Ac-SE IhC(1)IWQDWEHRA(1)TEA-NH2 (analog of compound 32), Ac-E IhC(1)IWQDWEHRA(1)TE-NH2 (analog of compound 33), Ac-E IhC(1)IWQDWEHRA(1)TEGE-NH2 (analog of compound 34), Ac-EGEIhC(1)IWQDWEHRA(1)EGE-NH2 (analog of compound 35), Ac-ESEIhC(1)IWQDWEHRA(1)EGE-NH2 (analog of compound 36), Ac-KEKIhC(1)IWQDWEHRA(1)TEKE-NH2 (analog of compound 37), Ac-EKGIhC(1)IWQDWEHRA(1)TEKP-NH2 (analog of compound 38), Ac-IhC(1)IWQDWEHRA(1)TEGK-NH2 (analog of compound 39), Ac-GSAIhC(1)IWQDWEHRA(1)[Sar]E-NH2 (analog of compound 40), Ac-SAIhC(1)IWQDWEHRA(1)[Sar]E-NH2 (analog of compound 41), Ac-SAIhC(1)IWQDWEHRA(1)TEG-NH2 (analog of compound 42), Ac-FhC(1)IWQDWEHRA(1)TGAE-NH2 (analog of compound 43), Ac-EGSAIhC(1)IWQDWEHRA(1)[Sar]EGE-NH2 (analog of compound 44), Ac-EGSAFhC(1)IWQDWEHRA(1)[Sar]E-NH2 (analog of compound 45), Ac-ESSAIhC(1)IWQDWAHRA(1)T-NH2 (analog of compound 46), Ac-IhC(1)IWQDWAHRA(1)TGES-NH2 (analog of compound 47), H-{d}YIhC(1)I[1-Me-Trp]QDWSarAHRA(1)[N-Me-Ile]-NH2 (analog of compound 48), Ac-EGSAIhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 49), Ac-EGSAIhC(1)I[2-Nal]QDWEHRA(1)[Sar]E-NH2 (analog of compound 50), Ac-IhC(1)I[1-Me-Trp]QDWEHRA(1)TGES-NH2 (analog of compound 51), Ac-IhC(1)I[2-Nal]QDWEHRA(1)TGES-NH2 (analog of compound 52), Ac-EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 53), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 54), Ac-EGSAIhC(1)IWQDWEHRA(1)TE-NH2 (analog of compound 55), Ac-EGSAFhC(1)I[1-Nal]QDWEHRA(1)TE-NH2 (analog of compound 56), Ac-EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)TE-NH2 (analog of compound 57), Ac-EGSAFhC(1)I[1-Me-Trp]QDWEHRA(1)EGE-NH2 (analog of compound 58), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)TE-NH2 (analog of compound 59), Ac-EGSAFhC(1)I[2-Nal]QDWEHRA(1)TE-NH2 (analog of compound 60), Ac-FhC(1)I[1-Me-Trp]QDWEHRA(1)TG AES-NH2 (analog of compound 61), Ac-YhC(1)I[1-Me-Trp]QDWEHRA(1)TG AES-NH2 (analog of compound 62), Ac-FhC(1)I[1-Nal]QDWEHRA(1)TG AES-NH2 (analog of compound 63), Ac-FhC(1)I[2-Nal]QDWEHRA(1)TG AES-NH2 (analog of compound 64), Ac-YhC(1)I[2-Nal]QDWEHRA(1)TG AES-NH2 (analog of compound 65), Ac-YhC(1)IWQDWEHRA(1)TG AES-NH2 (analog of compound 66), Ac-SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TG AES-NH2 (analog of compounds 67 and 151), Ac-YhC(1)I[1-Me-Trp]QDWEHRA(1)TEAGS-NH2 (analog of compound 68), Ac-YhC(1)I[1-Me-Trp]QDWEHRA(1)TESGA-NH2 (analog of compound 69), Ac-EGSA YhC(1)I[1-Me-Trp]QEWEHRA(1)[Sar]E-NH2 (analog of compound 70), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 71), Ac-FhC(1)I[1-Me-Trp]QD W[Sar]EHRA(1)TG AES-NH2 (analog of compound 72), H-{d}YFhC(1)I[1-Me-Trp]QD W[Sar]EHRA(1)TG AES-NH2 (analog of compound 73), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]GAES-NH2 (analog of compound 74), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 75), Ac-SefhC(1)I[1-Me-Trp]QDWSar]EHRA(1)[Sar]EA-NH2 (analog of compound 76), Ac-SefhC(1)I[1-Me-Trp]QDWSar]EHRA(1)TEA-NH2 (analog of compound 77), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 78), Ac-SefhC(1)I[1-Me-Trp]QDWSar]EHRA(1)[Sar]E-NH2 (analog of compound 79), Ac-EfhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 80), Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 81), Ac-SE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)TEA-NH2 (analog of compound 82), Ac-SefhC(1)I[1-Me-Trp]QEWEHRA(1)[Sar]EA-NH2 (analog of compound 83), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)SEA-NH2 (analog of compound 84), Ac-EfhC(1)I[1-Me-Trp]QDWEHRA(1)ES-NH2 (analog of compound 85), Ac-SefhC(1)I[1-Me-Trp]QDWEHK A(1)[Sar]EA-NH2 (analog of compound 86), Ac-GEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 87), Ac-GE[Sar]hC(1)I[1-Me-Trp]QDWEHRA(1)TEA-NH2 (analog of compound 88), Ac-SE[Sar]hC(1)I[1-Me-Trp]QEWSar]EHRA(1)TEA-NH2 (analog of compound 89), Ac-SE[Sar]hC(1)I[1-Me-Trp]QEWEHRA(1)[Sar]EA-NH2 (analog of compound 90), or H-{d}Y[Sar]hC(1)I[1-Me-Trp]QDWGEHRA(1)TEA-NH2 (analogue of compound 91) The statin analogue according to claim 1 or a pharmaceutically acceptable salt and / or solvate thereof, wherein the side chains of the residues designated hC(1) and A(1) form a cystathionine bridge.

3. Ac-I A(1)IWQDWAHRhC(1)T-NH2 (analogue of compound 1) Ac-I A(1)IWQDWGEHRhC(1)T-NH2 (analogue of compound 2) Ac-ESSAI A(1)IWQDWGEHRhC(1)T-NH2 (analogue of compound 3) Ac-I A(1)I[1-Me-Trp]QDWGEHRhC(1)T-NH2 (analogue of compound 4) Ac-I A(1)IWQDWGKHRhC(1)T-NH2 (analogue of compound 5) Ac-I A(1)IWQDWGSHRhC(1)T-NH2 (analogue of compound 6) Ac-I A(1)IWQKWGEHRhC(1)T-NH2 (analogue of compound 7) Ac-I A(1)IWQKWGAHRhC(1)TGAES-NH2 (analogue of compound 8) Ac-Y A(1)IWQDWGEHRhC(1)T-NH2 (analogue of compound 9) Ac-ESSAY A(1)IWQDWGEHRhC(1)T-NH2 (analogue of compound 10) Ac-[Sar]A(1)IWQDWGEHRhC(1)T-NH2 (analogue of compound 11) Ac-I A(1)IWQDWAHRhC(1)E-NH2 (analogue of compound 12) Ac-I A(1)IWQDWGEHRhC(1)[Sar]-NH2 (analogue of compound 13) Ac-ESSAI A(1)IWQDWGEHRhC(1)TGAES-NH2 (analogue of compound 14) Ac-I A(1)IWQDWGEHRhC(1)TGAES-NH2 (analogue of compound 15) Ac-I A(1)IWQEWGEHRhC(1)T-NH2 (analogue of compound 16) Ac-I A(1)IWQDWDHRhC(1)T-NH2 (analogue of compound 17) Ac-I A(1)IWQDWRHRhC(1)T-NH2 (analogue of compound 18) Ac-I A(1)IWQDWAHShC(1)T-NH2 (analogue of compound 19) Ac-I A(1)IWQDWGEHShC(1)T-NH2 (analogue of compound 20) Ac - IA(1)IWQDWEHRhC(1)S - NH₂ (analog of compound 21), Ac - IA(1)IWQDWEHRhC(1)E - NH₂ (analog of compound 22), Ac - FA(1)IWQDWEHRhC(1)T - NH₂ (analog of compound 23), Ac - IA(1)IWQDWEHRhC(1)TEGE - NH₂ (analog of compound 24), Ac - IA(1)IWQDWEHRhC(1)TEA - NH₂ (analog of compound 25), Ac - IA(1)IWQDWEHRhC(1)TE - NH₂ (analog of compound 26), Ac - IA(1)IWQDWEHRhC(1)EGE - NH₂ (analog of compound 27), Ac - EGSAIA(1)IWQDWEHRhC(1)[Sar]E - NH₂ (analog of compound 28), Ac - EGSAIA(1)IWQDWEHRhC(1)T - NH₂ (analog of compound 29), Ac - EGEIA(1)IWQDWEHRhC(1)T - NH₂ (analog of compound 30), Ac - ESEIA(1)IWQDWEHRhC(1)T - NH₂ (analog of compound 31), Ac - SEIA(1)IWQDWEHRhC(1)TEA - NH₂ (analog of compound 32), Ac - EIA(1)IWQDWEHRhC(1)TE - NH₂ (analog of compound 33), Ac - EIA(1)IWQDWEHRhC(1)TEGE - NH₂ (analog of compound 34), Ac - EGEIA(1)IWQDWEHRhC(1)EGE - NH₂ (analog of compound 35), Ac - ESEIA(1)IWQDWEHRhC(1)EGE - NH₂ (analog of compound 36), Ac - KEKIAA(1)IWQDWEHRhC(1)TEKE - NH₂ (analog of compound 37), Ac - EKGIA(1)IWQDWEHRhC(1)TEKP - NH₂ (analog of compound 38), Ac - IA(1)IWQDWEHRhC(1)TEGK - NH₂ (analog of compound 39), Ac - GSAIA(1)IWQDWEHRhC(1)[Sar]E - NH₂ (analog of compound 40), Ac - SAIA(1)IWQDWEHRhC(1)[Sar]E - NH₂ (analog of compound 41), Ac - SAIA(1)IWQDWEHRhC(1)TEG - NH₂ (analog of compound 42), Ac - FA(1)IWQDWEHRhC(1)TGAE - NH₂ (analog of compound 43), Ac-EGSAIA(1)IWQDWEHRhC(1)[Sar]EGE-NH2 (analog of compound 44), Ac-EGSAFA(1)IWQDWEHRhC(1)[Sar]E-NH2 (analog of compound 45), Ac-ESSAAIA(1)IWQDWAHRhC(1)T-NH2 (analog of compound 46), Ac-IA(1)IWQDWAHRhC(1)TGES-NH2 (analog of compound 47), H-{d}YIA(1)I[1-Me-Trp]QDWSarAHRhC(1)[N-Me-Ile]-NH2 (analog of compound 48), Ac-EGSAIA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-NH2 (analog of compound 49), Ac-EGSAIA(1)I[2-Nal]QDWEHRhC(1)[Sar]E-NH2 (analog of compound 50), Ac-IA(1)I[1-Me-Trp]QDWEHRhC(1)TGES-NH2 (analog of compound 51), Ac-IA(1)I[2-Nal]QDWEHRhC(1)TGES-NH2 (analog of compound 52), Ac-EGSAFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-NH2 (analog of compound 53), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-NH2 (analog of compound 54), Ac-EGSAIA(1)IWQDWEHRhC(1)TE-NH2 (analog of compound 55), Ac-EGSAFA(1)I[1-Nal]QDWEHRhC(1)TE-NH2 (analog of compound 56), Ac-EGSAFA(1)I[1-Me-Trp]QDWEHRhC(1)TE-NH2 (analog of compound 57), Ac-EGSAFA(1)I[1-Me-Trp]QDWEHRhC(1)EGE-NH2 (analog of compound 58), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)TE-NH2 (analog of compound 59), Ac-EGSAFA(1)I[2-Nal]QDWEHRhC(1)TE-NH2 (analog of compound 60), Ac-FA(1)I[1-Me-Trp]QDWEHRhC(1)TGES-NH2 (analog of compound 61), Ac-YA(1)I[1-Me-Trp]QDWEHRhC(1)TGES-NH2 (analog of compound 62), Ac-FA(1)I[1-Nal]QDWGEHRhC(1)TG AES-NH2 (analog of compound 63), Ac-FA(1)I[2-Nal]QDWGEHRhC(1)TG AES-NH2 (analog of compound 64), Ac-YA(1)I[2-Nal]QDWGEHRhC(1)TG AES-NH2 (analog of compound 65), Ac-YA(1)IWQDWGEHRhC(1)TG AES-NH2 (analog of compound 66), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TG AES-NH2 (compound 151; analog of compound 67), Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TEAGS-NH2 (analog of compound 68), Ac-YA(1)I[1-Me-Trp]QDWGEHRhC(1)TESGA-NH2 (analog of compound 69), Ac-EGSAYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]E-NH2 (analog of compound 70), Ac-SEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (analog of compound 71), Ac-FA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TG AES-NH2 (analog of compound 72), H-{d}YFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TG AES-NH2 (analog of compound 73), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]GAES-NH2 (analog of compound 74), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (analog of compound 75), Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EA-NH2 (analog of compound 76), Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)TEA-NH2 (analog of compound 77), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (analog of compound 78), Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E-NH2 (analog of compound 79), Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (analog of compound 80), Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (analogue of compound 81), Ac-SE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (analogue of compound 82), Ac-SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (analogue of compound 83), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)SEA-NH2 (analogue of compound 84), Ac-EFA(1)I[1-Me-Trp]QDWGEHRhC(1)ES-NH2 (analogue of compound 85), Ac-SEFA(1)I[1-Me-Trp]QDWGEHKhC(1)[Sar]EA-NH2 (analogue of compound 86), Ac-GEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EA-NH2 (analogue of compound 87), Ac-GE[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (analogue of compound 88), Ac-SE[Sar]A(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)TEA-NH2 (analogue of compound 89), Ac-SE[Sar]A(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA-NH2 (analogue of compound 90), or H-{d}Y[Sar]A(1)I[1-Me-Trp]QDWGEHRhC(1)TEA-NH2 (analogue of compound 91) wherein the side chains of the residues designated A(1) and hC(1) form a cystathionine bridge, the compstatin analogue according to claim 1 or a pharmaceutically acceptable salt and / or solvate thereof.

4. Ac-IC(1)IWQDWAHRA(1)T-NH2 (analogue of compound 1), Ac-IC(1)IWQDWEHRA(1)T-NH2 (analogue of compound 2), Ac-ESSAIIC(1)IWQDWEHRA(1)T-NH2 (analogue of compound 3), Ac-IC(1)I[1-Me-Trp]QDWEHRA(1)T-NH2 (analogue of compound 4), Ac-IC(1)IWQDWGKRA(1)T-NH2 (analogue of compound 5), Ac-IC(1)IWQDWSRA(1)T-NH2 (analogue of compound 6), Ac-IC(1)IWQKWGEHRA(1)T-NH2 (analogue of compound 7), Ac-IC(1)IWQKWGAHRA(1)TGAES-NH2 (analog of compound 8), Ac-YC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 9), Ac-ESSAYC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 10), Ac-[Sar]C(1)IWQDWGEHRA(1)T-NH2 (analog of compound 11), Ac-IC(1)IWQDWGAHRA(1)E-NH2 (analog of compound 12), Ac-IC(1)IWQDWGEHRA(1)[Sar]-NH2 (analog of compound 13), Ac-ESSAIC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 14), Ac-IC(1)IWQDWGEHRA(1)TGAES-NH2 (analog of compound 15), Ac-IC(1)IWQEWGEHRA(1)T-NH2 (analog of compound 16), Ac-IC(1)IWQDWGDHRA(1)T-NH2 (analog of compound 17), Ac-IC(1)IWQDWGRHRA(1)T-NH2 (analog of compound 18), Ac-IC(1)IWQDWGAHSA(1)T-NH2 (analog of compound 19), Ac-IC(1)IWQDWGEHSA(1)T-NH2 (analog of compound 20), Ac-IC(1)IWQDWGEHRA(1)S-NH2 (analog of compound 21), Ac-IC(1)IWQDWGEHRA(1)E-NH2 (analog of compound 22), Ac-FC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 23), Ac-IC(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 24), Ac-IC(1)IWQDWGEHRA(1)TEA-NH2 (analog of compound 25), Ac-IC(1)IWQDWGEHRA(1)TE-NH2 (analog of compound 26), Ac-IC(1)IWQDWGEHRA(1)EGE-NH2 (analog of compound 27), Ac-EGSAIC(1)IWQDWGEHRA(1)[Sar]E-NH2 (analog of compound 28), Ac-EGSAIC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 29), Ac-EGEIC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 30), Ac-ESEIC(1)IWQDWGEHRA(1)T-NH2 (analog of compound 31), Ac-SEIC(1)IWQDWDGEHRA(1)TEA-NH2(analogue of compound 32), Ac-EIC(1)IWQDWDGEHRA(1)TE-NH2(analogue of compound 33), Ac-EIC(1)IWQDWDGEHRA(1)TEGE-NH2(analogue of compound 34), Ac-EGEIC(1)IWQDWDGEHRA(1)EGE-NH2(analogue of compound 35), Ac-ESEIC(1)IWQDWDGEHRA(1)EGE-NH2(analogue of compound 36), Ac-KEKIC(1)IWQDWDGEHRA(1)TEKE-NH2(analogue of compound 37), Ac-EKGIC(1)IWQDWDGEHRA(1)TEKP-NH2(analogue of compound 38), Ac-IC(1)IWQDWDGEHRA(1)TEGK-NH2(analogue of compound 39), Ac-GSAIC(1)IWQDWDGEHRA(1)[Sar]E-NH2(analogue of compound 40), Ac-SAIC(1)IWQDWDGEHRA(1)[Sar]E-NH2(analogue of compound 41), Ac-SAIC(1)IWQDWDGEHRA(1)TEG-NH2(analogue of compound 42), Ac-FC(1)IWQDWDGEHRA(1)TGAE-NH2(analogue of compound 43), Ac-EGSAIC(1)IWQDWDGEHRA(1)[Sar]EGE-NH2(analogue of compound 44), Ac-EGSAFC(1)IWQDWDGEHRA(1)[Sar]E-NH2(analogue of compound 45), Ac-ESSAIC(1)IWQDWAHRA(1)T-NH2(analogue of compound 46), Ac-IC(1)IWQDWAHRA(1)TGAS-NH2(analogue of compound 47), H-{d}YIC(1)I[1-Me-Trp]QDWSarAHRA(1)[N-Me-Ile]-NH2(analogue of compound 48), Ac-EGSAIC(1)I[1-Me-Trp]QDWDGEHRA(1)[Sar]E-NH2(analogue of compound 49), Ac-EGSAIC(1)I[2-Nal]QDWDGEHRA(1)[Sar]E-NH2(analogue of compound 50), Ac-IC(1)I[1-Me-Trp]QDWDGEHRA(1)TGAS-NH2(analogue of compound 51), Ac-IC(1)I[2-Nal]QDWDGEHRA(1)TGAS-NH2(analogue of compound 52), Ac-EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 53), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analog of compound 54), Ac-EGSAIC(1)IWQDWEHRA(1)TE-NH2 (analog of compound 55), Ac-EGSAFC(1)I[1-Nal]QDWEHRA(1)TE-NH2 (analog of compound 56), Ac-EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)TE-NH2 (analog of compound 57), Ac-EGSAFC(1)I[1-Me-Trp]QDWEHRA(1)EGE-NH2 (analog of compound 58), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)TE-NH2 (analog of compound 59), Ac-EGSAFC(1)I[2-Nal]QDWEHRA(1)TE-NH2 (analog of compound 60), Ac-FC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-NH2 (analog of compound 61), Ac-YC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-NH2 (analog of compound 62), Ac-FC(1)I[1-Nal]QDWEHRA(1)TGAES-NH2 (analog of compound 63), Ac-FC(1)I[2-Nal]QDWEHRA(1)TGAES-NH2 (analog of compound 64), Ac-YC(1)I[2-Nal]QDWEHRA(1)TGAES-NH2 (analog of compound 65), Ac-YC(1)IWQDWEHRA(1)TGAES-NH2 (analog of compound 66), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-NH2 (analogs of compounds 67 and 151), Ac-YC(1)I[1-Me-Trp]QDWEHRA(1)TEAGS-NH2 (analog of compound 68), Ac-YC(1)I[1-Me-Trp]QDWEHRA(1)TESGA-NH2 (analog of compound 69), Ac-EGSAYC(1)I[1-Me-Trp]QEWEHRA(1)[Sar]E-NH2 (analog of compound 70), Ac-SEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA-NH2 (analog of compound 71), Ac-FC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)TGAES-NH₂ (analog of compound 72), H-{d}YFC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)TGAES-NH₂ (analog of compound 73), Ac-SEFC(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]GAES-NH₂ (analog of compound 74), Ac-SEFC(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]EA-NH₂ (analog of compound 75), Ac-SEFC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)[Sar]EA-NH₂ (analog of compound 76), Ac-SEFC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)TEA-NH₂ (analog of compound 77), Ac-SEFC(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]E-NH₂ (analog of compound 78), Ac-SEFC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)[Sar]E-NH₂ (analog of compound 79), Ac-EFC(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]EA-NH₂ (analog of compound 80), Ac-SE[Sar]C(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]EA-NH₂ (analog of compound 81), Ac-SE[Sar]C(1)I[1-Me-Trp]QD WGEHR A(1)TEA-NH₂ (analog of compound 82), Ac-SEFC(1)I[1-Me-Trp]QE WGEHR A(1)[Sar]EA-NH₂ (analog of compound 83), Ac-SEFC(1)I[1-Me-Trp]QD WGEHR A(1)SEA-NH₂ (analog of compound 84), Ac-EFC(1)I[1-Me-Trp]QD WGEHR A(1)ES-NH₂ (analog of compound 85), Ac-SEFC(1)I[1-Me-Trp]QD WGEHK A(1)[Sar]EA-NH₂ (analog of compound 86), Ac-GEFC(1)I[1-Me-Trp]QD WGEHR A(1)[Sar]EA-NH₂ (analog of compound 87), Ac-GE[Sar]C(1)I[1-Me-Trp]QD WGEHR A(1)TEA-NH₂ (analog of compound 88), Ac-SE[Sar]C(1)I[1-Me-Trp]QE W[Sar]EHR A(1)TEA-NH₂ (analog of compound 89), Ac - SE[Sar]C(1)I[1 - Me - Trp]QEWGEHRA(1)[Sar]EA - NH2 (analogue of compound 90), or H - {d}Y[Sar]C(1)I[1 - Me - Trp]QDWEHRA(1)TEA - NH2 (analogue of compound 91), wherein the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge, the compstatin analogue according to claim 1 or a pharmaceutically acceptable salt and / or solvate thereof.

5. Formula: Y1 - P - Y2 A compstatin analogue represented by, wherein, Y1 is hydrogen, acetyl or a lipophilic group Φ; Y2 is NH ２ , OH or a lipophilic group Φ; P is as follows: (I) [K ＊ GSAIhC(1)IWQDWEHRA(1)TEGE(analog of compound 100), ASGEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 113), EFhC(1)I[1-Me-Trp]QDWEHRA(1)EGE-[K ＊ (Analogues of Compounds 134 and 161), EGSA IhC(1) IWQDWGEHRA(1) TEG[K ＊ (Analog of Compound 101), EGSAYhC(1)I[1-Me-Trp]QDWEH[K ＊ A(1)[Sar]E(analog of compound 103), EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-[K ＊ (analog of compound 104), EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 109), EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-[K ＊ (analog of compound 110), EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]-[K ＊ (Analogues of Compounds 111 and 159) FhC(1)I[1-Me-Trp]QDWEHRA(1)TGAS-[K ＊ (Analog of Compound 102), IhC(1)IWQDWEHRA(1)TEG-[K ＊ (Analog of Compound 92), IhC(1)IWQDWEHRA(1)TEGE-[K ＊ (Analog of Compound 94), SAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-[K ＊ (Analog of Compound 105), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ (analogues of compounds 119, 154), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Compound 152; analog of Compounds 123 and 146) SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGEGGG-[K ＊ (Analog of Compound 129), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]-[K ＊ (Analog of Compound 138), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ (Analog of Compound 140), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analogues of Compounds 127 and 160), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGESES-[K ＊ (Analog of Compound 139), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]GGG-[K ＊ (analog of compound 132), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]-[K ＊ [](analog of compound 136), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]E-[K ＊ (Analog of Compound 137), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEGEGGG-[K ＊ (Analog of Compound 130), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[Peg3]ES-[K ＊ (Compound 165; analog of Compounds 142, 148, 163) SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[Peg3][Peg3]-[K ＊ (Analogues of Compounds 126 and 156), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TEK[γGlu]GGG-[K ＊ (Analog of Compound 133), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)TGES-[K ＊ (Analog of Compound 135), SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ (Analog of Compound 120), SEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Compound 167; analog of Compounds 124 and 153) SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ (analog of compound 112), SEYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analog of Compound 117), SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 114), SEYhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K ＊ (Analog of Compound 121), SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ (Analog of Compound 122), SEYhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analog of Compound 125), EGSEYhC(1)I[1 - Me - Trp]QDWEHRA(1)[Sar]E (analogue of compound 107), ESSAIhC(1)IWQDWEHRA(1)TEGE (analogue of compound 99), SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ (Analog of Compound 143), SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-[K ＊ (Compound 164; analog of Compounds 144, 147, 162) EFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Analog of Compound 145), GEFhC(1)I[1-Me-Trp]QDW[Sar]EHR A(1)[Sar]EAE[Peg3][Peg3]-[K ＊ (Analog of Compound 149), SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-[K ＊ (Compound 166; an analog of Compound 150), GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ (analog of compound 155), and EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Analog of Compound 158) comprising a sequence selected from, and the side chains of the residues designated as hC(1) and A(1) form a cystathionine bridge, or (II) [K ＊ GSAI A(1)IWQD WGEHR hC(1)TEGE(analog of compound 100), ASGEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-[K ＊ (analogue of compound 113), EFA(1)I[1-Me-Trp]QDWEHRhC(1)EGE-[K ＊ (Compound 161; analog of Compound 134), EGSAIA(1)IWQDWGHRhC(1)TEG[K ＊ (Analog of Compound 101), EGSAYA(1)I[1-Me-Trp]QDWEH[K ＊ hC(1)[Sar]E(analogue of compound 103), EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EG-[K ＊ (analog of compound 104), EGSA-YA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE-[K ＊ (Analog of Compound 109), EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGK-[K ＊ (Analog of Compound 110), EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EK[γGlu]-[K ＊ (Compound 159; an analog of Compound 111), FA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAS-[K ＊ (Analog of Compound 102) IA(1)IWQDWEHRhC(1)TEG-[K ＊ (Analog of Compound 92), IA(1) IWQDWGEHRhC(1)TEGE - [K ＊ (Analog of Compound 94) SAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-[K ＊ (analog of compound 105), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGA-[K ＊ (Compound 154; an analog of Compound 119), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Compound 146; analog of Compounds 123 and 152) SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGEGGG-[K ＊ (analog of compound 129), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3]-[K ＊ (Analog of Compound 138), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3]ES-[K ＊ (Analog of Compound 140), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Compound 160; an analog of Compound 127), SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGESES-[K ＊ (Analog of Compound 139), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EK[γGlu]GGG-[K ＊ [](Analog of Compound 132) SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[8-aminooctanoyl]-[K ＊ [](analog of compound 136) SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TEGE[8-aminooctanoyl]E-[K ＊ (analog of compound 137), SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGEGGG-[K ＊ (Compound 157; analog of Compound 130), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TEGE[Peg3]ES-[K ＊ (Compound 148, 163; analogs of Compound 142, 165), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TEGE[Peg3][Peg3]-[K ＊ (Compound 156; analog of Compound 126), SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K ＊ [](Analog of Compound 133) SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TGAES-[K ＊ (Analog of Compound 135), SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K ＊ (analog of compound 120), SEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ [](Compound 153; analog of Compounds 124, 167) SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGA-[K ＊ (Analog of Compound 112), SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (analog of compound 117), SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-[K ＊ (analogue of Compound 114), SEYA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K ＊ (Analog of Compound 121), SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K ＊ (analog of compound 122), SEYA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analog of Compound 125), EGSEYA(1)I[1 - Me - Trp]QDWEHRhC(1)[Sar]E (analogue of compound 107), ESSAI A(1)IWQDWEHRhC(1)TEGE (analogue of compound 99), SEFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ (analog of compound 143), SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-[K ＊ (compounds 147, 162; analogs of compounds 144, 164) EFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Analog of Compound 145), GEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K ＊ (Compound 149), SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-[K ＊ (Compound 150; analog of Compound 166) GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K ＊ (Compound 155), and EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Compound 158) comprising a sequence selected from, and the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge, or (III) [K ＊ GS AIC(1)IWQD WGEHR A(1)TEGE(analog of compound 100), ASGEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 113), EFC(1)I[1-Me-Trp]QDWEHRA(1)EGE-[K ＊ (Analogues of Compounds 134 and 161), EGSAIC(1) IWQDWGEHRA(1) TEG[K ＊ (Analog of Compound 101), EGSAYC(1)I[1-Me-Trp]QDWEH[K ＊ A(1)[Sar]E(analogue of compound 103), EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-[K ＊ (Analog of Compound 104), EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 109), EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-[K ＊ (analog of compound 110), EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]-[K ＊ (analogues of compounds 111, 159) FC(1)I[1-Me-Trp]QDWEHRA(1)TGAS-[K ＊ (Analog of Compound 102) IC(1) IWQDWGEHRA(1) TEG - [K ＊ (analog of compound 92), IC(1) IWQDWGEHRA(1) TEG-E-[K ＊ (Analog of Compound 94), SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-[K ＊ (Analog of Compound 105), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ (Analog of Compound 119), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analogs of Compounds 123, 146, and 152), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGEGGG-[K ＊ (Analog of Compound 129), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]-[K ＊ (analog of compound 138), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ (analog of Compound 140), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (analogues of Compounds 127 and 160), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGESES-[K ＊ (analog of compound 139), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]GGG-[K ＊ (analogue of compound 132), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]-[K ＊ (analog of compound 136), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]E-[K ＊ (analogue of Compound 137), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGEGGG-[K ＊ (Analogues of Compounds 130 and 157), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[Peg3]ES-[K ＊ (Analogs of Compounds 142, 148, 163, 165) SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[Peg3][Peg3]-[K ＊ (Analogues of Compounds 126 and 156), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEK[γGlu]GGG-[K ＊ (analog of compound 133), SEFC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-[K ＊ (analog of compound 135), SEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ (analogue of compound 120), SEFC(1)I[1-Me-Trp]QE WGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (analogues of compounds 124, 153, 167), SEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ (analog of compound 112), SEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analog of Compound 117), SEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ (Analog of Compound 114), SEYC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-[K ＊ (Analog of Compound 121) SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ (Analog of Compound 122), SEYC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ (Analog of Compound 125), EGSEYC(1)I[1 - Me - Trp]QDWEHRA(1)[Sar]E (analogue of compound 107), ESSAI C(1)IWQDWEHRA(1)TEGE (analogue of compound 99), SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ (analog of compound 143), SEFC(1)I[1-Me-Trp]QDW[Sar]EHR A(1)[Sar]E[Peg3][Peg3]-[K ＊ (analogues of compounds 144, 147, 162, 164), EFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Analog of compound 145), GEFC(1)I[1-Me-Trp]QD W[Sar]EHR A(1)[Sar]EAE[Peg3][Peg3]-[K ＊ (analog of compound 149), Ac-Sefc(1)I[1-Me-Trp]Qdw[Sar]Ehra(1)[Sar]Ege[Peg3]Es-[K ＊ (Analogues of Compounds 150 and 166) GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ (analog of compound 155), and EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ (Analog of Compound 158) comprising a sequence selected from, and the side chains of the residues designated as C(1) and A(1) form a lanthionine bridge, wherein Peg3 represents 8 - amino - 3,6 - dioxaoctanoic acid, Here, when Φ exists, Z １ -, or Z １ -Z ２ - is (wherein, Z １ is A-C １２～２２ alkylene-(CO)-, wherein A is H or - COOH, Z ２ is a sequence of 1 to 6 residues of a compound selected from γ-Glu, E, K, Orn, S, T, A, β-Ala, G, P, V, L, I, Y, Q, N, Dapa, GABA or Aib or their corresponding D-forms, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10-aminodecanoyl, 8-amino-3,6-dioxaoctanoic acid (Peg3), 11-amino-3,6,9-trioxaundecanoic acid (Peg4), and (piperazin-1-yl)-carboxylic acid), the compstatin analogue or a pharmaceutically acceptable salt and / or solvate thereof.

6. Ac-[K ＊ GSAIhC(1)IWQDWEHRA(1)TEGE-NH2 (analogue of compound 100), Ac-ASGEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analogue of compound 113), Ac-EFhC(1)I[1-Me-Trp]QDWEHRA(1)EG-[K ＊ -NH2 (analog of Compounds 134 and 161), Ac-EGSAIhC(1)IWQDWEHRA(1)TEG-[K ＊ -NH2 (analogue of compound 101), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEH[K ＊ A(1)[Sar]E-NH2 (analog of compound 103), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-[K ＊ -NH2 (analogue of compound 104), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analog of compound 109), Ac-EGSAYhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-[K ＊ -NH2 (analog of compound 110), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]-[K ＊ -NH2 (analog of compounds 111, 159), Ac-FhC(1)I[1-Me-Trp]QDWEHRA(1)TGES-[K ＊ -NH2 (analog of compound 102), Ac-IhC(1)IWQDWEHRA(1)TEG-[K ＊ -NH2 (analogues of compounds 92, 93, 95, 96, 98) Ac-IhC(1)IWQDWEHRA(1)TEGE-[K ＊ -NH2 (analogues of compounds 94, 97) Ac-SAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-[K ＊ -NH2 (analogues of compounds 105, 106), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ -NH2 (analogues of compounds 119, 154), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogues of compound 152, compound 123 and 146), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGEGGG-[K ＊ -NH2 (analog of compound 129), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]-[K ＊ -NH2 (analog of compound 138), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (analog of compound 140), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogues of compounds 127, 128, 160), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGESES-[K ＊ -NH2 (analogues of Compounds 139, 141), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]GGG-[K ＊ -NH2 (analog of compound 132), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]-[K ＊ -NH2 (analogue of compound 136), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]E-[K ＊ -NH2 (analog of compound 137), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGEGGG-[K ＊ -NH2 (analogues of compounds 130, 131, 157), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE-[Peg3]ES-[K ＊ -NH2 (Compound 165; analog of Compounds 142 and 148), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE-[Peg3]ES-[K ＊ -OH (analog of compound 163), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE-[Peg3][Peg3]-[K ＊ -NH2 (analog of compounds 126, 156), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEK[γGlu]GGG-[K ＊ -NH2 (analog of compound 133), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TGAS-[K ＊ -NH2 (analog of compound 135), Ac-SefhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ -NH2 (analog of compound 120), Ac-SefhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (Compound 167; analog of Compounds 124 and 153), Ac-SeyhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ -NH2 (analogues of compounds 112, 118) Ac-SeyhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 117), Ac-SeyhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analogues of compounds 114, 115, 116), Ac-SeyhC(1)I[1-Me-Trp]QEW[Sar]EHR A(1)[Sar]EK[γGlu]A-[K ＊ -NH2 (analog of compound 121), Ac-SeyhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ -NH2 (analog of compound 122), Ac-SeyhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 125), Φ - EGSEYhC(1)I[1 - Me - Trp]QDWEHRA(1)[Sar]E - NH2 (analogues of compounds 107, 108), Φ - ESSAIhC(1)IWQDWEHRA(1)TEGE - NH2 (analogue of compound 99), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 143), Ac-SefhC(1)I[1-Me-Trp]QDW[Sar]EHR A(1)[Sar]E[Peg3][Peg3]-[K ＊ -NH2 (Compound 164; analog of Compounds 144 and 147), Ac-SefhC(1)I[1-Me-Trp]QDW[Sar]Ehra(1)[Sar]E[Peg3][Peg3]-[K ＊ -OH (analogue of compound 162), Ac-EFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 145), Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHR A(1)[Sar]EAE[Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 149), Ac-SefhC(1)I[1-Me-Trp]QDW[Sar]Ehra(1)[Sar]Ege[Peg3]ES-[K ＊ -NH2 (Compound 166; analog of Compound 150), Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (analog of compound 155), and Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 158) The compstatin analog according to claim 5, or a pharmaceutically acceptable salt and / or solvate thereof, comprising an array selected from the side chains of residues designated hC(1) and A(1) that form a cystathionine bridge.

7. Ac-[K ＊ GSAIA(1)IWQDWEHRhC(1)TEGE-NH2 (analogue of compound 100), Ac-ASGEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-[K ＊ -NH2 (analogue of compound 113), Ac-EFA(1)I[1-Me-Trp]QDWEHRhC(1)EGE-[K ＊ -NH2 (analog of compound 134), Ac - EGSAIA(1)IWQDWEHRhC(1)TEG - [K ＊ - NH2 (analog of compound 101), Ac-EGSAYA(1)I[1-Me-Trp]QDWGEH[K ＊ hC(1)[Sar]E-NH2 (analog of compound 103), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EG-[K ＊ -NH2 (analog of compound 104), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-[K ＊ -NH2 (analogue of compound 109), Ac-EGSAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGK-[K ＊ -NH2 (analog of compound 110), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EK[γGlu]-[K ＊ []-NH2 (Compound 159; an analog of Compound 111), Ac-FA(1)I[1-Me-Trp]QDWEHRhC(1)TGAS-[K ＊ -NH2 (analogue of compound 102), Ac-Ia(1)IWQDWEHRhC(1)TEG-[K ＊ -NH2 (analogues of compounds 92, 93, 95, 96, 98) Ac-Ia(1)IWQDWEHRhC(1)TEGE-[K ＊ -NH2 (analogues of compounds 94, 97), Ac-SAYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-[K ＊ -NH2 (analogues of compounds 105, 106), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGA-[K ＊ -NH2 (Compound 154; analog of Compound 119), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (Compound 146; analog of Compounds 123, 152), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGEGGG-[K ＊ -NH2 (analog of compound 129), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[Sar]EGE[Peg3]-[K ＊ -NH2 (analog of compound 138), Ac-Sefa(1)I[1-Me-Trp]QDWGEhRc(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (analog of compound 140), Ac - SEFA(1)I[1 - Me - Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (Compound 160; analog of Compounds 127, 128) Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[Sar]EGESES - [K ＊ - NH2 (analog of compounds 139, 141), Ac-Sefa(1)I[1-Me-Trp]QDWGEhRc(1)[Sar]EK[γGlu]GGG-[K ＊ -NH2 (analog of compound 132), Ac-Sefa(1)I[1-Me-Trp]QDWGEhRhC(1)TEGE[8-aminooctanoyl]-[K ＊ -NH2 (analogue of compound 136), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)TEGE[8-aminooctanoyl]E-[K ＊ -NH2(analog of compound 137), Ac-SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TEGEGGG-[K ＊ -NH2 (Compound 157; analog of Compounds 130 and 131), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TEGE - [Peg3]ES - [K ＊ - NH2 (Compound 148; analog of Compounds 142, 165), Ac-SEFA(1)I[1-Me-Trp]QDWEHRhC(1)TEGE-[Peg3]ES-[K ＊ -OH (Compound 163), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)TEGE-[Peg3][Peg3]-[K ＊ -NH2 (Compound 165; analog of Compound 126), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEK[γGlu]GGG-[K ＊ -NH2 (analog of compound 133), Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TGAS-[K ＊ -NH2 (analog of compound 135), Ac-Sefa(1)I[1-Me-Trp]QEWGEhR hC(1)[Sar]EGA-[K ＊ -NH2 (analog of compound 120), Ac-Sefa(1)I[1-Me-Trp]QEWGEhR hC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (Compound 153; analog of Compounds 124, 167) Ac-SeyA(1)I[1-Me-Trp]QDWGEhRc(1)[Sar]EGA-[K ＊ -NH2 (analogues of compounds 112, 118), Ac-SeyA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 117), Ac-SeyA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-[K ＊ -NH2 (analogues of compounds 114, 115, 116), Ac-SeyA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-[K ＊ -NH2 (analogue of compound 121), Ac-SeyA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-[K ＊ -NH2 (analogue of compound 122), Ac-SeyA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 125), Φ-EGSEYA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]E-NH2 (analog of compounds 107, 108), Φ-ESSAI A(1)IWQDWGEHRhC(1)TEGE-NH2 (analog of compound 99), Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ -NH2 (analog of compound 143), Ac-Sefa(1)I[1-Me-Trp]QDw[Sar]EhrhC(1)[Sar]E[Peg3][Peg3]-[K ＊ -NH2 (Compound 147; analog of Compounds 144 and 164), Ac-Sefa(1)I[1-Me-Trp]QDW[Sar]EhrhC(1)[Sar]E[Peg3][Peg3]-[K ＊ -OH (Compound 162), Ac-EFA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 145), Ac-GEFA(1)I[1-Me-Trp]QDw[Sar]EHRhC(1)[Sar]EAE[Peg3][Peg3]-[K ＊ -NH2 (Compound 149), Ac-Sefa(1)I[1-Me-Trp]QDWE[Sar]EhrC(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (Compound 150; analog of Compound 166), Ac-GEFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (Compound 155), and Ac-EFA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (Compound 158) The compstatin analog according to claim 5, or a pharmaceutically acceptable salt and / or solvate thereof, comprising an array selected from the side chains of residues designated A(1) and hC(1) that form a cystathionine bridge.

8. Ac-[K ＊ GSAIC(1)IWQDWEHRA(1)TEGE-NH2 (analogue of compound 100), Ac-ASGEYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analog of compound 113), Ac-EFC(1)I[1-Me-Trp]QDWEHRA(1)EGE-[K ＊ -NH2 (analog of compound 134), Ac-EGSAIC(1)IWQDWEHRA(1)TEG-[K ＊ -NH2 (analog of compound 101), Ac-EGSAYC(1)I[1-Me-Trp]QDWEH[K ＊ A(1)[Sar]E-NH2 (analogue of compound 103), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-[K ＊ -NH2 (analogue of compound 104), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analog of compound 109), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-[K ＊ -NH2 (analogue of compound 110), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]-[K ＊ -NH2 (analogues of compounds 111, 159), Ac-FC(1)I[1-Me-Trp]QDWGEHRA(1)TGAS-[K ＊ -NH2 (analogue of compound 102), Ac-IC(1)IWQDWEHRA(1)TEG-[K ＊ -NH2 (analogues of compounds 92, 93, 95, 96, 98) Ac-IC(1) IWQDWGEHRA(1) TEG-E-[K ＊ -NH2 (analogues of compounds 94, 97), Ac-SAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-[K ＊ -NH2 (analogues of compounds 105, 106), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ -NH2 (analogues of compounds 119, 154), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogues of compounds 123, 146 and 152), Ac-SEFC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGEGGG-[K ＊ -NH2 (analog of compound 129), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]-[K ＊ -NH2 (analog of compound 138), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (analog of compound 140), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogues of compounds 127, 128, 160), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGESES-[K ＊ -NH2 (analogues of compounds 139, 141), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK[γGlu]GGG-[K ＊ -NH2 (analog of compound 132), Ac - SEFC(1)I[1 - Me - Trp]QDWEHRA(1)TEGE[8 - aminooctanoyl]-[K ＊ -NH2 (analog of compound 136), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]E-[K ＊ -NH2 (analogue of compound 137), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TEGEGGG-[K ＊ -NH2 (analogues of compounds 130, 131, 157), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)TEGE-[Peg3]ES-[K ＊ -NH2 (analogues of compounds 142, 148, 165), Ac - SEFC(1)I[1 - Me - Trp]QDWEHRA(1)TEGE - [Peg3]ES - [K ＊ -OH (analogue of compound 163), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)TEGE-[Peg3][Peg3]-[K ＊ -NH2 (analog of compounds 126 and 156), Ac - SEFC(1)I[1 - Me - Trp]QDWEHRA(1)TEK[γGlu]GGG - [K ＊ - NH2 (analog of compound 133), Ac-SEFC(1)I[1-Me-Trp]QDWEHRA(1)TGAS-[K ＊ -NH2 (analog of compound 135), Ac-Sefc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ -NH2 (analog of compound 120), Ac-Sefc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogues of compounds 124, 153, 167), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-[K ＊ -NH2 (analogues of compounds 112, 118), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 117), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-[K ＊ -NH2 (analogues of compounds 114, 115, 116), Ac-Seyc(1)I[1-Me-Trp]QEW[Sar]Ehra(1)[Sar]EK[γGlu]A-[K ＊ -NH2 (analog of compound 121), Ac-Seyc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-[K ＊ -NH2 (analog of compound 122), Ac-Seyc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 125), Φ-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2 (analog of compounds 107, 108), Φ-ESSAI C(1)IWQDWGEHRA(1)TEGE-NH2 (analog of compound 99), Ac - SEFC(1)I[1 - Me - Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 143), Ac-Sefc(1)I[1-Me-Trp]Qdw[Sar]Ehra(1)[Sar]E[Peg3][Peg3]-[K ＊ -NH2 (analogs of compounds 144, 147, 164), Ac-Sefc(1)I[1-Me-Trp]QDW[Sar]Ehra(1)[Sar]E[Peg3][Peg3]-[K ＊ -OH (analogue of compound 62), Ac-EFC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (analogue of compound 145), Ac-GEFC(1)I[1-Me-Trp]QDW[Sar]EHR A(1)[Sar]EAE[Peg3][Peg3]-[K ＊ -NH2 (analog of compound 149), Ac - SEFC(1)I[1 - Me - Trp]QDW[Sar]Ehra(1)[Sar]EGE[Peg3]ES - [K ＊ - NH2 (analogs of compounds 150, 166), Ac-GEFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-[K ＊ -NH2 (Compound 155), and Ac-EFC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-[K ＊ -NH2 (Compound 158) The compstatin analog according to claim 5, or a pharmaceutically acceptable salt and / or solvate thereof, comprising an array selected from the side chains of residues designated C(1) and A(1) that form a lanthionine bridge.

9. Z １ is Dodecanoyl, that is, H-(CH ２ ), １１ -(CO)-; Tetradecanoyl, i.e., H-(CH ２ ), １３ -(CO)-; Hexadecanoyl, i.e., H-(CH ２ ) １５ -(CO)-; 13-carboxytridecanoyl, i.e., HOOC-(CH ２ ) １２ -(CO)-; 15-carboxypentadecanoyl, i.e., HOOC-(CH ２ ), １４ -(CO)-; 17-carboxyheptadecanoyl, i.e., HOOC-(CH ２ ), １６ -(CO)-; 19-carboxynonadecanoyl, i.e., HOOC-(CH ２ ), １８ -(CO)-; and 21-carboxyheneicosanoyl, i.e., HOOC-(CH ２ ), ２０ -(CO)-selected from the group consisting of, a compstatin analog according to any one of claims 1 to 8 or a pharmaceutically acceptable salt and / or solvate thereof.

10. Z ２ is [γGlu]; [γGlu][Peg3][Peg3]-; [(piperazin-1-yl)-acetyl][Peg3][Peg3]; [γGlu]G[γGlu]; [γGlu]K[γGlu]; [γGlu]KG[γGlu]; or [γGlu]G[Peg3][γGlu][Peg3] The compstatin analog according to any one of claims 1 to 8, or a pharmaceutically acceptable salt and / or solvate thereof, selected from the following.

11. Z １ - or Z １ -Z ２ - is, 15-carboxy-pentadecanoyl; 15-carboxy-pentadecanoyl[γGlu]-; 15-carboxy-pentadecanoyl[γGlu][Peg3][Peg3]-; 19-carboxy-nonadecanoyl[γGlu][Peg3][Peg3]-; 15-carboxy-pentadecanoyl-[(piperazin-1-yl)-acetyl][Peg3][Peg3]; 17-carboxy-heptadecanoyl[γGlu]G[γGlu]; 17-carboxy-heptadecanoyl[γGlu]K[γGlu]; 17-carboxy-heptadecanoyl[γGlu]KG[γGlu]; 17-carboxy-heptadecanoyl[γGlu]G[Peg3][γGlu]-[Peg3]; 15-carboxy-hexadecanoyl[γGlu]G[γGlu]; 17-carboxy-heptadecanoyl; 17-carboxy-heptadecanoyl[γGlu]; 19-carboxy-nonadecanoyl[γGlu]G[γGlu]; and 17-carboxy-heptadecanoyl[γGlu][Peg3][Peg3] A compstatin analog or a pharmaceutically acceptable salt and / or solvate thereof according to any one of claims 1 to 8, selected from

12. Ac-IhC(1)IWQDWEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2(analog of compound 92), Ac-IhC(1)IWQDWEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 93), Ac-IhC(1)IWQDWEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 94), Ac-IhC(1)IWQDWEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2(analog of compound 95), Ac-IhC(1)IWQDWEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 96), Ac-IhC(1)IWQDWEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 97), Ac-IhC(1)IWQDWEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 98), [15-carboxy-pentadecanoyl]-ESSAIhC(1)IWQDWEHRA(1)TEGE-NH2(analog of compound 99), Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIhC(1)IWQDWEHRA(1)TEGE-NH2(analog of compound 100) Ac-EGSAIhC(1)IWQDWEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analogue of compound 101), Ac-FhC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 102), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (analogue of compound 103), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 104), Ac-SAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (analogue of compound 105), Ac-SAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 106), [15-carboxy-pentadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analogue of compound 107), [17-carboxy-heptadecanoyl]-EGSEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]E-NH2 (analogue of compound 108), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 109), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 110), Ac-EGSAYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2(analog of compounds 111, 159), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analog of compound 112), Ac-ASGEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analog of compound 113), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analog of compound 114), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analog of compound 115), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2(analog of compound 116), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analog of compound 117), Ac-SEYhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analog of compound 118), Ac-SEFhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2(analog of compounds 119, 154), Ac-SefhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 120), Ac-SeyhC(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 121), Ac-SeyhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 122), Ac-SefhC(1)I[1-Me-Trp]QDWG EHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 152; analogue of compounds 123 and 146), Ac-SefhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(compound 167; analogue of compounds 124, 153), Ac-SeyhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 125), Ac-SefhC(1)I[1-Me-Trp]QDWG EHRA(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl)[γGlu]G[γGlu]])-NH2(analogues of compounds 126, 156), Ac-SefhC(1)I[1-Me-Trp]QDWG EHRA(1)[Sar]-EGE-[Peg3][Peg3]-K([15-carboxy-pentadecanoyl][γGlu]G[γGlu])-NH2(analogues of compounds 127, 160), Ac-SefhC(1)I[1-Me-Trp]QDWG EHRA(1)[Sar]EGE[Peg3][Peg3]-K([19-carboxy-nonadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 128), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogue of compound 129), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEEGGG-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogues of compounds 130, 157), Ac-SefhC(1)I[1-Me-Trp]-QDWEHRA(1)TEEGGG-K([15-carboxy-pentadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 131), Ac-SefhC(1)I[1-Me-Trp]-QDWEHRA(1)[Sar]EK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 132), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEK[γGlu]GGG-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 133), Ac-EfhC(1)I[1-Me-Trp]QDWEHRA(1)EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogues of compounds 134, 161), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-K([15-carboxy-hexadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 135), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 136), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)TEGE[8-aminooctanoyl]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu]])-NH2(analogue of compound 137), Ac-SefhC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogue of compound 138), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogue of compound 139), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogue of compound 140), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGESES-K([17-carboxy-heptadecanoyl][γGlu])-NH2(analogue of compound 141), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2(compound 165; analogue of compounds 142 and 148), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-OH(analogue of compound 163), Ac-SefhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 143), Ac-SefhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 164; analogue of compounds 144 and 147), Ac-SefhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH(analogue of compound 162), Ac-EFhC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 145), Ac-GEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 149), Ac-SEFhC(1)I[1-Me-Trp]QDW[Sar]EHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (compound 166; analog of compound 150), Ac-GEFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 155), and Ac-EFhC(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analog of compound 158) selected from, wherein the side chains of the residues designated hC(1) and A(1) form a cystathionine bridge, the compstatin analog according to claim 5 or a pharmaceutically acceptable salt and / or solvate thereof.

13. Ac-IA(1)IWQDWGHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 92), Ac-IA(1)IWQDWGHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 93), Ac-IA(1)IWQDWGHRhC(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 94), Ac-IA(1)IWQDWGHRhC(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (analog of compound 95), Ac-IA(1)IWQDWGHRhC(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 96) Ac-I A(1)IWQDWEHRhC(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 97), Ac-I A(1)IWQDWEHRhC(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 98), [15-carboxy-pentadecanoyl]-ESSAIA(1)IWQDWEHRhC(1)TEGE-NH2 (analogue of compound 99), Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIA(1)IWQDWEHRhC(1)TEGE-NH2 (analogue of compound 100), Ac-EGSAIA(1)IWQDWEHRhC(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analogue of compound 101), Ac-FA(1)I[1-Me-Trp]QDWEHRhC(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 102), Ac-EGSAYA(1)I[1-Me-Trp]QDWEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-hC(1)[Sar]E-NH2 (analogue of compound 103), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analogue of compound 104), Ac-SAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2 (analogue of compound 105), Ac-SAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2 (analogue of compound 106), [15-carboxy-pentadecanoyl]-EGSEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-NH2 (analogue of compound 107), [[17-Carboxy-heptadecanoyl]]-EGSEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]E-NH2(Analog of Compound 108), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-K([[17-Carboxy-heptadecanoyl]][[γGlu]]G[[γGlu]])-NH2(Analog of Compound 109), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGK-K([[17-Carboxy-heptadecanoyl]][[γGlu]]G[[γGlu]])-NH2(Analog of Compound 110), Ac-EGSAYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EK([[γGlu]]-K([[17-Carboxy-heptadecanoyl]][[γGlu]](peg3)(peg3))-NH2(Compound 159; Analog of Compound 111), Ac-SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGA-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(Analog of Compound 112), Ac-ASGEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(Analog of Compound 113), Ac-SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(Analog of Compound 114), Ac-SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGK-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(Analog of Compound 115), Ac-SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-K[[γGlu]])-NH2(Analog of Compound 116), Ac-SEYA(1)I[1-Me-Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([[17-Carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(Analog of Compound 117), Ac-SeyA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 118), Ac-Sefa(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2(compound 154; analogue of compound 119), Ac-Sefa(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 120), Ac-SeyA(1)I[1-Me-Trp]QEW[Sar]EHRhC(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 121), Ac-SeyA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 122), Ac-Sefa(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 146; analogue of compounds 123, 152), Ac-Sefa(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3[Peg3]-K([17-carboxy-heptadecanoyl]-[γGlu]G[γGlu])-NH2(analogue of compounds 153, 124, 167), Ac-SeyA(1)I[1-Me-Trp]QEWGEHRhC(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 125), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)TEGE[Peg3][Peg3]−K([17−carboxy−heptadecanoyl)[γGlu]G[γGlu]])−NH2(compound 156; analog of compound 126), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)[Sar]−EGE−[Peg3][Peg3]−K([15−carboxy−pentadecanoyl][γGlu]G[γGlu])−NH2(compound 160; analog of compound 127), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)[Sar]EGE[Peg3][Peg3]−K([19−carboxy−nonadecanoyl][γGlu]G[γGlu])−NH2(analog of compound 128), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)[Sar]EGEGGG−K([17−carboxy−heptadecanoyl]−[γGlu]G[γGlu])−NH2(analog of compound 129), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)TEGGG−K([17−carboxy−heptadecanoyl]−[γGlu]G[γGlu])−NH2(compound 157; analog of compound 130), Ac−SEFA(1)I[1−Me−Trp]−QDWEHRhC(1)TEGGG−K([15−carboxy−pentadecanoyl][γGlu]−G[γGlu])−NH2(analog of compound 131), Ac−SEFA(1)I[1−Me−Trp]−QDWEHRhC(1)[Sar]EK[γGlu]GGG−K([17−carboxy−heptadecanoyl][γGlu]−G[γGlu])−NH2(analog of compound 132), Ac−SEFA(1)I[1−Me−Trp]QDWEHRhC(1)TEK[γGlu]GGG−K([17−carboxy−heptadecanoyl][γGlu]−G[γGlu])−NH2(analog of compound 133), Ac−EFA(1)I[1−Me−Trp]QDWEHRhC(1)EGE−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(compound 161; analog of compound 134), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TGAES - K([[15 - carboxy - hexadecanoyl]][[γGlu]]G[[γGlu]]) - NH₂(analog of compound 135), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TEGE[[8 - aminooctanoyl]] - K([[17 - carboxy - heptadecanoyl]][[γGlu]] - G[[γGlu]]) - NH₂(analog of compound 136), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TEGE[[8 - aminooctanoyl]]E - K([[17 - carboxy - heptadecanoyl]][[γGlu]]G[[γGlu]]) - NH₂(analog of compound 137), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[[Sar]]EGE[[Peg3]] - K([[17 - carboxy - heptadecanoyl]] - [[γGlu]]G[[γGlu]]) - NH₂(analog of compound 138), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[[Sar]]EGESES - K([[17 - carboxy - heptadecanoyl]] - [[γGlu]]G[[γGlu]]) - NH₂(analog of compound 139), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[[Sar]]EGE[[Peg3]]ES - K([[17 - carboxy - heptadecanoyl]] - [[γGlu]]G[[γGlu]]) - NH₂(analog of compound 140), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[[Sar]]EGESES - K([[17 - carboxy - heptadecanoyl]][[γGlu]]) - NH₂(analog of compound 141), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TEGE[[Peg3]]ES - K([[17 - carboxy - heptadecanoyl]][[γGlu]]) - NH₂(compound 148; analog of compounds 142, 165), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)TEGE[[Peg3]]ES - K([[17 - carboxy - heptadecanoyl]][[γGlu]]) - OH(compound 163), Ac - SEFA(1)I[1 - Me - Trp]QDWEHRhC(1)[[Sar]]EGE[[Peg3]][[Peg3]][[Peg3]] - K([[17 - carboxy - heptadecanoyl]][[γGlu]]G[[γGlu]]) - NH₂(analog of compound 143), Ac-Sefa(1)I[1-Me-Trp]QDw[Sar]EhrC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 147; analog of compounds 144, 164), Ac-Sefa(1)I[1-Me-Trp]QDw[Sar]EhrC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-OH(compound 162), Ac-Efa(1)I[1-Me-Trp]QDwGEhrC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analog of compound 145), Ac-Gefa(1)I[1-Me-Trp]QDw[Sar]EhrC(1)[Sar]EAE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 149), Ac-Sefa(1)I[1-Me-Trp]QDw[Sar]EhrC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 150; analog of compound 166), Ac-Gefa(1)I[1-Me-Trp]QewGEhrC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 155), or Ac-Efa(1)I[1-Me-Trp]QewGEhrC(1)[Sar]EA[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(compound 158) wherein the side chains of the residues designated A(1) and hC(1) form a cystathionine bridge, a compstatin analog according to claim 5 or a pharmaceutically acceptable salt and / or solvate thereof.

14. Ac-IC(1)IWQDwGEhRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2(analog of compound 92), Ac-IC(1)IWQDwGEhRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2(analog of compound 93), Ac-IC(1)IWQDWEHRA(1)TEGE-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 94), Ac-IC(1)IWQDWEHRA(1)TEG-K((15-carboxy-pentadecanoyl)-[(piperazin-1-yl)-acetyl][Peg3][Peg3])-NH2 (analog of compound 95), Ac-IC(1)IWQDWEHRA(1)TEG-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 96), Ac-IC(1)IWQDWEHRA(1)TEGE-K([17-carboxy-heptadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 97), Ac-IC(1)IWQDWEHRA(1)TEG-K([19-carboxy-nonadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 98), [15-carboxy-pentadecanoyl]-ESSAIC(1)IWQDWEHRA(1)TEGE-NH2 (analog of compound 99), Ac-[K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])]-GSAIC(1)IWQDWEHRA(1)TEGE-NH2 (analog of compound 100), Ac-EGSAIC(1)IWQDWEHRA(1)TEG-K([15-carboxy-pentadecanoyl][γGlu])-NH2 (analog of compound 101), Ac-FC(1)I[1-Me-Trp]QDWEHRA(1)TGAES-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 102), Ac-EGSAYC(1)I[1-Me-Trp]QDWEH-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-A(1)[Sar]E-NH2 (analog of compound 103), Ac-EGSAYC(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EG-K([15-carboxy-pentadecanoyl][γGlu][Peg3][Peg3])-NH2 (analog of compound 104), Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]KG[γGlu])-NH2(analogue of compound 105), Ac-SAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 106), [15-carboxy-pentadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2(analogue of compound 107), [17-carboxy-heptadecanoyl]-EGSEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]E-NH2(analogue of compound 108), Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 109), Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogue of compound 110), Ac-EGSAYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EK([γGlu]-K([17-carboxy-heptadecanoyl][γGlu](peg3)(peg3))-NH2(analogues of compounds 111, 159), Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 112), Ac-ASGEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 113), Ac-SEYC(1)I[1-Me-Trp]QDWGEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 114), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGK-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 115), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE-K([17-carboxy-heptadecanoyl][γGlu]-K[γGlu])-NH2(analogue of compound 116), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]-G[γGlu])-NH2(analogue of compound 117), Ac-Seyc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 118), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2(analogues of compounds 119, 154), Ac-Sefc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 120), Ac-Seyc(1)I[1-Me-Trp]QEW[Sar]EHRA(1)[Sar]EK[γGlu]A-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 121), Ac-Seyc(1)I[1-Me-Trp]QEWGEHRA(1)[Sar]EGA-K([17-carboxy-heptadecanoyl]-[γGlu]G[Peg3][γGlu][Peg3])-NH2(analogue of compound 122), Ac-Sefc(1)I[1-Me-Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2(analogues of compounds 123, 146 and 152), Ac - SEFC(1)I[1 - Me - Trp]QEWGEHRA(1)[Sar]EGE[Peg3[Peg3] - K([17 - carboxy - heptadecanoyl] - [γGlu]G[γGlu]) - NH2 (analog of compounds 124, 153, 167), Ac - SEYC(1)I[1 - Me - Trp]QEWGEHRA(1)[Sar]EGE[Peg3][Peg3] - K([17 - carboxy - heptadecanoyl][γGlu]G[γGlu]) - NH2 (analog of compound 125), Ac - SEFC(1)I[1 - Me - Trp]QDWGEHRA(1)TEGE[Peg3][Peg3] - K([17 - carboxy - heptadecanoyl)[γGlu]G[γGlu]]) - NH2 (analog of compounds 126, 156), Ac - SEFC(1)I[1 - Me - Trp]QDWGEHRA(1)[Sar] - EGE - [Peg3][Peg3] - K([15 - carboxy - pentadecanoyl][γGlu]G[γGlu]) - NH2 (analog of compound 127), Ac - SEFC(1)I[1 - Me - Trp]QDWGEHRA(1)[Sar]EGE[Peg3][Peg3] - K([19 - carboxy - nonadecanoyl][γGlu]G[γGlu]) - NH2 (analog of compound 128), Ac - SEFC(1)I[1 - Me - Trp]QDWGEHRA(1)[Sar]EGEGGG - K([17 - carboxy - heptadecanoyl] - [γGlu]G[γGlu]) - NH2 (analog of compound 129), Ac - SEFC(1)I[1 - Me - Trp]QDWGEHRA(1)TEGEGGG - K([17 - carboxy - heptadecanoyl] - [γGlu]G[γGlu]) - NH2 (analog of compounds 130, 157), Ac - SEFC(1)I[1 - Me - Trp] - QDWGEHRA(1)TEGEGGG - K([15 - carboxy - pentadecanoyl][γGlu] - G[γGlu]) - NH2 (analog of compound 131), Ac - SEFC(1)I[1 - Me - Trp] - QDWGEHRA(1)[Sar]EK[γGlu]GGG - K([17 - carboxy - heptadecanoyl][γGlu] - G[γGlu]) - NH2 (analog of compound 132), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TEK[[γGlu]]GGG-K([[17-carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(analogue of compound 133), Ac-Efc(1)I[1-Me-Trp]QDWGEHRA(1)EGE-K([[17-carboxy-heptadecanoyl]][[γGlu]]G[[γGlu]])-NH2(analogue of compounds 134, 161), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TGAS-K([[15-carboxy-hexadecanoyl]][[γGlu]]G[[γGlu]])-NH2(analogue of compound 135), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[[8-aminooctanoyl]]-K([[17-carboxy-heptadecanoyl]][[γGlu]]-G[[γGlu]])-NH2(analogue of compound 136), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[[8-aminooctanoyl]]E-K([[17-carboxy-heptadecanoyl]][[γGlu]]G[[γGlu]])-NH2(analogue of compound 137), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)[[Sar]]EGE[[Peg3]]-K([[17-carboxy-heptadecanoyl]]-[[γGlu]]G[[γGlu]])-NH2(analogue of compound 138), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)[[Sar]]EGESES-K([[17-carboxy-heptadecanoyl]]-[[γGlu]]G[[γGlu]])-NH2(analogue of compound 139), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)[[Sar]]EGE[[Peg3]]ES-K([[17-carboxy-heptadecanoyl]]-[[γGlu]]G[[γGlu]])-NH2(analogue of compound 140), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)[[Sar]]EGESES-K([[17-carboxy-heptadecanoyl]][[γGlu]])-NH2(analogue of compound 141), Ac-Sefc(1)I[1-Me-Trp]QDWGEHRA(1)TEGE[[Peg3]]ES-K([[17-carboxy-heptadecanoyl]][[γGlu]])-NH2(analogues of compounds 142, 148, 165), Ac−SEFC(1)I[1−Me−Trp]QDWEHRA(1)TEGE[Peg3]ES−K([17−carboxy−heptadecanoyl][γGlu])−OH(analogue of compound 163), Ac−SEFC(1)I[1−Me−Trp]QDWEHRA(1)[Sar]EGE[Peg3][Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogue of compound 143), Ac−SEFC(1)I[1−Me−Trp]QDWSarEHRA(1)[Sar]E[Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogues of compounds 144, 147, 164), Ac−SEFC(1)I[1−Me−Trp]QDWSarEHRA(1)[Sar]E[Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−OH(analogue of compound 162), Ac−EF[C(1)I[1−Me−Trp]QDWEHRA(1)[Sar]EA[Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogue of compound 145), Ac−GEFC(1)I[1−Me−Trp]QDWSarEHRA(1)[Sar]EAE[Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogue of compound 149), Ac−SEFC(1)I[1−Me−Trp]QDWSarEHRA(1)[Sar]EGE[Peg3]ES−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogues of compounds 150, 166), Ac−GEFC(1)I[1−Me−Trp]QEWGEHRA(1)[Sar]EGE[Peg3]ES−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogue of compound 155), or Ac−EFC(1)I[1−Me−Trp]QEWGEHRA(1)[Sar]EA[Peg3][Peg3]−K([17−carboxy−heptadecanoyl][γGlu]G[γGlu])−NH2(analogue of compound 158) The side chains of the residues designated as C(1) and A(1) form a lanthionine bridge, the complestatin analog according to claim 5, or a pharmaceutically acceptable salt and / or solvate thereof.

15. A complestatin analog of Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]E[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2, wherein the side chains of the residues designated as C(1) and A(1) form a cystathionine bridge, and Peg3 represents 8-amino-3,6-dioxaoctanoic acid, or a pharmaceutically acceptable salt and / or solvate thereof.

16. A complestatin analog of Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)TEGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu])-NH2, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge, and Peg3 represents 8-amino-3,6-dioxaoctanoic acid, or a pharmaceutically acceptable salt and / or solvate thereof.

17. A complestatin analog of Ac-SEFA(1)I[1-Me-Trp]QDW[Sar]EHRhC(1)[Sar]EGE[Peg3]ES-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge, and Peg3 represents 8-amino-3,6-dioxaoctanoic acid, or a pharmaceutically acceptable salt and / or solvate thereof.

18. A complestatin analog of Ac-SEFA(1)I[1-Me-Trp]QDWGEHRhC(1)[Sar]EGA-K([17-carboxy-heptadecanoyl][γGlu]G[Peg3][γGlu][Peg3])-NH2, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge, and Peg3 represents 8-amino-3,6-dioxaoctanoic acid, or a pharmaceutically acceptable salt and / or solvate thereof.

19. A compstatin analog which is Ac-Sefa(1)I[1-Me-Trp]QDWEHRhC(1)TEGE[Peg3][Peg3]-K([17-carboxy-heptadecanoyl][γGlu]G[γGlu])-NH2, wherein the side chains of the residues designated as A(1) and hC(1) form a cystathionine bridge, and Peg3 represents 8-amino-3,6-dioxaoctanoic acid, or a pharmaceutically acceptable salt and / or solvate thereof.

20. A composition comprising the compstatin analog according to any one of claims 1 to 19, or a pharmaceutically acceptable salt and / or solvate thereof, in a mixture with a carrier.

21. The composition according to claim 20, which is a pharmaceutical composition and wherein the carrier is a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the compstatin analog according to any one of claims 1 to 19, or a pharmaceutically acceptable salt and / or solvate thereof, in a mixture with a pharmaceutically acceptable carrier, excipient or vehicle.

23. A composition for use in therapy, comprising the compstatin analog according to any one of claims 1 to 19, or a pharmaceutically acceptable salt and / or solvate thereof.

24. A composition for use in a method of inhibiting complement activation, comprising the compstatin analog according to any one of claims 1 to 19, or a pharmaceutically acceptable salt and / or solvate thereof.

25. The composition for use according to claim 24, wherein the inhibition of complement activation comprises one or more biological activities selected from (1) inhibition of binding to C3 protein, (2) inhibition of binding to C3b protein, and / or (3) inhibition of cleavage of native C3 by C3 convertase.

26. For use in a method for the prevention or treatment of age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis or antiphospholipid syndrome, a composition comprising a compstatin analog according to any one of claims 1 to 19 or a pharmaceutically acceptable salt and / or solvate thereof.

27. A composition comprising a compstatin analog according to any one of claims 1 to 19 or a pharmaceutically acceptable salt and / or solvate thereof for use in a method for inhibiting complement activation occurring during cell transplantation or organ transplantation.

28. A composition comprising a compstatin analog according to any one of claims 1 to 19 or a pharmaceutically acceptable salt and / or solvate thereof for performing inhibition of complement activation in order to treat a subject in need thereof.

29. The composition according to claim 28, wherein the subject has age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis or antiphospholipid syndrome.

30. Use of a compstatin analog according to any one of claims 1 to 19 or a pharmaceutically acceptable salt and / or solvate thereof in the preparation of a medicament for inhibiting complement activation.

31. Use of a compstatin analog according to any one of claims 1 to 19 or a pharmaceutically acceptable salt and / or solvate thereof in the preparation of a medicament for the treatment of age-related macular degeneration, Stargardt's disease, periodontitis, diabetic retinopathy, glaucoma, uveitis, rheumatoid arthritis, spinal cord injury, stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cancer and respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic inflammation, emphysema, bronchitis, bronchiectasis, cystic fibrosis, tuberculosis, pneumonia, respiratory distress syndrome (RDS - neonatal and adult), rhinitis and sinusitis; bacterial infections such as sepsis, ischemia-reperfusion injury in various tissues, myocardial infarction, anaphylaxis, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, psoriasis, hidradenitis suppurativa, myasthenia gravis, systemic lupus erythematosus, CHAPLE syndrome, C3 glomerulopathy, IgA nephropathy, atypical hemolytic uremic syndrome, Crohn's disease, ulcerative colitis or antiphospholipid syndrome.

Images